PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 1  
 
 
 
 
 
 
 
 
 
 
 UNIVERSITY OF VIRGINIA  
HUMAN IMMUNE THERAPY CENTER  
 
 
 
PHASE I/II TRIAL OF A LONG PEPTIDE VACCINE ( LPV7 ) PLUS TLR AGONISTS  
FOR RESECTED STAGE IIB – IV MELANOMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATTACH TO THE FRONT OF EVERY COPY OF THIS PROTOCOL  
 
  Confidentiality Statement  
The information contained in this document is the property of the University of Virginia Human 
Immune Therapy Center.  Distributing, copying, or disclosing information contained in this 
document requires  prior authorization  from the Human Immune Therapy Center, except that 
this document may be disclosed to the appropriate institutional review boards and 
representatives of the U.S. Food and Drug Administration.   
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 2  
Signature Page  
 
 
Sponsor’s Representative  
 
 
 
______________________    _______________________    _______________  
Name               Signature             Date 
 
 
 
 
 
 
Investigator  
 
 
                        
_______________________   _________________________   ________________  
Name              Signature             Date 
 
 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 3 UNIVERSITY OF VIRGINIA  
HUMAN IMMUNE THERAPY CENTER  
 
 
PHASE I/II TRIAL OF A LONG PEPTIDE VACCINE ( LPV7 ) PLUS TLR AGONISTS  
FOR RESECTED STAGE IIB – IV MELANOMA  
 
Principal Investigator  (UVA) : Craig L. Slingluff, Jr., M.D.  
University of Virginia  
434-924-1730  
cls8h@virginia.edu  
 
Principal Investigator (MDA)  Sapna Patel, M.D.  
The University of Texas MD Anderson 
Cancer Center  
713-792-2921  
sppatel@mdanderson.org  
 
Co-Investigators:  Patrick Hw u, M.D., Ph.D.  
The University of Texas MD Anderson 
Cancer Center  
713-563-1728  
phw u@mdanderson.org  
 
Merrick Ross, M.D.  
The University of Texas MD Anderson 
Cancer Center  
713-792-0025  
mross@mdanderson.org  
 
Elizabeth Gaughan, M.D.  
Unviersity of Virginia  
434-924-1904  
emg5x@virginia.edu  
 
William W. Grosh, M.D.  
University of Virginia  
434-924-1904  
ww g9u@virginia.edu  
 
Carmel Nail , F.N.P. 
University of Virginia  
434-982-4042  
cjn2r@virginia.edu  
 
Kathleen Haden, RN MSN ANP -C 
University of Virginia  
434-924-1730  
km3s@virginia.edu  
 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 4 Walter C. Olson, Ph.D.  
University of Virginia  
434-243-9688  
w co3j@virginia.edu  
 
 
Kimberly A. Bullock, Ph.D.  
University of Virginia  
434-924-0180  
kb9d@virginia.edu  
 
Willem Overw ijk, Ph.D.  
The University of Texas MD Anderson 
Cancer Center  
713-563-5294  
WOverw ijk@mdanderson.org  
 
 
Biostatisticians:  Gina R. Petroni, Ph.D.  
University of Virginia  
434-924-8363  
grp4c@virginia.edu  
 
Mark Smolkin, M.S.  
University of Virginia  
434-982-1032  
mes6r@virginia.edu  
 
  
Research Nurses : 
 Carmel J. Nail, F.N.P.  
Kathleen Haden, RN MSN ANP -C 
 
Clinical Research Coordinators  
and Data Management - 
University of Virginia  
  
Emily  Allred, PhD  
434-982-1902  
eh4m@virginia.edu  
 
Jessica Zareno, MS  
434-982-1901  
jhz4f@virginia.edu   
 
Alexandra Carney, MPH  
434-982-6714  
alc6a@virginia.edu   
 
Kendall Pettaw ay, BS  
434-982-6584  
kp8ac@virginia.edu   
 
Annika Shuali, MS  
434-243-7242  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 5 ah2ze@virginia.edu  
 
Sarah  Lew is, BA  
434-924-8709  
set5v@virginia.edu  
  
Authors:  
 Craig L. Slingluff, Jr., M.D.  
Jade Homsi , M.D.  (Part 1)  
Willem Overw ijk, Ph.D.  (Part 1)  
Gina R. Petroni, Ph.D.  
Kimberly A. Bullock, Ph.D.  
Walter Olson, Ph.D.  
Sapna Patel , M.D. (Part 1)  
 
 
  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 6 1.0 INTRODUCTION  ................................ ................................ ................................ ..............  14 
Abstract  ................................ ................................ ................................ ................................ ................................ .............. 14 
1.1 Study Rationale ................................ ................................ ................................ ................................ ........................... 14 
1.2 Vaccine Design and Surgical Excision  ................................ ................................ ................................ ..................... 16 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ ...... 23 
2.1 Part  1 (completed)  ................................ ................................ ................................ ................................ ..................... 23 
2.2 Part 2  ................................ ................................ ................................ ................................ ................................ ............ 24 
3.0 STUDY OUTLINE  ................................ ................................ ................................ .............  24 
3.1 Type of Study ................................ ................................ ................................ ................................ ............................... 24 
4.0 PARTICIPANT SELECTION  ................................ ................................ ............................  24 
4.1 Inclusion Criteria  ................................ ................................ ................................ ................................ ......................... 24 
4.2 Exclusion Criteria  ................................ ................................ ................................ ................................ ........................ 25 
4.3 Demographics of Participant Population  ................................ ................................ ................................ ............... 27 
4.4 Registration, Randomization, and Management of Participants  ................................ ................................ ......27 
5.0 STUDY MEDICATION FORMULATION, DOSAGE, ACCOUNTABILITY AND 
ADMINISTRATION  ................................ ................................ ................................ .................  28 
5.1 Study Medication Formulation  ................................ ................................ ................................ ................................ 28 
5.2 Preparation, Dosage, and Storage of Study Drug ................................ ................................ ................................ .29 
5.3 Drug Accountability and Distribution  ................................ ................................ ................................ ..................... 31 
5.4 Administration of Vaccines  ................................ ................................ ................................ ................................ .......31 
5.5 Modification/Discontinuation of Treatment  ................................ ................................ ................................ ......... 33 
5.6 Concomitant Medications ................................ ................................ ................................ ................................ ......... 35 
6.0 CLINICAL AND LABORATORY EVALUATION ................................ .............................  36 
6.1 Screening ................................ ................................ ................................ ................................ ................................ ......36 
6.2 Treatment  ................................ ................................ ................................ ................................ ................................ ....37 
6.3 Tumor tiss ue collection ................................ ................................ ................................ ................................ .............. 41 
7.0 REGULATORY AND REPORTING REQUIREMENTS  ................................ ..................  41 
7.1 Definitions ................................ ................................ ................................ ................................ ................................ ....42 
7.2 Attribut ion Assessment  ................................ ................................ ................................ ................................ ............. 43 
7.3 Data collection  ................................ ................................ ................................ ................................ ............................ 44 
7.4 Risks and Safety  ................................ ................................ ................................ ................................ .......................... 44 
7.5 Adve rse Event Classifications  ................................ ................................ ................................ ................................ ...47 
7.6 Reporting Adverse Events  ................................ ................................ ................................ ................................ ......... 49 
7.7 Adverse Event Review and Monitoring ................................ ................................ ................................ ................... 52 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 7 7.8 Adverse Event Stopping Guidelines  ................................ ................................ ................................ ......................... 53 
7.9 Responsibility  ................................ ................................ ................................ ................................ .............................. 54 
7.10 Endpoint Data  ................................ ................................ ................................ ................................ ........................... 54 
8.0 EVALUATION OF IMMUNOLOGIC RESULTS ................................ ...............................  54 
8.1 Immunohistochemistry and Immunofluorescence of skin biopsy specimens  ................................ .................. 55 
8.2 ELIspot assay  ................................ ................................ ................................ ................................ ............................... 55 
8.3 Tetramer assay and multiparameter flow cytometry ................................ ................................ .......................... 56 
8.4 Proliferation assay / Cytokine Analysis ................................ ................................ ................................ ................... 56 
8.5 Antibody responses  ................................ ................................ ................................ ................................ .................... 56 
8.6 Evaluation of tumor  ................................ ................................ ................................ ................................ ................... 57 
9.0 STATISTICAL CONSIDERATIONS  ................................ ................................ ................  57 
9.1 Study design Part 1 (completed) ................................ ................................ ................................ .............................. 57 
9.2 Combination allocation Part 1 (completed) ................................ ................................ ................................ ........... 58 
9.3 Statistical properties Part 1 (completed)  ................................ ................................ ................................ ............... 60 
9.4 Study design Part 2  ................................ ................................ ................................ ................................ .................... 61 
9.5 Sample size/accrual  ................................ ................................ ................................ ................................ ................... 61 
9.6 Stopping rules:  ................................ ................................ ................................ ................................ ............................ 62 
9.7 Analyses  ................................ ................................ ................................ ................................ ................................ .......63 
10.0 Appendices ................................ ................................ ................................ ....................  64 
10.1 Appendix 1: X -page  ................................ ................................ ................................ ................................ .................. 65 
10.2  Appendix 2: AJCC Staging System, 7th Edition  ................................ ................................ ................................ .....66 
10.3 Appendix 3: ECOG Performance Status  ................................ ................................ ................................ ................ 68 
10.4 Appendix 4: New York Heart Association Disease Classification  ................................ ................................ .....69 
10.5 Appendix 5: Lot Testing ................................ ................................ ................................ ................................ ........... 70 
10.6 Appendix 6: NCI Common Terminology Criteria for Adverse Events v4.03  ................................ .................... 72 
10.7 Appendix 7:  Summary of Changes  ................................ ................................ ................................ ....................... 73 
11.0 Reference List  ................................ ................................ ................................ ...............  78 
 
 
 
 
 
 
 
 
 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 8 Protocol Precis   
 
Title: Phase I/II trial of a long peptide vaccine ( LPV7 ) + TLR agonists for resected stage IIB -
IV melanoma  
Objectives : 
Part 1 (completed)  
(1) To test safety of vaccination w ith a mixture of long peptides for patients w ith high-risk 
melanoma, in each of 7 adjuvant  preparations, including TLR agonists and/or  
incomplete Freund’s adjuvant ( IFA) 
(2) To estimate the immunogenicity of  7 long peptides in each of 7 adjuvant  preparations  
 
Exploratory objective:  
(3) To evaluate the molecular and cellular changes at the vaccine site and systemically  
 
Part 2  
(4) To assess safety of vaccination of the optimal combination identified in Part 1 w hen 
administered in the same skin site for all 6 vaccines (same site vaccination).  
(5) To estimate the immunogenicity of the optimal combination identified in Part 1 w hen 
administered in the same skin site for a ll 6 vaccines (same site vaccination).  
 
Design:   This is an open -label, randomized, phase I/II  study , using an  adaptive design, of 
the safety and immunogenicity of a novel melanoma vaccination approach using long 
peptides plus TLR agonists, along w ith char acterization of cellular and molecular events at 
the cutaneous site s of immunization  and systemically .   
This trial involves tw o parts, w hich differ in the location of vaccine injections.  For part 1, 
each vaccine was administered in a skin site that differs on each vaccine date (rotating 
vaccine sites).  For part 2, each vaccine w ill be administered in the same skin site for all 6 
vaccines (same site vaccination).  
 
Table 1A. Clinical Trial Design for Part 1  
 
For part 2, the vaccine regimen is selected based on available data and the study decision 
rules from Part 1  w hich w as determined to be Arm E. For Part 2 , accrual w ill be to Study 
Arm E2.   How ever, a modification is made to exclude the tetanus helper pepti de, due to (a) 
lack of availability of that peptide component, (b) the finding that, in part 1, LPV7 peptides do Zone  Study 
Arm Peptide 
vaccine  Adjuvant   Dose of TLR 
agonist  Route 
vax 
injection  Admin of  
TLR agonist  
1 A LPV7  + tet IFA  --- Id/sq  -- 
1 B  LPV7  + tet PolyICLC  1 mg  Id/sq  Id/sq  
1 C LPV7 + tet  Resiquimod  1000  mcg Id/sq  Topical  
2 D LPV7  + tet PolyICLC + resiquimod  1 mg/ 1000  mcg Id/sq  Id/sq (PolyICLC) & 
topical  (resiquimod)  
2 E LPV7  + tet IFA + PolyICLC  1 mg  Id/sq  Id/sq  
2 F LPV7  + tet IFA + resiquimod  1000  mcg Id/sq  Topical  
3 G LPV7  + tet IFA + PolyICLC + resiquimod  1 mg/ 1000  mcg Id/sq  Id/sq  (PolyICLC) & 
topical  (resiquimod)  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 9 induce helper T cell responses themselves (unpublished data), and prior data that adding 
the tetanus helper peptide did not add significantly t o immunologic or clinical outcome of a 
peptide vaccine designed to induce CD8 T cells1. 
Table 1B. Clinical Trial Design for Part 2  
 
Regimen :  Patients w ill be registered on this phase I/II trial and w ill be vaccinated w ith 
LPV7  at 300 mcg peptide/dose  every w eek x 3 then every 3 w eeks x 3.   
For Part 1, t he adjuvants are described, and w ill be administered to patie nts in 7 study  
groups as show n in Table 1A.  This incorporates an adaptive design w ith  sequential 
initiation of accrual to study Zones  w ith increasing numbers of adjuvants (Arms A -C, then D -
F, then G) . Details are in Section 9 .0 and Appendix 1  (X-page).  
For Part 2, the adjuvants w ill be administered to patients in 1 study group as show n in 
Table 1B.  
Vaccine site biopsies :  In each patient, three 4 -mm punch biopsies w ill be performed of 
the skin at vaccine sites at tw o time points: 1 w eek after vaccine #1 (day 8) and one w eek 
after vaccine #3 (day 22). As negative controls, 3 punch biopsies w ill be obtained of 
clinically normal skin (not at the vaccine site) in the first 6 patients  in Part 1  at the same 
time points  (days 8 and 22) . Details are provided in section 5.4.6.2.  
Leadership : This trial w ill be per formed at tw o institutions in patients w ith high -risk 
resected stage IIB -IV melanoma. The lead institution for this trial w ill be the University of 
Virginia, and the PI w ill be Dr. Craig Slingluff. The institutional PI at M.D. Anderson 
Cancer Center w ill b e Dr. Patrick Hw u . Part 2 w ill be conducted at the University of 
Virginia  only.  
Population :  Criteria for inclusion include:  
 age 18 years or older  
 expression of  HLA-A1, -A2, -A3, -B35, or -B51 
 histologically o r cytologically proven  Stage IIB -IV melanoma rendered clinically free 
of disease by surgery, other therapy, or spontaneous remission .  Small (<1cm) 
findings that are equivocal on radiologic or clinical imaging w ill not be a basis for 
exclusion.  
 ECOG performance status 0 -1 (Appendix 3 ) 
 Adequate hepatic and renal function  
 Weight at least 50 kg (110 lbs)  
NOTE: Patients w ill be excluded if they are pregnant or are immunosuppressed , or 
have previously received vaccines containing an incomplete Freund’s adjuvant.  
Accrual: For Part 1 , the maximum accrual to the study is estimated from the simulations to 
be approximately 52 patients. Adjusting for 10% ineligibility/dropout/w ithdraw al rate, 
maximum total target accrual is estimated at 58 patients.  For Part 2 , target  accrual is 
estimated to be 16 eligible patients. Adjusting for 10% i neligibility/dropout/w ithdraw al rate, 
maximum total accrual for part 2 is estimated at 18 patients .  Zone  Study 
Arm Peptide 
vaccine  Adjuvant   Dose of TLR 
agonist  Route 
vax 
injection  Admin of  
TLR agonist  
2 E2 LPV7  IFA + PolyICLC  1 mg  Id/sq  Id/sq  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 10 Clinical outcome :  The primary goals are to assess safety and immunogenicity .  The study is 
not pow ered for differences in clinical outcome, but w e w ill track disease -free survival, and 
overall survival. Significant differences in clinical outcome are not anticipated among  the 
study arms, but trends in clinical outcome w ill be assessed in the context of the immunologic 
data to support decisions about the preferred vaccination strategy to test further in 
combination w ith other immune therapies.  
Vaccine composition:   The pept ides described in Table 2 w ill be used in the vaccines.  
Table 2: 7 long Melanoma Peptides Restricted by MHC Class I and the corresponding 
defined minimal epitope  
 
 
Endpoints:  
Primary:   
 Safety and t oxicity follow ing  vaccination w ith  7 long peptides in melanoma patients  
w ith and w ithout TLR agonists  
 Levels of p eptide -reactive CD8+ T cells in the peripheral blood  (peak and durable at 
26 w eeks)  and vaccine site  
Secondary:  
 CD4+ T cell responses to peptides in the vaccine, and their functio n. 
Exploratory : 
 To analyze c ellular infiltrates in the VSME  
 To identify c ytokine profiles of the VSME as a function of TLR signaling  
 To identify t oll-like recep tor signaling in the VSME  
 To understand r egulatory processes in the replicate immunization sites  
o Regulatory T cells (CD4+CD25hiFoxP3+) 
o Myeloid -derived  suppressor cells  
 Overall Survival and disease -free survival  
 
 
 
   Short Peptides  Long Peptide (30 -mers)  in LPV7  for the present proposal  
Allele  Minimal Epitope  Sequence (minimal epitope underlined)  Source  (# residues)  
HLA-A1 Tyrosinase 240-251S* FTIPYWDWR DAEK SDICTDEY MGGQ HPTN  Tyrosinase 231-259 S* (29 ) 
HLA-A2 
 
 Tyrosinase 369-377  SMHNALHI YMDGTMSQV QGSANDPIFLLHH  Tyrosinase 361-390  (30) 
gp100 209-217-2M  #  VPLAHSSSAFT IMDQVPFSV SVSQLRALDG   gp100 198-227 #  (30) 
MAGE -A10 254-262 VIWEALNMM GLYDGMEHL IYGEPRKLLTQD  MAGE -A10 245-274 (30)  
HLA-A3 
 gp100 17-25 LLHLAVIG ALLAVGATK VPRNQDWLGVSRQL  gp100 9-39  (31) 
MAGE -A1 96-104 SREEEGPSTSCILE SLFRAVITK KVADLVG  MAGE -A1 82-111 (30)    
HLA-B35/B51  NY-ESO -1 94-102 GARGPESRLLEFYLA MPFATPMEA ELARRS  NY-ESO -1 79-108 (30) 
*(substitution of S for C at residue 244);   (post -translational change of N to D at residue 371);   #(209 -2M, substitution of M for T 
at position 210)     
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 11  
List of Abbreviations  
Abbreviation  Full text  
HCG Beta Human chorionic gonadotropin (pregnancy test)  
12-MP 12 melanoma -derived class I MHC -restricted peptides  
AE adverse event  
AGC absolute granulocyte count  
AJCC  American Joint Committee on Cancer  
ALT alanine aminotransferase  
ANC absolute neutrophil count  
APC antigen presenting cell  
AST aspartate aminotransferase  
BTRF  Biorepository and Tissue Research Facility  
CC Cancer Center  
cc cubic centimeter  
CFR Code of Federal Regulations  
cm centimeter  
CO 2 carbon dioxide  
CRF case report form  
C3TO  Cancer Center Clinical Trials Database  
CT computed tomography  
CTA cancer -testis antigens  
CTCAE  Common Terminology Criteria for Adverse Events  
CTL cytotoxic T lymphocyte  
CTO Clinical Trials Office  
DC dendritic cells  
DFS Disease -free survival  
dL deciliter  
DLT dose limiting toxicity  
DSMC  Data and Safety Monitoring Committee  
ECOG  Eastern Cooperative Oncology Group  
ELISA  enzyme linked immunosorbent assay  
FACS  fluorescence activated cell sorter  
FBS fetal bovine serum  
FDA Food and Drug Administration  
FITC Fluorescein isothiocyanate  
g gram  
GLP good laboratory practice  
GM-CSF granulocyte -macrophage colony -stimulating factor  
GMP good manufacturing practice  
Hgb hemoglobin  
HGBA1C  hemoglobin a1c  
HITC Human Immune Therapy Center  
HIV human immunodeficiency virus  
HLA human leukocyte antigen  
HPLC  high performance liquid chromatography  
HR Hazard ratio  
IBW ideal body w eight  
id intradermal  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 12 IFA incomplete Freund’s adjuvant  
IFN interferon  
IHC immunohistochemistry  
IL-2 interleukin -2 
IL-7 interleukin -7 
IL-15 interleukin -15 
IML Immune Monitoring Laboratory  
in inch 
IND investigational new  drug  
ip intraperitoneal  
IRB Institutional Review  Board  
IRR immunologic response rate  
IU international unit  
IV intravenous  
kg kilogram  
KLH keyhole limpet hemocyanin  
LC Langerhans cells  
LDH lactate dehydrogenase  
LNLA  Lymph -node -like aggregate  
LPV7  Long peptide vaccine w ith 7 melanoma peptides  
LyNeo  lymphoid neogenesis  
m meter  
mcCi microcurie  
mcg microgram  
mcl microliter  
MDACC  M.D. Anderson Cancer Center  
MDP melanocyte differentiation proteins  
mg milligram  
MHC major histocompatibility  complex  
mIU million international units  
ml milliliter  
mm millimeter  
MRI magnetic resonance imaging  
NBT/BCIP  Nitro blue tetrazolium chloride/5 -Bromo -4-Chloro -3-Indolyl 
Phosphate  
NED No evidence of disease, i.e. no clinical evidence of melanoma  
NCI National Cancer Institute  
NOS not otherw ise specified  
NSAID  non-steroidal anti -inflammatory drug  
OS overall survival  
PBL peripheral blood lymphocytes  
PBMC  peripheral blood mononuclear cells  
PBS phosphate buffered saline  
PET positron emission tomography  
PHA phytohemagglutinin  
PI Principal Investigator  
PMA phorbol myristate acetate  
PolyICLC  polyinosinic -polycytidylic acid  stabilized w ith 
carboxymethylcellulose , and poly -L-lysine double -stranded RNA 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 13 ppm parts per million  
PRC protoc ol review  committee  
RCC renal cell carcinoma  
RPMI  Rosw ell Park Memorial Institute  
SD standard deviation  
SIN sentinel immunized node  
SQ subcutaneous  
TAA tumor associated antigens  
tet tetanus helper peptide  
TFA trifluoroacetic acid  
Th CD4+ helper T cells  
TIL tumor infiltrating lymphocytes  
TLR Toll-like receptor  
TNF tumor necrosis factor  
ULN upper limits of normal  
USP United States Pharmacopeia  
UVA University of Virginia  
VSME  Vaccine site microenvironment  
WBC w hite blood cell  
w /v w eight to volume  
v/v volume to volume  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 14 1.0   INTRODUCTION  
 
Abstract  
Identification of minimal peptide epitopes for melanoma reactive T cells in the early 1990s 
has provided useful tools for evaluating T cell responses to melanoma; how ever, the 
immune responses to vaccines using short peptides are often transient and of low  
magnitude, and they have had limited clinical activity.  Recent w ork suggests that 
vaccination w ith longer (30 -mer) peptides that encompass these short peptides may be a 
more effective strategy and has been associated w ith clinical regressions of squamous  
vulvar neoplasia1. The most common adjuvant for peptide vaccines for melanoma has 
been a form of incomplete Freund’s adjuvant (IFA).  How ever, Toll -like receptor (TLR) 
agonists offer the potential to improve the magnitude and persistence of antitumor T cell 
responses, and findings from a few  clinical trials support this potential2-4. How ever, there 
has been very limited characterization of the molecular and cellular effects of TLR 
agonists at the vaccine site microenvironment (VSME). A randomized trial of high -dose 
interleukin -2 (IL2) vs. IL2 + peptide vaccine show ed improved response rat e and 
progression free survival w ith addition of the peptide vaccine  5. Other preclinical studies 
show  improved tumor control by adding vaccines to adoptive T cell therapy and to 
blockade of immunologic checkpoints. An optimized vaccine strategy, relevant across the 
large range of HLA alleles is needed.  
The proposal is  for a clinic al trial, performed in a collaborative multicenter setting 
involving 2 academic institutions. T his trial w ill accrue approximately  52 eligible  patients  
(Part 1) and  approximately eligible 18 patients  (Part 2)  in a phase I/II design  w ith a long 
peptide vaccine ( LPV7 ) in one of 7 adjuvant  strategies of IFA alone , TLR agonist(s) 
alone, or a combination of IFA plus TLR agonist (s). Goals of this trial w ill include a safety 
assessment and measures of immunogenicity , and characterization of the ce llular and 
molecular events induced by each TLR agonist in the VSME.  This w ill be a first -in-
humans evaluation of the safety and immunogenicity of 7 long 30-mer peptides ( LPV7 ) 
for melanoma, w hich incorporate 7 w ell-characterized minimal epitopes restrict ed by 
HLA-A1, A2, and A3 ( approximately 80% of melanoma patients)  and a w ell -characterized 
epitope restricted by HLA -B35/B51 .  We propose to test these peptides in IFA alone, an 
adjuvant combining IFA w ith each of the follow ing polyICLC/Hiltonol (TLR3 agon ist), 
resiquimod (TLR7/8 agonist), and both polyICLC and resiquimod , to be administered  
locally at the site of vaccination.  
 
1.1   Study Rationale  
Cancer immunotherapy for solid tumors is coming of age, w ith FDA -approved immuno -
therapeutics now  available for the treatment of multiple  tumor types .  In melanoma, 
checkpoint inhibitors specific for CTLA -4 and PD -1 have been show n to induce durable 
clinical regressions and improve overall survival . There is excitement about th e grow ing 
armamentari um of systemic immunotherapeutics, w hose effects are mediated 
predominantly by T lymphocytes.  How ever, d espite the effectiveness of those therapies, 
checkpoint inhibitors fail in about  70-80% of patients, and these patients often succumb 
to their disease . There is a need for new  combination approaches that build on the 
demonstrated clinical value of immune therapy.  
Cancer vaccines inducing antigen -specific T cell responses are emerging as a 
component of combination immunotherapy.  In the past few  years, a cancer vaccine has 
been approved for prostate cancer, based on tw o randomized trials show ing improved 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 15 survival and a randomized prospective trial show ed that adding a peptide vaccine to high -
dose IL -2 significantly prolonged progression -free survival (PFS)  w hen compared to IL -2 
alone .83;5  Thus, after several decades of development and optimization, there is now  
evidence that cancer vaccines may improve clinical outcomes, in partic ular in 
combination w ith other therapy.  
 
There is a  need to improve defined antigen s for melanoma  vaccines .  Peptide vaccines for 
melanoma offer the promise of inducing T cells reactive to w ell -characterized tumor antigens 
and also enabling assessment  of effectiveness of the vaccinations by monitoring antigen -
specific T cell responses.  How ever, clinical experience w ith peptide vaccines has been 
mixed.  On one hand, w e and others have found that selected peptides can induce 
circulating T cell responses  in a majority of patients,8;9 and that vaccination w ith a mixture of 
peptides can be immunogenic in up to 100% of patients.8  In some trials, circulating immune 
responses have correlated w ith clinical outcome8;10, but this has not been the rule.  Also, the 
magnitude of T cell responses so metimes is substantial, w ith 1 -5% of circulating CD8 T cells 
reactive to a single antigen 4;11;12; how ever, responses in most patients repr esent T cell 
percentages that are 1 -2 orders of magnitude low er, w hich may or may not be adequate for 
clinical benefit. The T cell responses to vaccines may be very durable, for months or years, 
but are at least as likely to be transient, sometimes declini ng even w hile still receiving 
vaccines.13 Clinically, there have been durable clinical responses in some patients receiving 
melanoma vaccines,  suggesting that there is clinical activity.14  How ever, the overall clinical 
response rates are only about 3 -5%.15  Thus, vaccines are not optimized, and both the 
antigens and the adjuvants may be improved.  
Long peptides .  Recent w ork w ith longer (30 -mer) peptides that encompass short minimal 
epitope peptides suggests that these longer peptides may be more effective immunogens 
than the minimal peptides. The extra length contributes to a tertiary structure that may 
protect f rom peptidases, and they are too long to be presented directly on MHC; so  
intracellular  processing is required.  Importantly, t his further ensures that the peptides are 
presented just on professional APC. A vaccine using long peptides for squamous vulvar 
neoplasia has been associated w ith high rates of clinical regressions.1  This proposal 
evaluates long peptides as immunogens for melanoma vaccines. It is for a first -in-human 
evaluation of safety and immunogenicity of  7 long peptides for  melanoma, w hich 
incorporate w ell -characterized minimal epitopes restricted by HLA -A1, A2, and A3  and 
HLA-B35/51 .   
Adjuvants for cancer vaccines . Some data have challenged the effectiveness of the 
current formulation of incomplete Freund’s adjuvant (IFA) w ith a peptide vaccine, 
especially for induction of Th1/Tc1 T cell responses ,16 w hile data from our ow n 
experience supports its  adjuvant icity17. How ever, data from our ow n experience, and f rom 
our collaborators also show  that vaccines using short peptides in IFA induce chronic 
inflammation at the site of vaccination that attracts and retains antigen -specific T cells at 
the vaccine site and may cause T cell dysfunction 18;19. Thus, there is a need to optimize 
adjuvants; there also is reason to expect that IFA w ill function differently w ith long than 
w ith short peptides, as the epitopes derived fr om processing the long peptides w ill be 
presented in the draining nodes, rather at the sites of  vaccination.  
Toll-like receptor (TLR) agonists offer the potential to improve the magnitude and 
persistence of antitumor T cell responses 4; how ever, most trials of TLR agonists have 
been limited to use of one TLR agonist formulation, and have not defined the molecular 
and cellular effects at the vaccine site microenvironment (VSME).  In the present study, 
w e propose to test each of 2 TLR agonists  in parallel  and in combination, w ith or w ithout 
IFA, and to evaluate the added value over IFA alone. These include agonists for TLR3, 
TLR7, and TLR 8, to be administered locally at the site of vaccination.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 16 Combination immune therapy : This proposal w ill en able selection of an effective 
immunization strategy for combination w ith other effective systemic immune therapies in  
future studies .  Vaccination w ith a single HLA -A2 restricted peptide in IFA improved 
response rate and progression -free survival w hen com bined w ith HD IL2 in a randomized 
prospective trial  for Stage IV melanoma5. Progression -free survival w as the primary 
endpoint for that study. Despite the fact that the study w as not pow ered to detect 
differences in survival, the vaccine -treated patients had a strong trend to improvement in 
overall survival  (p = 0.06)5. How ever, vaccination w ith HLA -A2 peptides plus IFA alone in 
another study had no impact on clinical response.20 The trial that produced th e 
encouraging positive finding in combination w ith HD IL2 needs to repeated both for 
confirmation of benefit and to evaluate impact on survival in an adequately sized study.  
Recent concerns w ith the inadequacy of IFA alone as an adjuvant have prevented 
inves tigators from moving to a confirmatory trial until a more optimal adjuvant is available.   
Other preclinical studies show  that adding a vaccine to adoptive T cell therapy increases 
its therapeutic efficacy.21-24 Also, vaccination can synergize w ith PD1/PDL1 blockade to 
increase immune responses and tumor  control.25  Thus, there is evidence to support the 
value of combining vaccin es plus any of several effective immune therapies.  How ever, 
vaccines are not yet optimized.  The present application w ill test a vaccine comprised of 
multiple long peptides and multiple adjuvants. The use of peptides restricted by HLA -A1, 
A2, A3 , and B al leles has a significant advantage for speeding accrual for a future 
definitive trial by almost doubling potential eligibility  over HLA -A2 restriction alone  (more 
than 80% vs. 45% HLA appropriate).  
Vaccine site selection:   Preliminary data from analysis of several clinical trials of peptide 
vaccines at the University of Virginia suggests that patients w ho have been vaccinated at 
the same skin site each w eek (for at least 3 vaccines, same site vaccination) have had 
stronger T cell responses than those w ith va ccines administered to a different skin site 
w ith each vaccine (rotating vaccine sites).  How ever, those data w ere based on 
retrospective assessments among trials w ith varied vaccine adjuvants and over extending 
time periods.  Also, the differences w ere no t definitive enough to be assured that site 
makes a difference in outcome, We hypothesize that same site vaccination w ith LPV7 w ill 
be safe and w ill result in stronger CD4+ and CD8+ T cell responses to those peptides.  
Preliminary data from Part 2 w ill assess w hether there may be a basis for exploring this 
question in a definitive randomized trial , and w ill provide a basis for pow ering such a 
study.  
 
1.2   Vaccine Design and Surgical Excision  
 
1.2.1   Antigen -Specific Immune Responses Induced by Peptide Vaccines  
We have substantial experience in studies w ith multipeptide vaccines, and w ith high 
antigen -specific immune response rates in the peripheral blood and in vaccine -draining 
nodes.8;9;12  These provide a strong foundation for evaluation of the multipeptide vaccines 
proposed in this application, and for the immunologic analyses.  
1.2.2   Melanoma Peptides Restricted by MHC Class I Molecules and Incorporated in the 
prior vaccine trials,  that are select ed for use in the LPV7  mixture  
Antigens representing the majority of melanoma -associated antigens identified thus far can 
be divided into tw o groups.  The first group consists of melanocytic differentiation proteins 
(MDP); such antigens are only expressed on cells of the melanocytic lineage and include 
MART -1/MelanA, gp100/Pmel17, tyrosinase, TRP -1/gp75 and TRP -2 proteins.  The second 
group consists of cancer -testis antigens (CTA) such as MAGE proteins, LAGE -1, and NY -
ESO-1.  These proteins are encoded by g enes expressed in several tumors of different 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 17 histologic types, but not in normal tissues, other than testis and placenta.  Peptides derived 
from these proteins are recognized by CTL in the context of various HLA allele s.  
 
Melanocytic differentiation prot eins: Gp100 is an enzyme involved in melanin synthesis.  
Multiple epitopes restricted by Class I MHC molecules have been identified from this protein, 
including peptides restricted by HLA -A2, and HLA-A3 26-28, and w e chose to incorporate  in 
the present proposal long peptides that represent the follow ing short epitopes:  gp100 209-217-
2M IMDQVPFSV (substitution of M for T at position 210; HLA -A2), and ALLAVGATK (HLA -
A3 17-25). The parent gp100 209-217 epitope (ITDQVPFSV) has been modified to incorporate a 
methionine residue at position 210 of the peptide (IMDQVPFSV).  This modification 
increases the binding affinity of the IMDQVPFSV peptide for HLA -A2 and i ncreases its 
immunogenicity in vivo  w hen compared to the native peptide29;30.  Another  gp100 derived 
epitope, ALLAVGATK, is also naturally processed and presented by melanoma cells, and 
holds promise for induction of HLA -A3 restricted responses in vivo 28.  CD8+ T cell  
responses to the ALLAVGATK peptide have been detected in multiple prior melanoma 
vaccine trials 12;31 -34. T-cell lines cultured from lymphocytes infiltrating human melanomas, 
w hen administered adopt ively to participants w ith metastatic melanoma, have induced 
partial or complete remissions in a large subset of participants. Clinical response to this 
therapy has been reported to be increased w hen the T -cells used for therapy recognize 
peptides derived from Pmel -17/gp100 35.  Thus, there is substantial evidence to support the 
use of the gp100 -derived peptides in the melanoma vaccines . 
 
Tyrosinase is an enzyme involved w ith melanin synthesis.  Epitopes derived from tyrosinase 
have been identified for HLA -A1, HLA -A2, and other class I alleles 26.  In the proposed 
study, w e are including long peptides incorporating one epitope (DAEKSDICTDEY ) 
restricted by HLA -A1 and one epitope (YMDGTMSQV) restricted by HLA -A2.  The parent 
epitope of tyrosinase 240-251, DAEKCDICTDEY, has been modified to incorporate a serine 
residue a t position 244 of the peptide (DAEKSDICTDEY). This modification prevents 
disulfide bond formation w ithin the peptide, but does not interfere w ith HLA -A1 binding or 
w ith T cell recognition 36. In phase II clinical trials conducted by the UVA HITC (UVA -Mel31,  
Mel36, Mel39 , Mel43, and Mel44 ), immunological responses against the DAEKSDICTDEY 
peptide w ere detected as the dominant peptide target for  participants w ho expressed HLA -
A1 and w ho w ere immunized w ith a synthetic peptide mixture containing the 
DAEKSDICTDEY peptide12;31 -34. CTL cultured from a vaccine draining node (sentinel 
immunized node, SIN) after vaccination w ith DAEKSDICTDEY w ere capable of lysing HL A-
A1+ tumor cells naturally expressing tyrosinase37.   The naturally occurring HLA -A2 restricted 
epitope from tyrosinase, tyrosinase 369-377 YMDGTMSQV, contains a post -translational 
modification of an asparagine to aspar tic acid at residue 371 38.  In phase II clinical trials 
conducted by the UVA HITC , immunological responses to the YMDGTMSQV peptide have 
been detected frequently in  stage III and IV melanoma participants w ho expressed HLA -A2, 
and w ere immunized w ith a synthetic peptide mixture containing this peptide 12;31 -34.   
 
MAGE -A1 and MAGE -A10 are members of the MAGE gene family and are expressed in the 
testes, as w ell as in several different tumor types such as melanoma, breast, prostate, 
esophagus, colon, and lung 26. One epitope derived from MAGE -A1 (SLFRAVITK) is 
included in the proposed study.  The MAGE -A1 96-104 epitope (SLFRAVITK) w as identified by 
Chaux et al. 39, and w as first  tested in humans in UVA-Mel39, in w hich immunogenicity and 
safety have been demonstrated 33.  It is a highly immunogenic peptide in the Mel39, Mel43, 
and Mel44 trials  8;12;40.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 18 The MAGE -A10 254-262 epitope (GLYDGMEHL) w as identified by Huang et al.,  and w as 
show n to be naturally processed and presented by HLA -A2+/MAGE -A10+ melanoma cell 
lines.41  In a report by Valmori et al., CTL responses to this epitope w ere readily detected in 
tw o-thirds of participants w ith melanoma w hose tumors tested positive for the expression of 
MAGE -A10.42  How ever, the ability of MAGE -A10 synthetic peptide to stimulate immunologic 
responses in humans had not been tested until UVA -Mel39, in w hich immunogenicity and 
safety have been demonstrated  and this w as found to be very immunogenic33. Follow up 
studies further support immunogenicity of this MAGE -A10 peptide12;34. 
 
The cancer testis antigen NY -ESO-1 has been extensively studied in human clinical trials , 
including peptide, protein, and DNA2;43-46.  Recently, a set of 4 overlapping long (30 -mer) 
peptides have been tested for safety and immunogenicity in patients w ith NY -ESO-1+ 
ovarian cancer, using either IFA alone, or IFA plus polyICLC (1.4 mg) 2.  That study 
incorporated the NY -ESO-1 peptide to be used in the c urrent trial (NY -ESO-179-108; CD4+ 
and CD8+ T cell responses w ere induced to a mixture of peptides covering the NY -ESO-1 
sequence over residues 79 -130, in a majority of evaluated patients.  
 
For the present study, the  7 peptides  have been  selected for use as long peptides. Their 
sequences are listed in Table 2  in the protocol précis.   The reason for selecting six of them 
is that their minimal epitopes are  among the  most immunogenic in the set of  12 peptides 
included in our prior trials 12;33;34: DAEKSDICTDEY, YMDGTMSQV, IMDQVPFSV, 
GLYDGMEHL, ALLAVGATK, SLFRAVITK, and they have been administered safely 12;33;34. 
We had al so selected the peptide EVDPIGHLY from those prior trials, but t he long peptide 
encompassing EVDPGIHLY could not be synthesized w ith adequate purity; the remaining 6 
peptides w ere selected for use.  
 
The NY -ESO-179-108 peptide w as included based on  the enc ouraging immunogenicity and 
safety findings referred to above  w ith four NY-ESO-1 peptides2.  Among the four peptides 
used in that trial, this one w as available  in adequate quantity as GMP -grade preparation.   
 
Selection and synthesis of l ong peptides  encompassing the short peptide antigens :  The 
NY-ESO-179-108 peptide incorporates a defined nonamer epitope r estricted by HLA -B35 and 
HLA-B51; the sequence w as one of 4 previously used as the 30 -mer peptide in a phase I 
trial.  For the present study, the 7 long peptides selected  for use have been designed to 
incorporate the minimal epitope sequences above, plus extension at the N and C terminal 
ends, w ith attention to avoid N -terminal glutamic acid or glutamine residues, to minimize 
cysteine residues, and to maximize incorporatio n of polar residues to aid in aqueous 
solubility. Their sequences are listed in Table 2  in the protocol précis.   
 
1.2.3   Montanide ISA -51 as a Vaccine Adjuvant .    
Montanide  adjuvant has been effective at inducing immune responses against murine viral 
antigens w hen administered w ith a synthetic peptide epitope 47;48.  Montanide ISA -51 has 
also been used w ith peptide s plus GM -CSF-in-adjuvant vaccine useful for enhancing both 
cellular and humoral immunity .49  The product consists of a mineral oil base comparable to 
incomplete Freund's adjuvant.  How ever, the Arlacel A emulsifying agent of incomplete 
Freund's, w hich has caused reactions in the past, has been replaced w ith a purified 
mannoside monooleate called "montanide", w hich appears to be safer. The UVA HITC has 
sponsored studies w here peptide -based vaccines in Montanide ISA -51 have been safely 
administered to more than 500 participants.  Immunological responses against t he 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 19 immunizing peptides have been detected in most participants.   Our recent experience w ith 
the current formulation of this adjuvant is published.17;50    
 
1.2.4   PolyICLC (Hiltonol, Oncovir Inc.) , TLR3 agonist.   
Polyinosinic -Polycytidylic acid (PolyIC) is a double -stranded  RNA (dsRNA) that acts as a 
TLR3 agonist. How ever, its short half -life limits its usefulness. To increase half -life and its 
practical use in clin ical settings, it has been stabilized w ith polylysine and 
carboxymethylcellulose as polyICLC. Like poly IC, polyICLC is a TLR3 agonist.  TLR3 is 
expressed in the early endosome of myeloid DC; thus polyICLC preferentially activates 
myeloid dendritic cells, f avoring a Th1 cytotoxic T -cell response.51;52 PolyICLC also activates 
NK cells and induces cytolytic potential.52 It has been administered in the emulsion w ith 
Montanide ISA -51 plus long peptides , w ith increased immunogenicity over Montanide ISA -
51 plus peptides alone; the combination w as safe, w ith some sig nificant local reactions but 
no DLTs 2. 
 
Source :  Hiltonol is pro vided by the Ludw ig Institute for Cancer Research and its Cancer 
Vaccine Consortium at no charge; as they have purchased a lot of it from Dr. Andres 
Salazar from Oncovir, Inc. (Washington, D.C.; letter provided ). It is provided as a clinical 
grade reagent for experimental use in single -use vials containing 1 mL of a 2 mg/mL 
solution.   
 
Dosing and preparation : It has been used safely in cancer patients, w ith intravenous doses 
up to 300 mcg/kg.53 We w ill administer 1 mg (0.5 m L) per vaccine, as used in other trials 
(e.g.: [STUDY_ID_REMOVED]).    
 
1.2.5   Resiquimod: TLR7 and 8 agonist .  
This agent is an agonist for both TLR7 and TLR8. TLR8 activation may reduce regulatory T 
cells.54 It has been safe w hen administered topically as a 0.05% gel once a w eek; more 
frequent administration led to dose -limiting local skin toxicity .55 Thus, w eekly dosing is 
selected for this trial. Other human experience w ith resiquimod is that oral dosing at 0.01 
mg/kg (700 mcg/70kg ) caused increases in serum IFN -alpha w ith associated side effects, 
but it w as w ell tolerated.56   It has been used ([STUDY_ID_REMOVED]) safely at 500 mg 0.2% 
resiquimod gel per application up to 3x/w eek after each vaccine, w ith the dose spread over 
a 25 cm2 area each time.  
 
Source : Resiquimod is provided by 3M Pharmaceuticals, St. Paul, MN.  It is not yet FDA 
approved, but is available as a clinical grade reagent for topical use.  We have approval 
from Mark Tomai at 3M to provide it for clinical use as a vaccine adjuvant.   
Dosing and preparation : Multi-dose tubes contain approximately 3 grams of 0.2% 
resiquimod gel.  The dose of resiquimod in 500 mg of 0.2% resiquimod gel is 1000 mcg.  
Immediately after vaccine injection,  measure out approximately 500 mg of 0.2% resiquimod 
on dosing paper and apply  resiquimod  gel w ith a gloved finger over a 2 5 cm2 area of the 
skin at the vaccine site .  Using this dosing method, the dose range of resiquimod w ill be 
approximately 400 -600 mg.  Rub the gel into the skin for 1 minute until it vanishes.   
Follow ing application, the site may be covered w ith an occlusive dr essing, such as 
Tegaderm, for about 8 hours.  Participants are encouraged to w ash the area at 8 hours 
after application. The tubes may be retained in the investigational pharmacy betw een 
uses.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 20 1.2.6   Integration of Peptide -Based Vaccines in the Adjuvant Setting   
High-dose interferon (IFN -alpha  therapy) is approved by the FDA for use in patients w ith 
resected stage IIB or III melanoma treated in the adjuvant setting.  Approval w as based 
largely on survival improvement observed follow ing a one -year regimen w ith IFN as 
described in ECOG 1684 .57  How ever, survival improvement is modest and data from a 
subsequent trial, ECOG 1690, failed to reproduce differences in survival .58  Data from a third 
trial, ECOG 1694, reveal a statistically significant, but still modest, survival improvement w ith 
IFN therapy compared to a ganglioside vaccine .59  Thus, any patient w ith resected stage IIB 
or III melanoma should be offered IFN therapy, w hich is routine practice at UVA  and 
MDACC . How ever, the toxicity of high -dose IFN therapy is substantial.  Approximately 25 -
30% of patients w ithdraw  from thera py because of toxicity, and approximately 60% of 
patients require dose reductions during treatment .57   
 
Ipilimamb 10mg/kg is approved by the FDA for use in the adjuvant setting for patients w ho 
have undergone complete resection of cutaneous melanoma w ith pathol ogical involvement 
of regional lymph nodes greater than 1  mm. Approval w as based largely on results from the 
the Phase 3 EORTC 18071/CA184029 trial .84 The ipilimumab 10mg/kg treatment yielded 
statistically significant prolonged distant metast asis-free survival, w ith five -year distant 
metastasis -free survival  rate 9% higher than the placebo.  How ever, the toxicty of 
ipilimumab 10mg/kg is is substantial, w ith approximately 50% of patients w ho started 
ipilimumab w ithdraw ing as a result of ipilimumab related toxicities.  
 
The experience at UVA is that most patients w ho  are candidates for therapy refuse IFN 
because of concerns w ith toxicity, despite being informed IFN therapy is one of the few  FDA 
approved adjuvant therap ies for melanoma and that therapy may provide a survival 
advantage.  In addition, many patients are not eligible for the current approved dose of 
ipilimumab (10 mg/kg) or decline treatment w ith ipilimumab because of the potential for 
serious immune -related toxicities .  Recent data from the E1609 study presented at ASCO  
show ed that there w as no  difference in disease -free-survival betw een ipilimumab 3 mg/kg 
and ipilimumab 10 mg/kg  (E1609); how ever , ipilimumab 10 mg/kg  w as associated w ith 
greater toxicity .85  Thus, f uture approved treatment options may include ipilimumab 
administered at the low er  dose of 3 mg/kg , although even the low er dose carries risk of 
death .  The same may be true for other checkpoint inhibitors  that are currently being 
explored in the adjuvant setting (e.g. PD -1 blockade).  
 
1.2.7   Toxicology  
There is no reason to expect direct toxicity of the melanoma peptides; they are not directly 
cytotoxic in vitr o and are not expected to have functional implications .  On the other hand, 
because some of these peptides are identical or similar to a portion of a normal protein, risks 
of autoimmunity in humans are reasonable to evaluate.  Unfortunately,  there is no murine 
system adequately modeling the human immune response to these peptides.  The most 
meaningful evaluation of this peptide vaccine mixture is in patients w ith melanoma.  This trial 
is for participants w ith resected stage IIB/C, III, or IV NED melanoma .  These individuals 
face a high risk (> 40%) of death  from melanoma , and the anticipated risk of short -term or 
long-term toxicity of this vaccine preparation is minimal, w hile the vaccine may delay or 
decrease the risk of morbidity and mortali ty due to melanoma in these participants.  The 
potential implications of autoimmunity against cells of melanocytic lineage are illustrated by 
reported cases of vitiligo occurring coincident w ith regressions of melanoma .60  Most of 
these are limited, often occurring in s kin surrounding the regressing melanoma, but 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 21 occasionally occurring systemically. While pathogenesis of this phenomenon can only be 
hypothesized, it is reasonable to consider this a w orst -case scenario.  
 
The loss of skin and hair pigment can be striking i n cases  of vitiligo , but is not a cause of 
morbidity or mortality.  Of greater potential concern is the theoretical risk of damage to the 
retinal pigment epithelium; how ever, visual loss has not been reported either as a 
complication of successful immunoth erapy w ith melanoma -reactive CTL or spontaneous 
vitiligo.  How ever, some ocular toxicity has been reported that resolved w ith steroid 
treatment .61   
 
Depigmentation of the retinal pigment epithelium has been observed in a small number of 
patients vaccinated w ith dendritic cells pulsed w ith MDP -derived peptides; how ever, this 
change w as asymptomati c and w as not associated w ith loss of visual acuity (personal 
communication – Frank Haluska).  A careful study of the retinal pigment epithelium using 
monobenzyl ether of hydroquinone to induce pigment cell destruction on a biochemical 
basis suggests the s afety of pigment cell destruction and supports immunotherapy directed 
against MDP as a strategy for melanoma therapy (personal communication, JM Kirkw ood).   
 
Thus far, 10 -15% of participants receiving peptide -based vaccines in the studies at UVA 
w ere diagnosed w ith definite vitiligo.  In all cases, the vitiligo w as asymptomatic.  No major 
visual/ocular toxicity w as reported for participants  on these prior trial s. 
 
Toxicities Previously Reported for Participants Receiving the 12 -MP vaccine administered in 
Montanide ISA -51 adjuvant  
Participants have been  vaccinated w ith a mixture of 12 short  melanoma peptide mixture, 
plus tetanus peptide, in Montanide ISA -51 adjuv ant (MELITAC 12.1)  in 62 participants on 
the UVA -Mel43 trial, to  about 8 0 participants in the UVA -Mel44 trial , and to about 40 
participants on the UVA -Mel48 trial .  Toxicity data for the first 102 participants on the Mel43 
and Mel44 trials w ere graded usin g the NCI Common Terminology Criteria for Adverse 
Events v3.0 and are listed regardless of attribution.  Maximum Grade 2 -4 toxicities 
experienced by at least 10% of participants are listed in Table 3 : 
 
Table 3 .  Toxicities related to administration of MELI TAC 12.1 melanoma 
vaccine administered with Montanide ISA -51 (IFA) in 102 patients on 
UVA-Mel43 and UVA -Mel44 clinical trials  
Toxicity  Grade 2  Grade 3  
Fatigue (lethargy, malaise, asthenia)  17% 3% 
Injection site reaction  87% 2% 
Ulceration  7% 3% 
 
The grading of injection site reactions w as modified from CTC v2.0 to CTCAE v3.0 , and now  
to v4.0 3.  CTC v2.0 did not have an ulceration Adverse Event Term, therefore participants 
w ith ulceration in conjunction w ith an injection site reaction w ere graded as experiencing a 
Grade 3 injection site reaction (ulceration or necrosis that is severe; operative  intervention 
indicated).  In prior UVA HITC studies, an injection site reaction w ith ulceration ≤ 2 cm in 
maximal diameter w as an expected adverse event in a subset of participants.  How ever, an 
injection site reaction that included ulceration >2 cm in di ameter, or an injection site reaction 
requiring debridement, narcotic analgesics for pain, or surgery w as not an expected toxicity 
and w as considered a dose -limiting toxicity (DLT) and w as graded as a Grade 3 injection 
site reaction. UVA -Mel43 used the CTC  v2.0 grading system w hereas UVA -Mel44 used the 
CTCAE v3.0 grading system.  In CTCAE v3.0, ulceration is a separate Adverse Event Term; 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 22 therefore, ulceration and injection site reactions can be graded separately .  For this study, 
participants w ho experienc e induration at their injection site, both injection site reaction and 
induration w ill be graded and reported.   The data in Table 3  have been corrected to be 
consistent w ith CTCAE v3.0. The criteria for each of these toxicity cat egories (fatigue, 
injection site reaction, and ulceration) have changed from v3.0 to v4.03, but are very similar.  
Thus, they are probably comparable, but the exact details for assessing them in v4.03 
require information that w as not collected at the time those studies w ere performed.  In the 
proposed study , w e w ill grade based on v4.03 , and w e do not expect Grade 3 injection site 
reactions; ulceration and injection site reaction toxicities w ill be expected at Grade 2.    
 
1.2.8   Patient acceptance of biopsies of skin at the Vaccine Site  
This study w ill include three punch biopsies 4mm in diameter of the vacc ine site, on tw o 
dates.  We have previously performed much larger  excision s of skin and subcutaneous 
tissue approximately 2 x 4 -6 cm in size.50  There w ere questions, prior to that study, of 
whether that size excision w ould be  too large to expect participants to tolerate or to accept  it.  
As a surgeon, the Principal Investigator (PI) routinely performs excisions 2 -4 cm w ide (an d 
about 6 -12 cm long) in patients w hen they have w ide excisions of melanoma, and these can 
reliably be closed primarily, w ithout a skin graft, w hen taken from the upper thigh and upper 
arm.  Thus, excisions of a 2x4 cm skin section (regardless of depth) ca n be closed primarily 
w ith minimal morbidity on those locations w here the vaccines w ould be given.   
 
Also, w e surveyed a convenience sample of 52 of our patients during clinic visits for their 
w illingness (on a scale of 1 to 9) to participate in a clinical trial of a melanoma vaccine w ith 
or w ithout a skin biopsy.  Forty -three (43) of the 52 patients (83% ), answ ered some of the 
questions, and 37 (71%) answ ered all questions.  Findings are summarized in Table 4  below  
and have been published62.  Willingness to enter such a trial w as d iminished by any biopsy 
requirement, but interest in accrual remained high even w ith a biopsy.  Interestingly the size 
of the biopsy had a much smaller impact than the fact that any biopsy w as required.  In prior 
trials, w e have included excision of a vacc ine-draining lymph node (sentinel immunized 
node), w hich requires a 3 cm incision, and w e have done over 150 of such biopsies on 
vaccine patients .31-33;37    Based on that questionnaire, patients w ere expected to  be about 
70-80% as likely to enroll on a trial w ith a 6 cm excision vs. a 3 cm excision  as w ithout a 
biopsy .  The actual accrual matched closely the predicted accrual .62 
 
The present proposal is to remove much less skin that w as done in that prior protocol 
(Mel48).   Thus, w e anticipate rapid accrual and high patient acceptance.  We typically have 
accrued 40 -60 patients per year on trials w ith sentinel immu nized node biopsies; so if w e 
accrue at even half that rate (20 -30 per year), w e expect to meet accrual goals.   
 
Table 4.  Findings from vaccine biopsy questionnaire  (n = 91)  
Willingness to enter 
vaccine trial with  or 
without skin excision  N  Likely (5)  
to highly likely  (9)  Moderately likely (7)  
to highly likely (9)  Highly likely  
(score 9)  
No skin excision  43 95 % 69 % 54 % 
3 cm scar  37 74 % 47 % 28 % 
 
1.2.9   Regulatory Issues  
The peptides for this trial have been  synthesized under G MP conditions by a commercial 
provider.  Prior experience has been w ith peptides  made by Polypeptide Group , San Diego, 
California.  They have been vialed under GLP conditions in our HITC lab clean room, w hich 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 23 has limited access, an entry room for gow ning and gloving, and positive pressure ventilation 
and laminar flow  hoods.  Lot release testing of the final vialed peptide s w ill be completed in 
accord w ith CFR guidelines .  Stabi lity testing w ill be conducted regularly, in accord w ith the 
Chemistry and Manufacturing section o f the IND application . 
 
Montanide ISA -51 is produced by Seppic, Inc. (Fairfield, NJ  and Paris, France ).  A master 
drug file for Montanide  ISA-51 is filed w ith the FDA.  This agent has been used in hundreds 
of patients in our ow n experience and in thousands of patients w orldw ide.   
 
This study w ill be approved by the Institutional Review  Board (IRB) of the University of 
Virginia  and by the I RBs of M.D. Anderson Cancer Center .  This protocol w ill be submitted to 
the FDA as an  IND application.  Records of all study review  and approval documents w ill be 
kept on file by the Principal Investigator, and are subject to FDA inspection during or after  
completion of the study.  The Institutional Review  Board w ill receive notification of study 
closure w ithin three months of study termination or completion.   
           
This study w ill be conducted in compliance w ith Good Clinical Practices and regulation s. 
 
1.2.10    Same site vaccination (Part 2)  
The clinical trials group at the University of Virginia has extensive experience in several 
hundred patients w ith administering peptide vaccines in IFA, w ith or w ithout other immune 
modulators, at the same skin site for each vaccine. This has been w ell -tolerated 34;77-99.  
Later trials w ith rotating vaccine sites w ere performed for several reasons, but w ith the 
expectation that vaccine site reactions w ould be less prominent; how ever, overall vaccine 
site reactions have be en similar w ith both approaches ( Table 5 ): 
 
Table 5:  Vaccine Site Reactions  
 Clinical trial  N CTCAE  Grade 1  Grade 2  Grade 3  
Injection site reaction  Mel44  170 V3 17% 75% 4% 
Mel58  51 V4 35% 61% 0% 
Ulceration  Mel44  170 V3 1% 19% 6% 
Mel58  51 V4 0% 4% 2% 
Note: data are from the published data from the Mel44 trial 2 and the 2017 IND report for the Mel58 
trial. 
 
The LPV7 vaccine has been w ell -tolerated in the patients on Part 1.  Same site vaccinat ion 
w ill be assessed for safety/tolerability and immunogenicity in a pilot cohort in Part 2.  
 
 
2.0   STUDY OBJECTIVES  
 
2.1   Part 1 (completed)  
(1) To assess safety of vaccination w ith a mixture of long peptides for patients w ith high-
risk melanoma, in each of 7 adjuvant  preparations , including TLR agonists and/or 
incomplete Freund’s adjuvant (IFA)  
(2) To estimate the immunogenicity of  7 long peptides in each of 7 adjuvant preparations  
Exploratory  
(3) To evaluate the molecular and cellular changes at the vaccine site and systemically  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 24 2.2   Part 2  
(4) To assess safety of vaccination of the optimal combination identified in Part 1  w hen 
administered in the same skin site for all 6 vaccines (same site vaccination).  
(5) To estimate the immunogenicity of the optimal combination identified in Part 1 w hen 
administered in the same skin site for all 6 vaccines (same site vaccination).  
 
3.0   STUDY OUTLINE  
3.1   Type of Study  
This is an open -label, randomized, phase I/II study , using an ada ptive design,  to tes t the 
safety and immunogenicity of a novel melanoma vaccination approach using long peptides 
plus TLR agonists, along w ith characterization of cellular and molecular events at the 
cutaneous site of immunization.   
 
Regimen :   
Part 1:  Patients w ill be registered  on this phase I/II trial and w ill be vaccinated w ith LPV7  
at 300 mcg peptide/dose , and tetanus peptide at 200 mcg/dose,  every w eek x 3 then 
every 3 w eeks x 3.  The adjuvants are described, and w ill be administered to patie nts in  7 
study  groups as show n in Table s 1 and 5 .  This incorporates an adaptive design w ith  
sequential initiation of accrual to study Zones  w ith increasing numbers of adjuvants (Arms A -
C, then D -F, then G) and  a 3 w eek interval betw een subjects 1 and 2 of each arm of the 
study .  The design allow s, during that 3 w eek interval, randomization to arms  that remain 
open.  
Part 2:  Patients w ill be registered  on this phase I/II trial and w ill be vaccinated w ith LPV7  
at 300 mcg peptide/dose every w eek x 3 then every 3 w e eks x 3.  For part 2, the vaccine 
regimen is selected based on available data and the study decision rules from Part 1 w hich 
w as determined to be Arm E. For Part 2 accrual w ill be to  Study Arm E2.  How ever, a 
modification is made to exclude the tetanus help er peptide, due to (a) lack of availability of 
that peptide component, (b) the finding that, in part 1, LPV7 peptides do induce helper T cell 
responses themselves (unpublished data), and prior data that adding the tetanus helper 
peptide did not add signifi cantly to immunologic or clinical outcome of a peptide vaccine 
designed to induce CD8 T cells1. 
 
4.0   PARTICIPANT SELECTION  
 
All questions regarding eligibility should be directed to the Human Immune Therapy Center 
(HITC) at the University of Virginia . 
 
4.1   Inclusion Criteria  
4.1.1   Histologically or cytologically proven Stage IIB -IV melanoma  (at diagnosis or at the 
time of recurrence)  rendered clinically free of disease by surgery, other therapy, or 
spontaneous remission w ithin 6 months prior to registration ; patients w ith  treated  brain 
metastases may be eligible if they meet the criteria in 4.1.4.   Small radiologic or clinical 
finding s of an indeterminate nature w ill not be a basis for exclusion, and brain metastases 
treated in accord w ith section 4.1.4 w ill not be a basis for exclusion . 
 
Staging of cutaneous melanoma w ill be based on the 7th edition AJCC staging system  
(Appendix 2 )63. 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 25 Staging of mucosal melanomas w ill be based on the follow ing system modified from the 
cutaneous melanoma staging system:  2.01 - 4mm primary w ith ulceration or > 4mm 
primary= stage IIB, lymph node metastases = stage III, distant metastases = stage IV.  
 
4.1.2    Patients may have had multiple primary melanomas.  
4.1.3   Patients may have had or may have a metastasis from a cutaneous primary site, 
mucosal primary site, or unknow n   primary site.  
4.1.4   Patients w ith brain metastases may be eli gible if all of the follow ing are true:  
 The total number of brain metastases ever is less than or equal to 3.  
 The brain metastases have been completely removed by surgery or 
have been treated completely by stereotactic radiotherapy.  
Stereotactic radiother apy, such as gamma knife, can be used up to 1 
w eek prior to study entry.   In the absence of concerning clinical 
findings, repeat scans are not required after stereotactic radiotherapy if 
the patient enrolls w ithin 8 w eeks of completing the stereotactic 
therapy.  
 There has been no evident grow th of any brain metastasis since 
treatment.  
 No treated brain  metastasis is greater than 2 cm in diameter at the time 
of protocol entry.  
 
4.1.5   Patients must have at least one axillary and/or inguinal lymph node basin  that is  
intact (no prior excisional biopsy of a node or complete lymph node dissection).  
4.1.6   All patients must have:  
 ECOG performance status of 0  or 1. 
 Ability and w illingness to give informed consent.  
4.1.7   Laboratory parameters as follow s:  
1) HLA-A1, A2,  A3, B35, or B51.    
2) ANC > 1000/mm3, and Platelets > 100,000/mm3 and Hgb > 9 g/dL  
3) AST and ALT up to 2.5 x upper limits of normal (ULN) . Patients 
know n to have Gilbert’s disease may be eligible w ith AST and ALT 
up to 5 x ULN.  
4) Bilirubin up to 2.5 x ULN  
5) Alkaline phosphatase up to 2.5 x ULN .  
6) Creatinine up to 1.5 x ULN  
7) Hgb-A1C level of ≤ 7.5% 
4.1.8   Patients must be 18 years or older at study entry.  
 
4.2    Exclusion Criteria  
 
4.2.1   Patients w ho have had brain metastases unless they meet the criteria outlined in 
section 4.1.4.  
4.2.2   Patients w ith melanoma arising from uveal/ocular primary sites  
4.2.3   Patients w ho are currently receiving systemic cytotoxic chemotherapy, radiation,  
target ed molecular  therapy (e.g. vemurafenib , other inhibitor of mutant BRAF , MEK, or cKit ), 
or other experimental therapy, or w ho have received this therapy w ithin the preceding 4 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 26 w eeks  (except as specified in section 4.2.4 ).  Gamma knife or stereotactic radios urgery may 
be administered w ithin the prior 4 w eeks, but must not be administered less than one w eek 
prior to study registration .  Patients w ho are currently receiving nitrosoureas or w ho have 
received this therapy w ithin the preceding 6 w eeks  are excluded .   
4.2.4   Patients w ho are receiving or have been treated w ith antibody to CTLA4 ( e.g. 
ipilimumab), PD -1, PD -L1, CD137, or CD27 w ithin the prior 12  months.  Any patient w ho has 
had one or more of these therapies  greater than 12  months prior and is clinically fre e of 
disease and totally recovered from toxicities related to those therapies  can be  eligible .  
4.2.5   Patients w ith know n or suspected allergies to any component of the vaccine.  
4.2.6   HIV positivity  or evidence of active Hepatitis C virus.  
4.2.7   Patients receiving the follow ing medications at study entry or w ithin the preceding 4 
w eeks are excluded:  
1) Agents w ith putative immunomodulating activity (w ith the 
exception of non -steroidal anti -inflammatory agents and topical 
steroids (see section 4.2. 7 (3)). 
2) Allergy desensitiz ation injections.  
3) Systemic c orticosteroids, administered parenterally or orally.  
Inhaled steroids (e.g. Advair®, Flovent®, Azmacort®) are not 
permitted.  Topical corticosteroids are acceptable, including 
steroids w ith very low  solubility administered nasa lly for local 
effects only (e.g. Nasonex®). 
4) Any grow th factors (e.g. GM -CSF, G -CSF, erythropoietin).  
5) Interferon therapy.  
6) Interleukin -2 or other interleukins.  
7) For immune modulating agents referred to in 4.2. 3 and 4.2. 4, it 
may be necessary for more than 4 w eeks to have elapsed 
since completion of that therapy (as specified in those 
sections).  
 
4.2.8   Prior melanoma vaccinations may be an exclusion criterion in the follow ing 
circumstances:  
1) Patients w ho have received, w ithin the prior 5 years, 
melanoma vaccines or o ther vaccines containing an 
incomplete Freund’s adjuvant (IFA; such as Montanide ISA -
51).   
2) Patients w ho have  received any melanoma vaccine w ithin the 
past 12 months.  
3) Patients w ho have been vaccinated in the past w ith any of the 
melanoma peptides in the LPV7 vaccine included in this study.  
 
 
4.2.9   Other investigational drugs or investigational  therapy if the patient is currently taking 
those drugs/therapy, or if they have received the drugs/therapy w ithin 1 month.  
4.2.10   Pregnancy or the possibility of becoming pregnant  during vaccine administration.   
Female patients of child -bearing potential must have a negative pregnancy test (urinary or 
serum beta -HCG) prior to administration of the first vaccine dose.  Males and females must 
agree, in the consent form, to use effec tive birth control methods during the course of 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 27 vaccination.  Women must also not be breast feeding.  This is consistent w ith existing 
standards of practice for vaccine and chemotherapy protocols.  
4.2.11   Participants must not have had prior autoimmune disorders r equiring cytotoxic or 
immunosuppressive therapy, or autoimmune disorders w ith visceral involvement.  
Participants w ith an active autoimmune disorder requiring these therapies are also excluded.  
The follow ing w ill not be exclusionary:  
 The presence of labor atory evidence of autoimmune disease (e.g. 
positive ANA titer) w ithout symptoms  
 Clinical evidence of vitiligo  
 Hypothyroidism of any etiology on stable thyroid hormone 
replacement therapy.  
 Other forms of depigmenting illness  
 Mild arthritis requiring NSAID medications  
 
4.2.12   Patients in w hom there is a medical contraindication or potential problem in 
complying w ith the requirements of the protocol, in the opinion of the investigator.  
 
4.2.13   Patients classified according to the New  York Heart Association classification a s 
having Class III or IV heart disease ( Appendix 4 ). 
 
4.2.14   Patients w ith a body w eight < 110 lbs  (50 kg)  because of the amount and frequency 
w ith w hich blood w ill be draw n, and because of the skin biops ies required.  
 
4.3   Demograp hics of Participant Population  
4.3.1   Age:  18 years or older.   
4.3.2   Sex:  Both male and female participants are eligible.  
4.3.3   Race :  All races and ethnic backgrounds are eligible.  
 
4.4   Registration, Randomization, and Management of Participants  
 
4.4.1   Participant Registration  
All participants must sign the consent form prior to determination of eligibility for this study.  
Participants eligible for interferon therapy w ill complete the interferon education packet  and 
review  their answ ers w ith the study team  and convince the stud y team that they answ ered 
the questions accurately or understand the correct answ ers .  Registration information, the 
eligibility checklist w ith supporting documentation, and the on -study case report form for 
potential participants at institutions other tha n UVA must be received by the UVA HITC prior 
to registration and randomization.  All participants w ho meet the inclusion/exclusion criteria 
may be registered to the study.  Registration w ill occur follow ing verification of eligibility by 
the treating physi cian or institutional PI.    
4.4.2   Randomization  
Randomization w ill be discussed w ith participants during the process of informed consent , 
and informed consent must be documented prior to randomization.  Randomization w ill 
occur after registration and no sooner than 5 days prior to the start of treatment.   In part 1, 
randomization w ill be based on equal allocation among allow able arms unless a w eighted 
allocation scheme is triggered ( section 9.2 .1). Randomization w ill not be stratified by 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 28 institution.  The randomization codes are generated by the study statisticians and stored in 
the Cancer Cente r Clinical Trials Database .  The UVA HITC w ill communicate w ith the 
outside site to let them know  w hich s tudy arm a pa rticipant  has been randomized to.  
Participants should receive the first scheduled vaccination or biopsy (if applicable) w ithin 2 
w eeks  of registration . Part 2 w ill not include randomization.  
4.4.3   Management of Participants  
This study w ill be conducted on an outpatient basis, w ith participants scheduled to be 
evaluated on days 1, 8, 15, 22, 36,  43, 57, 78, and 85, and w eek 26  (or more often if needed 
for testing or medical reasons).  As needed, there may also be follow -up w ithin 1 -3 w eeks 
after biopsies performed on days 8 or 22  for w ound evaluation.  Participants w ill also be  
follow ed-up at 52 w eeks  (1 year) and at 2 years w ith blood draw s for studies of immune 
response durability.  During  off treatment follow -up, participants w ill be follow ed yearly for 
survival and disease status.  
 
 
5.0   STUDY MEDICATION FORMULATION, DOSAGE, ACCOUNTABILITY AND 
ADMINISTRATION  
 
5.1   Study Medication Formulation  
5.1.1   Peptide Synthesis and Storage  
All peptides are synthesized directly from amino acids , and then are purified by h igh 
performance liquid chromatography (HPLC).  The identity of the synthetic peptides w ill be  
confirmed by verifying their mass and amino acid sequences by mass spectrometry.  Details 
of the synthesis, certificates of analysis, and technical summaries are included in the 
Chemistry and Manufacturing section of the IND application. Each bulk peptide is supplied 
as lyophilized pow der w ithout excipients and stored at a temperature ≤ -70°C and protected 
from light.  
 
5.1.2   Preparation of peptide vaccine vials for patient use.  
For the 6 peptides prepared at UVA, the bulk peptides are solubilized in aqueous solution , 
sterile -filtered , and mixed  to provide a final  concentration of 600 mcg/ml for each of the 6 
peptides.  The peptide mixture is  then aliquoted at 1 ml pe r vial into sterile borosilicate vials  
in the HITC clean room .  The mixture is slightly cloudy, as the pH of the mixture supports 
solubility of most of the peptides, but some peptides are partially in suspension at that pH.  
The 7th peptide, from NY -ESO-1 is provided as single use vials of lyophilized peptide, at 600 
mcg/vial, from the Ludw ig Institute for Cancer Research, prepared under GMP conditions.  
 
5.1.3   Storage of Vialed Peptides  
The vials of peptide are stored by the HITC at a temperature ≤ -70°C and prot ected from 
light.  On the day of use, they are thaw ed at room  temperature or in a w ater bath up to 
37°C.  They should be sw irled gently as they are thaw ed and moved to a refrigerator as 
soon as they are thaw ed if not being injected immediately. Once thaw e d, the vial(s) must be 
used for preparation of the vaccine w ithin 24 hours.  
 
5.1.4   Lot Testing  
Each lot of peptide vaccine is evaluated as required by the FDA to confirm identity, sterility, 
general safety, purity, lack of peptide aggregation and is tested for endotoxin .  In addition, 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 29 studies of stability w ill be performed  over time .  The details of these tests are outlined in 
Appendix 5 . 
 
5.1.5   Labeling  
The labeling of vials w ill occur as specified below .  
 
Each vial of lyophilized  peptide is labeled w ith the follow ing information:  
Short name of the product :  “LPV 6” 
Product number    
Proper name of the product :  “6 long melanoma peptides”  
Name and address of the vialing facility :  “UVA -HITC”  
Lot number  
Date of manufacture (the date of vialing the reconstituted peptides)  
Serial number  
Quantity of each peptide per vial :  600 mcg/ml  
Vial contains no preservative, store at ≤ -70°C 
“Caution:  New  Drug – Limited by US Federal law  to investigational use”  
 
5.2   Preparation, Dosage, and Storage of  Study Drug  
5.2.1   Dosage and Preparation of Peptide Vaccine   
Part 1:  
The peptides w ill be prepared by combining the LPV 6 mixture of 6 peptides w ith one NY -
ESO-1 long peptide.  The long melanoma peptides ( LPV6) w ill be available as single -use 
vials of 1 ml volume  containing 600 mcg/ml of each peptide . The NY-ESO-1 peptide is 
provided as lyophilized preparation  w ith 600 mcg of peptide  in single use vials.   The tetanus 
peptide is vialed as 300 mcg lyophilized peptide per vial.  For each vaccine, the full 1  ml of 
the peptide solution  of LPV6 (600 mcg) w ill be w ithdraw n  and injected into the vial of 
lyophilized NY -ESO-1 peptide, creating a solution/suspension of all  7 long peptides, each at 
600 mcg/ml.  Then 0.75 ml of this suspension/solution w ill be w ithdra w n and injected into 
one vial of lyophilized tetanus peptide, to create a suspension/ solution of 450 mcg of each of 
the 7 long peptides, and 300 mcg of tetanus peptide in 0.75 ml. Then,  the full  0.75 ml of this 
solution /suspension  (450 mcg of all 7 long peptides, plus 300 mcg tetanus peptide) w ill be 
w ithdraw n into a syringe for injection as specified below  for each study arm.  Details of 
making emulsions w ith IFA (Montanide ISA -51) are provided in the Investigator’s Brochure  
and Study Manual .   
 
Part 2:  
The peptides w ill be prepared by combining the LPV6 mixture of 6 peptides w ith one NY -
ESO-1 long peptide.  The long melanoma peptides (LPV6) w ill be available as single -use 
vials of 1 ml volume containing 600 mcg/ml of each peptide. The NY-ESO-1 peptide is 
provided as lyophilized preparation w ith 600 mcg of peptide in single use vials.   For each 
vaccine, the full 1 ml of the peptide solution of LPV6 (600 mcg) w ill be w ithdraw n and 
injected into the vial of lyophilized NY -ESO-1 peptide, creating a solution/sus pension of all 7 
long peptides, each at 600 mcg/ml.  Then 0.75 ml of this solution/suspension (450 mcg of all 
7 long peptides) w ill be w ithdraw n into a syringe for injection as specified below  for each 
study arm.  Details of making emulsions w ith IFA (Mont anide ISA -51) are provided in the 
Investigator’s Brochure and Study Manual.   
 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 30 Study Arm A (IFA) :  Sterile saline solution 0. 75ml w ill be added to 0. 75 ml of LPV7  + 
tetanus peptide  (total 1.5 ml) . This w ill be combined w ith 1 .5 ml of Montanide  ISA-51VG to 
create an emulsion . Tw o (2) ml w ill be injected half -intradermally and half -subcutaneously in 
one skin location.  
Study Arm B (polyICLC) :  PolyICLC (Hiltonol) is provided from Oncovir, Inc. (Washington, 
D.C.) as a clinical grade reagent for exp erimental use in single -use vials containing 1 mL of 
a 2 mg/mL solution.  We w ill administer 1 mg (0.5 ml) per vaccine. PolyICLC (Hiltonol) 0. 75 
ml w ill be added to 0.75 ml of LPV7 + tetanus peptide. One (1) ml of this w ill be injected half -
intradermally an d half -subcutaneously in one skin location.  
Study Arm C (resiquimod) :  Resiquimod  is provided by 3M (Minneapolis, MN) and is  
packaged in multi-dose tubes  (typically 3 g of 0.2% gel). Sterile saline solution 0. 75ml w ill be 
added to 0. 75 ml of LPV7 + tetanus  peptide. One (1) ml of this w ill be injected half -
intradermally and half -subcutaneously in one skin location. Immediately after vaccine 
injection , apply approximately 500 mg  of 0.2% resiquimod  gel w ith a gloved finger over a 
25 cm2 area of the skin at the  vaccine site. Rub the gel into the skin fo r 1 minute until it 
vanishes.  Follow ing application, the site may be covered w ith an occlusive dressing, such 
as Tegaderm, for about 8 hours.  Participants are encouraged to w ash the area at 8 
hours after application.  
Study Arm D (polyICLC + resiquimod) :  PolyICLC (Hiltonol) 0. 75 ml w ill be added to 0.75 
ml of LPV7 + tetanus peptide. One (1) ml of this w ill be injected half -intradermally and half -
subcutaneously in one skin location  Immediately after vaccine  injection , apply 
approximately 500 mg of 0.2% resiquimod gel w ith a gloved finger over a 2 5 cm2 area of 
the skin at the vaccine site. Rub the gel into the skin for 1 minute until it vanishes.  
Follow ing application, the site may be covered w ith an occlusiv e dressing, such as 
Tegaderm, for about 8 hours.  Participants are encouraged to w ash the area at 8 hours 
after application.  
Study Arm E (IFA + polyICLC) :  Part 1:  PolyICLC (0.75 ml)  w ill be added to 0. 75 ml of 
LPV7 + tetanus peptide  (total 1.5 ml) . This w ill be combined w ith 1 .5 ml of Montanide ISA -
51VG to create an emulsion . Tw o (2) ml w ill be  injected half -intradermally and half -
subcutaneously in one skin location.   
 
Study Arm E2 (IFA + polyICLC):  Part 2:    PolyICLC (0.75 ml)  w ill be added to 0. 75 ml of 
LPV7 (total 1.5 ml). This w ill be combined w ith 1.5 ml of Montanide ISA -51VG to create an 
emulsion. Tw o (2) ml w ill be injected half -intradermally and half -subcutaneously in one skin 
location (as in study arm A).   
 
Study Arm F (IFA + resiquimod) :  Sterile saline solution 0. 75ml w ill be added to 0. 75 ml 
of LPV7  + tetanus  peptide  (total 1.5 ml) . This w ill be combined w ith 1 .5 ml of Montanide ISA -
51VG to create an emulsion . Tw o (2) ml w ill be  injected half -intradermally and half -
subcutaneously in one skin location  (as in study arm A) .  Immediately after vaccine 
injection , apply approximately  500 mg of 0.2%  resiquimod  gel w ith a gloved finger over a 
25 cm2 area of the skin at the vaccine site. Rub the gel into the skin for 1 minute until it 
vanishes.   Follow ing application, the site may be covered w ith an occlusive dressing, 
such as Tegaderm, for about 8 hours.  Participants are encouraged to w ash the area at 8 
hours after application.  
Study Arm G (IFA + polyICLC + resiquimod) : PolyICLC (0.75 ml)  w ill be added to 0. 75 
ml of LPV7 + tetanus peptide  (total 1.5 ml) . This w ill be combined w ith 1 .5 ml of Montanide 
ISA-51VG to create an emulsion . Tw o (2) ml w ill be  injected half -intradermally and half -
subcutaneously in one skin location (as in study arm A).  Immediately after vaccine  and 
polyICLC  injection , apply approximately 500 mg  of 0.2% resiquimod  gel w ith a gloved 
finger over a 2 5 cm2 area of the skin at the vaccine site. Rub the gel into the skin for 1 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 31 minute until it vanishes.   Follow ing application, the site may be covered w ith an occlusive 
dressing, such as Tegaderm, for about 8 hours.  Participants are encouraged to w ash the 
area at 8 hours after application.  
 
Storage of Prepared Peptide Vaccines  
The prepared peptide vaccines w ill be stored in a plastic syringe and     delivered to the 
clinicians in a plastic bag.  This bag w ith the syringe w ill be stored at room temperature until 
the vaccine is administered.  Ideally, the vaccine should be administered w ithin 1-2 hours 
after m ixing.  If the vaccine is not administered w ithin 4 hours after mixing, it should be 
discarded.  
 
5.3   Drug Accountability  and Distribution  
Study drug w ill be accounted for and distributed to UVA patients and the outside sites using 
the HITC InvestMed Database.   The InvestMed Database is an Access database that 
interfaces w ith the Cancer Center Clinical Trials clinical database so that drug may be 
allocated and dispensed on a per patient basis to UVA patients.  For the outside sites, drug 
is dispensed to the corr esponding inst itution and tracked on a per institution basis.  Study 
drug w ill be sent to the outside sites by HITC personnel.  
 
5.4   Administration of Vaccines  
5.4.1   Designation of Vaccine Sites  
Evidence suggests nodes proximal to a tumor site may be relatively immunosuppressed  64; 
therefore , the vaccination sites w ill be distant from sites of know n tumor w henever possible.  
In general, participants w ill be vaccinated in upper arm or thigh locations.  If a participant 
has received a prior experimental vaccine, vaccines should not be administered at the same 
site as the prior experi mental vaccine , but they may be administered on the same extremity 
as prior vaccines .   
5.4.2   Regimen  
Part 1:  Each vaccine w ill be administered at a different site, rotating among available 
extremities w hen possible.    
 
Part 2:  The same skin location w ill be used for all vaccines.  If the vaccine site has sever e 
inflammation or ulceration after multiple vaccines, the next vaccine may be placed adjacent 
to the original site.  
 
Chronic inflammatory reactions at the vaccine sites are expected to occur in all parti cipants 
w ho receive Montanide ISA -51.  Induration may persist for days to months, but is not 
expected to require additional therapy.  Sterile abscesses may occur in some participants.  
These are not a basis for discontinuation of the vaccines.  How ever, if  the inflammatory 
reactions develop significant ulceration of the skin (> 2 cm), then this w ould be considered a 
dose -limiting toxicity and the patient w ould be taken off the study.  
5.4.3   Vaccination doses:    
Part 1:  
For each vaccine, 300 mcg of each of the long  peptides in LPV7  and 200 mcg of the tetanus 
helper peptide w ill be administered, plus 1 ml IFA or the dose of TLR agonists as specified 
in Table_1A  and section 5.2.1 . 
 
Part 2:  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 32 For each vaccine, 300 mcg of each of the long peptides in LPV7 w ill be administered, plus 1 
ml IFA and the dose of TLR agonists as specified in Table 1B  and Section 5.2.1 . 
   
5.4.4   Route of administration:   
At each injection site  for emulsions w ith IFA , a single needle puncture is to be  performed, 
w ith delivery of 1  cc volume into the subcutaneous tissue  and 1  cc volume into the dermis .  
This usually w ill require advancing the needl e into the subcutaneous tissue  to deliver the 
first 1  cc over an area w ithin reach of that needle , then pulling the needle back to near the 
skin puncture site, and advancing it into the intradermal  tissue for delivery of the remaining 1 
cc.  For injections  w ith peptides in polyICLC w ithout IFA, the total volume w ill be 1 ml, w hich 
w ill be divided betw een subcutaneous tissue and dermis  as above.  
 
5.4.5   Post-Vaccination Observation  
All participants w ill be closely observed for adverse events for at least 20 m inutes  follow ing 
each vaccination.  Any time thereafter, participants should report any adverse events to the 
research coordinator or research clinician.  
 
5.4.6   Biopsies of Vaccine site  and normal skin :   
Each participant in Part 1 and Part 2 w ill undergo biopsy of the vaccine site at tw o time 
points  (days 8 and 22; one w eek after vaccines 1 and 3) .  Control biopsies of clinically 
normal skin  (three  4-mm punch biopsies of the dermis and subcutaneous tissue) w ill be 
taken at the same time points (days 8 and 22),  for the first 6 participants  enrolled in Part 1 .   
 
The biopsies w ill consist of three  4-mm punch biopsies of skin . Note that vaccine sites w ill 
be rotated to different skin sites for each vaccination; so there w ill not be repeat injection of 
vaccines into the prior skin biopsy sites.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 33 5.4.6.1   The punch biopsies of normal skin w ill be  taken from an upper thigh or upper 
arm, and w ill be  preserved/processed as follow s:  
5.4.6.1.1 Normal 1:  quick -frozen  in liquid nitrogen.  
5.4.6.1.2 Normal 2:  preserved in formalin , then paraffin -embedded  
5.4.6.1.3 Normal 3:  preserved in RNA later.  
5.4.6.2   The punch biopsy specimens of the VSME w ill be preserved/processed as 
follow s:  
5.4.6.2.1 VSME sample 1: quick -frozen  in liquid nitrogen.  
5.4.6.2.2 VSME sample 2:  preserved in  formalin, then paraffin -embedded  
5.4.6.2.3 VSME sample 3: preserved in RNA later.  
5.4.6.3   Their evaluation is summarized in the Study Manual .   
5.4.6.4   The specimens should be put into liquid nitrogen, formalin, or RNA later w ithin 
15 minutes if at all possible, and ideally w ithin 5 min of excision.  Delays beyond 15 
minutes should be documented .  This information should be documented on the Skin 
Biopsy Submission Form.  
 
5.5   Modification/Discontinuation of Treatment  
 
5.5.1   Dose Modifications  
There w ill be no dose modifications of the vaccine components.  
 
5.5.2   Discontinuation  
If participants are discontinued prior to one or more scheduled skin biopsies, the y w ill not 
receive those  biopsies .  Protocol treatment w ill be discontinued for any of the follow ing 
reasons:  
5.5.2.1   Any dose -limiting toxicity as defined in Section 7.4 . 
5.5.2.2   In circumstances w here assessment of an AE is limited, such as by 
intercurrent illness, or w hen laboratory studies are required to assess for other causes 
of toxicity, the vaccine/biopsy schedule may be interrupted for up to 7 days .  Delay of 
one vaccine adminis tration, biopsy, or evaluation visit by up to 7 days w ill not be 
considered a protocol violation, regardless of attribution.  If more than one vaccine is 
delayed by 8 days o r more, treatment must be discontinued.  
 
5.5.2.3   Disease progression requiring other therap y (e.g. surgery under general 
anesthesia, radiation, chemotherapy, or steroid therapy).  The appearance of small 
metastases or recurrent tumor deposits w ill not be a basis for discontinuing the 
vaccinations.  Biopsy to determine the nature of new  lesions, or minor surgical 
procedures to excise a new  lesion, w ill not be a basis for discontinuing vaccinations.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 34 5.5.2.4   Initiation of cytotoxic chemotherapy, radiation therapy, steroid therapy as 
detailed under Section 4.2.5, or other immunosuppressive therapy.  
 
5.5.2.5   Any oth er potential adverse reaction deemed sufficiently serious to w arrant 
discontinuation of therapy by the Principal Investigator or one of the sub -investigators.  
 
5.5.2.6   Noncompliance w ith the requirements of the study.  
 
5.5.2.7   Therapy may be discontinued at the participan t's request.  
 
5.5.2.8   Therapy may be discontinued at the discretion of an investigator.  
 
5.5.2.9   Pregnancy.  Pregnant participants w ill continue to be follow ed for the duration 
of the pregnancy.  
 
5.5.3   Elective Withdraw al  
A participant w ho is enrolled but neither receives any study drug nor has a skin biopsy on 
protocol may be replaced.  Every attempt w ill be made to evaluate any data from these 
participants for endpoint assessment.   
 
5.5.4   Delayed Visit for Reasons Other Than Toxicity  
A schedule for return visits should be established at the first visit.  If a participant misses a 
treatment, the missed treatment w ill be administered as soon as possible, so that the 
subsequent vaccinations are given in the appropriate intervals.   Treatment may be 
continued for an additional time period, if needed.  Participants w ho are vaccinated outside 
of the established schedule should return to the original schedule as soon as possible.  
 
The table below  defines w hat constitutes a delayed visi t, w hether the participant should 
continue to be treated, and w hether a protocol violation /deviation  should be reported and 
recorded.   The range of days is counted from the original scheduled date.   
 
 
Table 6.  Delayed Visit for Reasons other than Toxicit y 
Treatment Period  Range of Days  Participant Treatment  Protocol  
Deviation  
Vaccine 1     
Day 1   2 days  Vaccine/Labs  No 
         3 to 7 days  Vaccine/Labs  Yes 
  8 or more days  Labs  Yes 
Vaccine 2/Biopsy *    
Day 8   2 days  Vaccine/Labs/Biopsy  No 
         3 to 7 days  Vaccine/Labs/Biopsy  Yes 
  8 or more days  Labs  Yes 
Vaccine 3 *    
Day 15   2 days  Vaccine/Labs  No 
         3 to 7 days  Vaccine/Labs  Yes 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 35   8 or more days  Labs  Yes 
Assessment/Biopsy     
Day 22   2 days  Biopsy/Labs  No 
  3 to 7 days  Biopsy/Labs  Yes 
  8 or more days  Labs  Yes 
    
Assessment     
Day 43     
  2 days  Labs  No 
  3 to 7 days  Labs  Yes 
  8 or more days  Labs  Yes 
    
Vaccines 4 -6*    
Days 36, 57, 78   7 days  Vaccine/Labs  No 
  8 to 14 days  Vaccine/Labs  Yes 
  15 or more days  Labs  Yes 
Assessment     
Day 85 (Week 12)   7 days  Labs/Scans  No 
  8 to 14 days  Labs/Scans  Yes 
  15 or more days  Labs  Yes 
Follow -up    
Week 26, Year 1 and 2   7 days  Scans/Labs  No 
  8 to 30 days  Scans/Labs  Yes 
* A participant will be taken off protocol treatment if more than one vaccination is 
delayed [  3 to 7 days] during the treatment period.  
 
5.6   Concomitant Medications  
Medications taken in the month prior to randomization  (Part 1) or arm assignment (Part 2)  
should be recorded on the baseline case report form.  This includes prescription 
medications, over -the-counter medications, injected medications, biological products, blood 
products, imported drugs, or street drugs.  Participants should be maintained on d rugs that 
they w ere taking prior to entry unless a change in regimen is medically indicated.  
5.6.1   Non-permitted medications or treatments  (w ithin 30 d of study treatment)  
5.6.1.1   Systemic cytotoxic chemotherapy  
5.6.1.2   Interferon therapy (e.g. Intron -A®) 
5.6.1.3   Radiation therapy  
5.6.1.4   Nitrosureas  
5.6.1.5   Allergy desensitization injections  
5.6.1.6   Systemic c orticosteroids, administered parenterally or orally.  Inhaled steroids 
(e.g. Advair®, Flovent®, Azmacort®) are not permitted.   
5.6.1.7   Grow th factors (e.g. Procrit®, Aranesp®, Neulasta®) 
5.6.1.8    Interleukins (e.g. Proleukin®) 
5.6.1.9   Other investigational medications  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 36 5.6.1.10   Street drugs  
5.6.1.11   Antibodies to CTLA -4, PD -1, PD -L1, or CD137  
5.6.1.12   Targeted molecular therapy ( e.g. vemurafenib, other inhibitor of mutant 
BRAF, MEK, or cKit) . 
 
5.6.2   Permitted medications or treatments  
 
5.6.2.1   Nonsteroidal anti-inflammatory agents  
5.6.2.2   Anti-histamines (e.g. Claritin®, Allegra®) 
5.6.2.3   Topical corticosteroids are acceptable, including steroids w ith very low  
solubility administered nasally for local effects only (e.g. Nasonex®). 
5.6.2.4   Short -term therapy for acute conditions not  specifically related to melanoma 
(except those listed under Section 5. 6.1) 
5.6.2.5   Chronic medications except those listed in Section 4.2. 7 or 5.6.1. 
5.6.2.6   Vaccines, including live vaccines  (e.g. FluMist ) are permitted, but should be 
administered at least 2 w eeks prior to or at least 2 w eeks after a study vaccine.  
5.6.2.7   Topical forms of chemotherapeutic reagents (e.g. Efudex®) are permitted, but 
should be administered at least 2 w eeks after a study vaccine.  
 
 
6.0   CLINICAL AND LABORATORY EVALUATION  
 
6.1   Screening  
The follow ing studies should be completed w ithin 6 w eeks prior to randomization unless 
otherw ise noted:  
 
6.1.1   Class I HLA -typing (any time prior to randomization; typing for HLA -A and HLA -B is 
sufficient) . If the patient is know n to express HLA -A1, A2, or A3, HLA -B testing is not 
required ).   
6.1.2   Review  of pathology at the treating and participating institution (any time prior to 
randomization) . Central pathology review  at UVA is not required for pathology review ed at 
other participating institutions.  
6.1.3   CBC w ith differential, including automated lymphocyte count if available (0.3 ml)  
6.1.4   Comprehensive chemistry panel to include sodium, potassium, creatinine, fasting  
glucose, calcium, total bilirubin, AST, ALT, and alkaline ph osphatase .  NOTE:  fasting blood 
sugars may be evaluated 4h or more after last eating  (0.9 ml)  
6.1.5   Lactate Dehydrogenase (LDH) (0.3 ml)  
6.1.6   Urinalysis  
6.1.7   β-HCG for w omen of childbearing potential (w ithin tw o w eeks prior to randomization)  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 37 6.1.8   HgB-A1C (only required at bas eline)  
6.1.9   HIV and HCV screening (w ithin 6 months prior to randomization)  
6.1.10   Chest x -ray or chest CT, abdominal and pelvic CT, and head CT or MRI.  PET/CT 
fusion scan may replace scans of the chest, abdomen, and pelvis.  
6.1.11   Complete history and physical examination, including:  
 Vital signs  
 Weight  
 Performance Status  
 Assessment of skin and nodal basins for evidence of disease 
recurrence or metastasis  
 Designation of vaccination sites  
 Medication review  
 
6.2   Treatment  
The follow ing evaluations w ill be performed on an outpatien t basis on each of the listed 
days.  Blood for these evaluations should be obtained prior to the vaccine injection if a 
vaccine is scheduled to be administered.   Results of those tests are not required prior to 
administering the vaccine on that date.  
 
6.2.1   Day 1 
 Interval history and physical examination directed at new  signs and  symptoms . 
 Vital signs  
 Weight  
 Performance status  
 Visual acuity exam using a Snellen chart, and color vision exam using an 
Ishihara eye chart  
 Neurologic function , general.  
 Note hair and e ye color  
 Assessment of skin for vitiligo  
 Anti-nuclear antibody and rheumatoid factor (4 ml total)  
 Baseline sympto ms, codable in the NIH CTCAE v.4.03 , to be recorded as pre -
existing conditions unrelated to the research protocol interventions  
 Distribute pa rticipant toxicity diary  
 Medication review  
 Blood collection for immunologic testing:  The follow ing blood samples for 
research w ill be provided to UVA and processed by the UVA BTRF and stored 
by the UVA -HITC IML:  
o 120 cc blood collected in heparinized green top tubes for 
lymphocytes . This may be decreased to 100 cc if more blood must be 
draw n for safety or screening labs, in order to comply w ith institutional 
limits on total blood draw n in a day.  
o 20 cc blood collected in red top tubes for serum  
 Vaccine administration  
 
6.2.2   Day 8 
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included..  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 38  Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 Review  of participant toxicity diary  and distribute new  toxicity diary  
 Medication review  
 Blood collection for immunologic testing:  The follow ing blood samples for 
research w ill be provided to UVA and processed by the UVA BTRF and 
stored by the UVA -HITC IML:  
o 80 cc blood collected in heparinized green top tubes for 
lymphocytes.  
o 20 cc blood collected in red top tubes for serum  
 Biopsies of 1st vaccine site (all patients), and biopsies of normal skin (patients 
1-6 only  in Part 1 ).  Details  in section 5.4.6 and in  Study Manual.     
 Vaccine administration  
 
6.2.3   Day 15  
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.  
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 Review  of participant diary and distribute new  toxicity diary  
 Medication review  
 Vaccine administration  
 
6.2.4   Day 22 
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.   
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 CBC w ith differential, including automated lymphocyte count if available (0.3 
ml) 
 Comprehensive chemistry panel to include sodium, potassium, creatinine, 
glucose, calcium, total bilirubin, AST, ALT, and al kaline phosphatase.  (0.9 
ml) 
 Lactate Dehydrogenase (LDH) (0.3 ml)  
 Anti-nuclear antibody and rheumatoid factor (4 ml total)  
 Assessment of skin for vitiligo  
 Neurologic function  
 Vaccine Site Biopsy ( 3) 
 Review  of participant diary and distribute new  toxicity  diary  
 Medication review  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 39  Blood collection for immunologic testing:  The follow ing blood samples for 
research w ill be provided to UVA and processed by the UVA BTRF 
and stored by the UVA -HITC IML:  
 80 cc blood collected in heparinized green top tubes for lymph ocytes.  
 20 cc blood collected in red top tubes for serum  
 Biopsies of 3rd vaccine site (all patients), and biopsies of normal skin (patients 
1-6 only , in Part 1 ).  Details  in section 5.4.6 and in Study Manual.     
 
6.2.5   Day 36  
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.  
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 Review  of participant diary and distribute new  toxicity diary  
 Medication review  
 Vaccine administration  
 
6.2.6   Day 43  
 Interval history and physical examination directed at new  signs and 
symptoms.  Examination of the vaccine site(s) should be included.  
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 Review  of participant diary and dist ribute new  toxicity diary  
 Medication review  
 Blood collec tion for immunologic testing:  The follow ing blood samples for 
research w ill be provided to UVA and processed by the UVA BTRF and 
stored by the UVA -HITC IML:  
o 80 cc blood collected in heparinized green top tubes for 
lymphocytes.  
o 20 cc blood collected in red top tubes for serum  
 
6.2.7   Day 57  
 Interval history and physical examination directed at new  signs and 
symptoms.  Examination of the vaccine site(s) should be incl uded.  
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 Review  of participant diary and distribute new  toxicity diary  
 Medication review  
 Vaccine administration  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 40 6.2.8   Day 78  
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.  
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 CBC w ith differential, including automated lymphocyte count if available (0.3 
ml) 
 Comprehensive chemistry panel to include sodium, pota ssium, creatinine, 
glucose, calcium, total bilirubin, AST, ALT, and alkaline phosphatase.  (0.9 
ml) 
 Lactate Dehydrogenase (LDH) (0.3 ml)  
 Anti-nuclear antibody and rheumatoid factor (4 ml total)  
 Review  of participant diary and distribute new  toxicity diary  
 Medication review  
 Vaccine administration  
 
6.2.9   Day 85  
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.   
 Vital signs  
 Weight  
 Performance status  
 Review  of adverse events  
 CBC w ith  differential, including automated lymphocyte count if available (0.3 
ml) 
 Comprehensive chemistry panel to include sodium, potassium, creatinine, 
glucose, calcium, total bilirubin, AST, ALT, and alkaline phosphatase.  (0.9 
ml) 
 Lactate Dehydrogenase (LDH) ( 0.3 ml)  
 Chest  X-ray or chest CT  
 Visual acuity exam using a Snellen chart, and color vision exam   
      using an Ishihara eye chart  
  Neurologic function  
  Note hair and eye color  
  Assessment of skin for vitiligo  
  Review  of participant diary  
  Medication review  
 Blood collection for immunologic testing:  The follow ing blood samples for 
research w ill be provided to UVA and processed by the UVA BTRF and 
stored by the UVA -HITC IML:  
o 80 cc blood collected in heparinized green top tubes for lymphocytes.  
o 20 cc blo od collected in red top tubes for serum  
 
6.2.10   Week 26  
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.   
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 41  Vital signs  
 Weight  
 Performance status  
 Anti-nuclear antibody and rheumatoid factor (4 ml total)  
 Chest x -ray or chest CT  
 Neurologic function  
 Assessment of skin for vitiligo   
 Medication review  
 Blood collection for immunologic testing:  The follow ing blood samples for 
research w ill be provided to UVA and processed by the UVA BTRF and 
stored by the UVA -HITC IML:  
o 80 cc blood collected in heparinized green top tubes for lymphocytes.  
o 20 cc blood collected in red top tubes for serum  
 
6.2.11   Weeks 52 and 104  (Year 1 and 2)  
 Interval history and physical examination directed at new  signs and 
symptoms .  Examination of the vaccine site(s) should be included.   
 Vital signs  
 Weight  
 Performance status  
 Medication review  
 Blood collection for immunologic testing:  The follow ing blood samples for 
research w ill be prov ided to UVA and processed by the UVA BTRF and 
stored by the UVA -HITC IML:  
o 80 cc blood collected in heparinized green top tubes for lymphocytes.  
o 20 cc blood collected in red top tubes for serum  
 
6.3   Tumor tissue collection  
If during the study, participants develop metastases or recurrences, these may be removed, 
and follow ing receipt by pathology, may be evaluated by the study research team .  Tissue 
samples may be screened for antigen expression or protein profiles using tes ts such as 
Western blots, immunohistochemistry, PCR, flow  cytometry or gene chip analysis.  Tumor 
escape mechanisms may also be evaluated.  Specimens w ill be used in immunological 
assays to assess T cell function or antibody response.  Assays generally use d for this type 
of testing include, but are not limited to, ELIspot assays, ELISAs, chromium -release assays, 
proliferation assays and intracellular cytokine staining.  Specimens may be used to study the 
immunologic aspects of the tumor microenvironment or as targets or controls in laboratory 
assays.  Specimens may be used to establish cell lines for long -term studies.  
 
This tissue may also be compared to lesions resected prior to enrollment, w hich w ill be 
requested from the pathology department of each inst itution as paraffin -embedded tissue 
samples, and these tissues may be banked for use in future studies.  If participants are 
removed from the study or progress during or after follow -up, tissue may be collected for use 
as part of this study, as described a bove, or banked for use in future studies  
 
 
7.0   REGULATORY AND REPORTING REQUIREMENTS  
Adverse event reporting requirements for this trial, as specified in this section, apply to 
patients accrued  at all participating  sites.  There w ill be accrual at UVA and at MD Anderson 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 42 Cancer Center; UVA w ill be the coordinating site, and responsibility for data coordination 
and reporting for the study as a w hole falls to the Human Immune Therapy Center (HITC).  
Throughout this se ction, w he n referring to 'Cancer Center Database', 'Cancer Center 
DSMC', 'CRC', 'PI' or, 'nurse practitioner' , they are preceded by ‘site’ w hen it refers to 
reporting w ithin either of the participating institutions, or are preceded by ‘UVA’ w hen it 
refers to central  reporting to the coordinating UVA center.  
  
In addition to the reporting requirements for the study, specified in this section of the 
protocol, investigators should also follow  their institutional policy for documentation in their 
database and reporting to the IRB locally at their ow n site.  
 
7.1   Definitions  
7.1.1   Adverse event (AE) –  
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated w ith the use of a medical treatment or 
procedure regardless o f w hether it is considered rela ted to the medical treatment or 
procedure (attribution of unrelated, unlikely, possible, probable, or definite).  Medical 
conditions or diseases present before starting the investigational drug w ill be 
considered as treatment -related AEs if they w orsen after starting study treatment.  
 
7.1.2   Unexpected AE –  
Any adverse event not listed in Section 7.4.3 . 
 
7.1.3   Serious AE –  
Any adverse drug experience occurring at any dose that results in any of the 
follow ing outcomes:  
 
 death;  
 a life-threatening adverse drug experience;  
 inpatient hospitalization, or prolongation of existing hospitalization (as defined 
below  in this section );  
 a persistent or significant disability/incapacity; or a congenital anomaly/birth 
defect.   
 Important medical events that may not result in death, be life threatening, or 
require  hospitalization may be considered a serious adverse drug experience 
w hen, based upon medical  judgment, they may jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  
 
Hospitalization for expedited AE reporting purposes is defined as an inpati ent 
hospital stay equal to or greater than 24 hours.  Hospitalization is used as an 
indicator of the seriousness of the adverse event and should be reserved for 
situations w here the adverse event truly fits this definition and not for 
hospitalizations asso ciated w ith less serious events.  For example, a hospital visit 
w here a patient is admitted for observation or minor treatment (e.g. hydration) and 
released in less than 24 hours w ould not be considered serious.  Furthermore, 
hospitalization for pharmacoki netic sampling is not an AE, and therefore is not to be 
reported either as a routine AE or in an expedited report.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 43 7.1.4   Unanticipated problem –  
An unanticipated problem is any event/experience that meets ALL 3 criteria below :  
 Is unexpected in terms of nature,  severity or frequency given the research 
procedures that are described in the protocol -related documents AND in the 
characteristics of the subject population being studied.  
 Is related or possibly related to participation in research.  This means that ther e 
is a reasonable possibility that the incident may have been caused by the 
procedures involved in the research study.  (see section 7.2 ) 
 The incident suggests that the research placed the subject or others at greater 
risk of harm than w as previously know n or recognized OR results in actual harm 
to the subject or others.  
 
7.1.5   Protocol Violation -   
A protocol violation is defined as any change, deviation, or departure from the study 
design or procedures of a research  project that is NOT approved by the institution’s 
IRB prior to its initiation or implementation, OR deviation from  standard operating 
procedures, Good Clinical Practices (GCPs), federal, state or local regulations.  
Protocol violations may or may not be u nder the control of the study team or UVa 
staff. These protocol violations may be major or minor violations.  
 
7.1.6   Suspected Adverse Reaction (as defined in 21 CFR 312.32 (a)) -  
Any adverse event for w hich there is a reasonable possibility that the drug caused 
the adverse event.  
 
7.2   Attribution Assessment  
7.2.1   Attribution – The determination of w hether an adverse event is related to a medical  
treatment or procedure.  The attribution groups are:  
 
Definite  – Applies to those adverse events w hich, the investigator feels are 
incontrovertibly related to the vaccine.  An adverse event may be assigned an 
attribution of definitely related if or w hen (must have all of the follow ing):  
 It follow s a reasonable temporal sequence from administration 
of the test drug.  
 It could not be reasonably explained by the know n 
characteristics of the subject’s clinical state, environmental or 
toxic factors, or other modes of therapy administered to the 
subject.  
 It disappears or decreases on cessation or reduction in dose 
w ith re -exposure to drug.  (Note: This is not to be constructed 
as requiring re -exposure of the subject; how ever, the group of 
definitely related can only be used w hen a recurrence is 
observed.)  
 It follow s a k now n pattern of response to the test drug.  
 
Probable  – Applies to those adverse events for w hich, after careful consideration at 
the time they are evaluated, are felt w ith a high degree of certainty to be related to 
the test drug.  An adverse event may be considered probably related if or w hen 
(must have three of the follow ing):  
 It follow s a reasonable temporal sequence from administration 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 44 of the test drug.  
 It could not be reasonably explained by the know n 
characteristics of the subject’s clinical state, en vironmental or 
toxic factors, or other modes of therapy administered to the 
subject.  
 It disappears or decreases on cessation or reduction in dose.  
There are important exceptions w hen an adverse event does 
not disappear upon discontinuation of the drug, ye t drug -
relatedness clearly exists (e.g. bone marrow  depression, fixed 
drug eruptions, tardive dyskinesia).  
 It follow s a know n pattern of response to the test drug.  
 
Possible  – Applies to those adverse events for w hich, after careful consideration 
at the ti me they are evaluated, a connection w ith the test drug administration 
appears unlikely but cannot be ruled out w ith certainty.  An adverse event may 
be considered possibly related if or w hen (must have tw o of the follow ing):  
 It follow s a reasonable temporal sequence from administration 
of the test drug.  
 It could not readily have been produced by the subject’s clinical 
state, environmental or toxic factors, or other modes of therapy 
administered to the subject.  
 It follow s a know n p attern of response t o the test drug.  
 
Unlikely  – Applies to those adverse events for w hich, after careful consideration 
at the time they are evaluated, are judged to be unrelated to the test drug.  An 
adverse event may be considered unlikely if or w hen (must have tw o of the 
follow ing):  
 It does not follow  a reasonable temporal sequence from 
administration of the test drug.  
 It could readily have been produced by the subject’s clinical 
state, environmental or toxic factors, or other modes of therapy 
administered to the subject.  
 It does not follow  a know n pattern of response to the test drug.  
 It does not reappear or w orsen w hen the drug is re -
administered.  
Unrelated  – Applies to those adverse events, w hich after careful consideration, 
are clearly and incontrovertibly due to extrane ous causes (disease, environment, 
etc.).  
 
7.3   Data collection  
Data w ill be collected using a centralized electronic case report form called ON-line Clinical 
Oncology Research Environment = Oncore . 
 
7.4   Risks and Safety  
7.4.1   Adverse Event Descriptions and Grading Scales  
The NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 w ill be 
used for the characterization and grading of adverse events  (see Appendix 6 ). 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 45 7.4.2   Time Span for Reporting Adverse Events  
Reporting of AEs w ill begin w hen the subject is administered the study drug or has a study 
related biopsy.  Events occurring  through 30 days after administration of the last vaccine, 
regardless of attribution, w ill be reported. AEs should be follow ed to resolution or  
stabilization.  If an AE w orsens and becomes an SAE, it should be reported as serious per 
the guidelines specified for SAE reporting.  
 
 
AEs that are possibly, probably, or definitely related to the vaccine w ill be recorded until the 
subject completes trea tment follow -up.  If, during treatment follow -up, the subject receives 
additional treatment, subjects w ill be off treatment follow -up and w ill be follow ed yearly for 
disease progression and survival.  
 
7.4.3   Agent -Specific Expected Adverse Events List:  
Any AE not  on this list w ill be considered an unexpected AE.  
 
Expected toxicities related to peptide vaccines .  This list of expected AEs for the LPV7  
vaccine is based on prior data from the UVA -Mel 44 clinical trial in w hich 41 participants in 
Arm A received a mixt ure of 12 Class I peptides plus a tetanus helper peptide in an 
emulsion w ith Montanide ISA -51 adjuvant.  AEs are listed only if observed in ≥ 5% of treated 
participants.  
 
Table 7:  Summary Toxicity Data from UVA -Me44  
Grade 2:     
CTCAE Category  Description  
Investigations  Lymphocyte count decreased  
General disorders and administration 
site conditions  Fatigue  
General disorders and administration 
site conditions   Fever  
Skin and subcutaneous tissue disorders  Hyperhidrosis  
Skin and subcutaneous tissue disorders  Skin induration  
Skin and subcutaneous tissue disorders  Skin ulceration  
General disorders and administration 
site conditions  Injection site reaction  
Gastrointestinal Disorders  Nausea  
Metabolism and nutrition disorders  Hyperglycemia  
 General disorders and administration 
site conditions  Flu-like symptoms  
Skin and subcutaneous disorders  Other:  any rash  
*NOTE:  Hyperglycemia ≥ Grade 3 is not an expected event.  If a non -fasting 
hyperglycemia adverse event occurs at a level ≥ Grade 3, a fasting serum 
glucose test will be ordered and the event will be re -graded appropriately.  The 
fasting serum glucose measurement will be used for the purpose of 
determining reporting requirements.  
 
Injection site reaction/induration w as experienced at ma ximum  grade 3 in 5% of patients in 
Arm A of Mel44.  Ulceration w as experienced as max imum  grade 3 in 7% of patients in Arm 
A of Mel 44.  By the rule above (observed in ≥5% of treated patients), injection site reaction, 
induration, and ulceration w ould be e xpected at grade  3.  Despite this and in the interest of 
the patients, w e w ould consider grade 3 injection site reaction w ith significant ulceration of 
the skin (> 2 cm)  as a DLT  (see section 7.8).  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 46  
 
Adverse Events Expected with Resiquimod application at the vaccine site.  
The investigator brochure specifies the follow ing adverse events in more than 1800 patients 
treated w ith topical resiquimod in 25 clinical studies.  Reported adverse events w ere 
prima rily local adverse events including protocol -defined local skin reactions (including, 
erythema, edema, ulceration, vesicles, w eeping, scabbing, and flaking); and protocol -
defined local symptoms at the site of administration (including pain, burning, prurit us, and 
numbness/tingling). Other adverse events at the application site include drainage, infection, 
and pigmentation changes. Systemic adverse events that may be related to resiquimod due 
to a systemic induction of cytokines and/or release of locally ind uced cytokines into the 
circulation include influenza -like symptoms ( e.g., fever, headache, arthralgia, myalgia, chills, 
asthenia, fatigue), and transient decreases in neutrophils and total leukocytes that may be 
related to cellular trafficking to the appl ication site. Other infrequent adverse events that 
w ere considered possibly or probably related to study medication included liver function test 
abnormalities, abdominal cramping, nausea, vomiting, diarrhea, backache, neck pain, 
rhinitis, urticaria, and di zziness.    
 
The formal  list, below , of expected AEs for resiquimod, for this study,  is based on published 
data related to its clinical use 65;66  The table below  is based on a study applying resiquimod 
3 times per w eek for 4 w eeks, for treatment of act inic keratosis. This study had 4 treatment 
arms, using 0.01, 0.03, 0.06, and 0.1% resiquimod gel.  We w ill be using 0. 2% resiquimod 
gel, only once a w eek; so toxicities from 3x/w eekly administration w ith 0.06% resiquimod 
use may exceed w hat w e observe65.  Overall in that study, no d eaths or serious adverse 
events w ere reported, but some adverse events are described as severe.  We expect grade 
2 toxicities in these categories. Listed in the table below  are those categories w here adverse 
events w ere recorded in 10% of patients or more,  in any study group, but the percentages 
listed are those for patients receiving resiquimod 0.06%  three times per w eek . 
 
Table 8:  Toxicity Data for Resiquimod  
Grade 2:  
CTCAE Category  Description  Percent with  
possibly or probably 
related AEs at 0.6% 
resiquimod three times 
per week  
General disorders and administration site 
conditions  
 Application site burning  25% 
Application site 
erythema  6% 
Application site pain  16% 
Application site pruritus  25% 
Application site reaction  None  
Fatigue  9% 
Rigors/chills  16% 
Musculoskeletal and connective tissue disorders  Arthralgia  16% 
Myalgia  6% 
Nervous system disorders  
 Headache  19% 
Lethargy/fatigue  13% 
Psychiatric disorders  Not specified  16% 
Skin and subcutaneous tissue disorders  Not specified  13% 
   Mild and transient leukopenia and thrombocytopenia have also been reported with use of  
   resiquimod, but these are expected only to be grade I toxicities.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 47  
Toxicities at sites of resiquimod application should be limited to grade 1 , 2, or 3 (w ith 
ulceration ≤ 2 cm)  dermatologic toxicities, and should be manageable either by continuation 
of  resiqui mod if the patient is tolerating the toxicities and if the toxicities are relatively stable, 
or they may be managed by holding vaccination  for one to severa l days (up to 7 days 
w ithout being a DLT).   
 
Adverse events expected with polyICLC (Hiltonol)  
The follow ing expected t oxicities for polyICLC are based on the data from 45 patients 
treated w ith 20 mcg/kg 3x/w eek.  This w ould be about 1.4 mg per dose and 4.2 mg per w eek 
(much higher than w e w ill use).  
 
Table 9:  Toxicity Data for PolyICLC  
Category  Toxicity  Grade  Comment  
Nervous system disorders  
 Headache  Grade 2  1 of 22 (<5%)  
Tremors  Grade 3  2 of 45 (4%) poss related  
Musculoskeletal and 
connective tissue disorders  Muscle weakness  Grade 2  1 of 45 (<2%)  experienced at 
Grade 3  
Respiratory, thoracic and 
mediastinal disorders  
 Dyspnea  Grade 2  1 of 45 (<2%)  experienced at 
Grade 3  
Hypoxia  Grade 2  1 of 45 (<2%)  experienced at 
Grade 3  
Metabolism and nutrition 
disorders  Hypernatremia  Grade 2  1 of 45 (<2%) experienced at 
Grade 3  
Investigations  
 Elevated 
transaminases (GPT)  Grade 3  4 of 45 ( 9%) 3 cases possibly 
related; one case probably 
related.  Typically transient.  
Elevated Alkaline 
phosphatase  Grade 3  7% of patients, in IB  
Leukocytopenia  Grade 3 2 of 45 (< 4%) in published 
work; 20% in IB  
Thrombocytopenia  Grade 3  14% of patients in IB  
Neutropenia  Grade 3  10% of patients in IB  
Blood/lymph disorders  Anemia  Grade 3  13-31% of patients in IB  
General disorders and 
administration site conditions  
 Vaccine site reaction  Grade 2  1 of 22 (<5%)  
Fever  Grade 3  14% of patients in RCC trial  
Chills  Grade 3  10% of patients in RCC trial  
Fatigue  Grade 3  10% of patients in RCC trial  
 
Adverse events expected from vaccine and normal skin  biopsies .   
Below  is a list of expected AEs related to skin biopsies:  
 
        Table 10:  Toxicity Data for Skin Biopsies  
    Grade 2:  
CTCAE Category  Description  
Pain Pain - Skin 
 
7.5   Adverse Event Classifications  
The determination under w hich adverse event classification an AE is reported.  The adverse 
event classifications are specified in the CTCAE  v4.03.  For specific classifications 
pertaining to the protocol, w e specify the follow ing:  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 48  
Hematolo gic/Metabolic - Any AE coded under one of the follow ing CTCAE v4.03 categories 
should be reported under the Hematologic/Metabolic adverse event classification:  
 
 
 
Table 11:  Hematologic/Metabolic Classifications  
Section  AE 
Blood and lymphatic  Anemia  
Leukocytosis  
Investigations  ALL EXCEPT:  
Carbon monoxide diffusing capacity decreased  
Ejection fraction decreased  
Forced expiratory volume decreased  
Vital capacity abnormal  
Weight gain  
Weight loss  
Metabolism and nutrition 
disorders  ALL EXCEPT:  
Alcohol intolerance  
Anorexia  
Dehydration  
Glucose intolerance  
Iron overload  
Obesity  
Tumor lysis syndrome  
 
Non-hematologic/Non -Metabolic - Any AE not reported under hematologic/metabolic, ocular, 
or allergic/autoimmune, should be reported under the non -hematologic/non -metabolic 
adverse event classification.  
 
Ocular  – Any AE coded under one of the follow ing CTCAE v4.03 Adverse Event Terms  
should be reported under the Ocular adverse event classification:  
1) A single treatment -related experience of the follow ing adverse events 
w ill be classified as a DLT:  
 Eye Disorders: Night blindness (nyctalopia)  
 Eye Disorders: Papilledema  
 Eye Disordersl: Reti nopathy  
 
Participants w ill be referred for an ophthalmologic exam if any of these 
ocular adverse events occur.  
 
2) A prolonged treatment -related experience (e.g., lasting > 5 days) of 
the follow ing non -severe adverse events w ill be classified as a DLT:  
 Eye Disorders: Blurred vision  
 Eye Disorders: Flashing lights  
 Eye Disorders: Floaters  
 
Participants w ill be referred for an ophthalmologic exam if any of these 
ocular adverse events occur.  
 
Allergic/Autoimmune  – Only AEs coded as Immune System Disorder: Allergic reaction, 
autoimmune disorder, or anaphylaxis should be reported under the Allergic/Autoimmune 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 49 adverse event classification.  Other AEs coded under Immune System Disorder should be 
reported under   Non-hematologic/Non -metabolic adverse event classification.  
 
7.6   Reporting Adverse Events  
7.6.1   Process for Reporting AEs:  
 
The process of reporting AEs  will occur as follows:  
 
A. Identify the type of event using the NCI CTCAE v4.03 (Appendix 6).  The CTCAE 
provides desc riptive terminology and a grading scale for each adverse event listed.  
B. Grade the event using the NCI CTCAE v4.03.  
C. Determine w hether the AE is related to the vaccine.  Attribution groups are defined 
in Section 7.2.1 . 
D. Determine the prior experience of the AE.  Expected events are those  that have 
been previously identified as resulting from administration of the vaccine.  An AE is 
expected w hen it is listed in Section 7.4.3 . 
E. Determine the adverse event classification of the AE , as specified and defined in 
Section 7.5 . 
F. Determine w hether the AE is a dose -limiting toxicity and report as specified below . 
G. De termine w hether the AE is an SAE and report as specified below . 
H. AEs determined to require expedited re porting to the Sponsor, UVA HITC , must 
also be reported to your ow n institution according to the local policy and 
procedures .  
 
Reporting Dose Limiting  Toxicities  
All DLT’s (defined in Section 7.8 ) should be reported by phone or fax to the HITC 
within 24 hours of when the site is notified of the event and entered into Oncore  
within 5 calendar days of when the site is notified of the event.  
 
DLT’s  that are deemed serious and unexpected should be submitte d to to a site ’s local IRB 
per their institutional  guidelines.  
 
SAE reporting  
 Report SAEs b y phone or fax to the HITC within  24 hours  of of when the 
site is notified of the event .  
 Send completed FDA MedWatch 3500a form and relevant supporting 
documentation (e.g. clinic notes, hospital case records) to the Sponsor 
within 3 calendar days for deaths or life -threatening events and  5 calendar 
events for other SAEs.  
 Enter SAE into Oncore per guidelines specified in the table below.  
 
DLT and SAE Reporting Information : 
UVA HITC  
Phone: (434) 982 -6714  
Fax: (434) 982 -6608  
Box 801457, 1352 Jordan Hall  
Charlottesville, VA 22908  
 
In addition  to DLT’s and SAE’s, a ll other AEs must be recorded into the University of Virginia 
Cancer Center OnCore database per the follow ing guidelines:  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 50  
 
 
Table 12:  AE reporting  
 High Risk Studies  
Reporting requirements for AEs that occur within 30 days of the last dose of protocol specified treatment  
 Grade 1  Grade 2  Grade 3  Grade  
4 & 5  
Expected  
and 
unexpected   
Expected   
 
Unexpected  Expected  
 Unexpected  Expected  
and 
Unexpected  Without  
hospitalization  With 
hospitalization  Without  
hospitalization  With 
hospitalization  
Unrelated  
Unlikely  OnCore  
30 daysa OnCore  
30 days  OnCore  
30 days  OnCore  
30 days  OnCore  
15 days  OnCore  
30 days  OnCore  
15 days  OnCore  
7 days  
Possible  
Probable  
Definite  OnCore  
30 daysa OnCore  
30 days  OnCore  
15 days  OnCore  
30 days  OnCore  
15 days  OnCore  
7 days  OnCore  
7 days  OnCore  
(24-hrs)*  
7 days  
 
*Enter into OnCore  database w ithin 24 hours if unexpected and definitely related to protocol specified treatment  
Hospitalization defined as an inpatient hospital stay or prolongation of a hospital stay equal to or greater than 24 hours  
a Grade 1 unexpected or expected hematologic/metabolic events w ill be recoreded in the Cancer Center Database; how ever, regardl ess 
of attribution, these events do not have to be reported.  
 
 
 
 
Pregnancy  
 Report pregnancy to the Sponsor w ithin 5 calendar days of w hen the site is 
notified of the event.  
 Report the pregnancy using the Safety Reporting Cover Sheet.  
 
 
 Pregnancy Reporting Information:  
 UVA HITC  
 Phone: (434) 982-6714  
 Fax: (434) 982 -6608  
 Box 801457, 1352 Jordan Hall  
  Charlottesville, VA 22908  
 
7.6.2   IRB Reporting Requirements  
Participating sites should follow  their institutional policies for reporting adverse events and 
serious adverse events to their local Institutional Review  Board.  
 
The Universi ty of Virginia is r esponsible for reporting to the UVA IRB -HSR per the follow ing 
guidelines:  
 
Table 13:  UVA IRB -HSR reporting  
Type of Event  To whom will 
it be reported:  Time Frame for 
Reporting  How reported?  
Any internal event 
resulting in death that 
is deemed 
DEFINITELY related to 
(caused by) study 
participation  IRB-HSR  Within 24 hours  IRB Online and phone call  
 
www.irb.virg inia.edu/  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 51 Type of Event  To whom will 
it be reported:  Time Frame for 
Reporting  How reported?  
(Note:  An internal 
event is one that 
occurs in a subject 
enrolled in a UVa 
protocol.)  
Internal, Serious, 
Unexpected adverse 
event.  
 IRB-HSR  Within 7 calendar 
days from the 
time the study 
team received 
knowledge of the 
event.  
 
Timeline includes 
submission of 
signed hardcopy 
of AE form.  IRB Online  
 
www.irb.virginia.edu/  
 
Unanticipated 
Problems that are not 
adverse events or 
protocol violations  
This would include a 
Data Breach.   IRB-HSR  
 
 Within 7 calendar 
days from the 
time the study 
team received 
knowledge of the 
event.  Unanticipated Problem 
report form.  
 
http://www.virgini a.edu/vprg
s/irb/HSR_docs/Forms/Rep
orting_Requirements -
Unanticipated_Problems.do
c ) 
 
  
Protocol Violations 
(The IRB -HSR only 
requires that MAJOR 
violation be reported, 
unless otherwise 
required by your 
sponsor, if applicable.)  
 
Or  
 
Enrollment Exceptions  IRB-HSR  
 
 Within 7 calendar 
days from the 
time the study 
team received 
knowledge of the 
event.  
 Protocol Violation and 
Enrollment Exception 
Reporting Form  
 
 
http://www.virginia.edu/vpr/i
rb/hsr/    
 
 
Data Breach  The UVa 
Corporate 
Compliance 
and Privacy 
Office and  
 
 
ITC:  if breach 
involves  
electronic 
data-  
 
 
 
UVa Police if 
breach 
includes such 
things as 
stolen 
computers.  As soon as 
possible and no 
later than 24 
hours from the 
time the incident 
is identified.  
 
As soon as 
possible and no 
later than 24 
hours from the 
time the incident 
is identified.  
 
 
IMMEDIATELY.  
 
 UVa Corporate Compliance 
and Privacy Office - Phone 
924-9741  
 
 
 
 
ITC:  Information Security 
Incident Reporting 
procedure ,  
http://www.itc.virginia.edu/s
ecurity/reporting.html  
 
 
Phon e- (434) 924 -7166  
 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 52 7.6.3   Additional Reporting Requirements for the Sponsor (UVA)  
Reporting to the FDA  
Serious and unexpected suspected adverse reactions w ill be reported to the FDA no later 
than 15 calendar days after th e sponsor determines that the requirements for an IND safety 
report have been met.  The FDA w ill be notified using an FDA Form 3500a.  
Unexpected fatal or life -threatening suspected adverse reactions w ill be reported to the FDA 
no later than 7 calendar days after the Sponsor receives the  initial information of the event. 
The FDA w ill be notified using an FDA Form 3500a.  
Other adverse event information w ill be sent to the FDA in the IND annual report.  
 
Reporting to the Sites  
The sponsor w ill report serious and unexpected suspected adverse reactions to the outside 
sites no later than 15 calendar days after the sponsor determines that the requirements for 
an IND safety report have been met.  
 
7.6.4   Reporting of Subject Withdraw als/Dropouts Prior to Study Comp letion  
Subjects  w ho w ithdraw consent and those dropping out of the study seco ndary to an AE w ill 
be reported to the UVA IRB yearly on the IRB continuation form.  These data should be 
reported to the sponsor w ithin 30 days of subject w ithdraw al or dropout.  
 
7.7   Adverse Event Review  and Monitoring  
7.7.1   In addition to clinic notes, a dverse events w ill be initially captured using study -specific 
tools and participant toxicity diaries.   
 
As specified in the study flow  chart ( Appendix  1), each participant w ill be evaluated by a 
licensed clinician.  The follow ing w ill be performed as designated in the protocol: routine 
disease -directed physical exam including performance status, blood collection, re -
assessment for vitiligo, and examination of the skin and nodal basins for evidence of 
metastasis.   
 
Participants w ill keep a daily diary of toxicities for days 1 through 85.  The diaries w ill be 
review ed by a research clinician prior to the next schedule d vaccine.  During clinic visits, 
participants w ill also be asked about subjective symptoms including headache, malaise, 
fatigue, dyspnea, nausea, rash, diarrhea, abdominal discomfort, peripheral nerve pain, 
visual changes, appetite, tremors, night sw eats,  and ability to concentrate.  Additional 
toxicities w ill be captured from laboratory tests.  For each AE  (w ith the exception of Grade 1 
hematologic/metabolic events) , date of onset, duration, grade, and attribution w ill be noted 
in the participant’s study chart , on study documents,  or in the clinic note, and w ill be entered 
into the UVA Cancer Center database.   
 
After each vaccination, participants w ill be observed for AEs for at least 20 minutes.  Follow -
up phone calls w ill be made per the judgment of the  research clinicians w ith regard to 
individual participant need.  Subjects w ill be instructed on how  to reach their provider should 
they have any questions and/or problems  during the study . 
 
In the event of an AE, appropriate action w ill be taken to ensure  adequate care for the 
participant.  If the participant is still on protocol, treatment delay or w ithdraw al from the 
protocol w ill be considered according to the protocol guidelines.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 53 7.7.2   Individual AEs w ill be review ed at each site by the Principal Investigat or, nurse 
practitioner(s), and clinical research coordinator(s)  (CRC) ,.   
 
7.7.3   SAEs experienced by participants at all sites w ill be review ed tw ice a month by the 
sponsor during the UVA Melanoma Team meeting.  This meeting w ill occur at least 20 times 
in a cal endar year.  Those present at the m eeting include the sponsor/ overall study PI , sub-
investigators, protocol development staff, biostatisticians, research nurses, research 
coordinators, laboratory specialists, and laboratory research managers.  These meetin gs 
may also include the review  of individual participants to assess w hether they are protocol 
candidates, w hether AEs w arrant discontinuation, and w hether existing protocols should be 
continued or closed.  
 
7.7.4   Monthly conference calls w ill be held w ith the Sponsor and the site designee to 
review  protocol status, accruals, and adverse events.  
 
7.7.5   The follow ing laboratory values w ill be recorded in the UVA Cancer Center database, 
graded using the CTCAE v4.03 (if a gr ading category exists), and reported as described in 
Section 7.6 : 
1. Alk Phosphatase  
2. ALT (GPT)  
3. ANA 
4. AST (GOT)  
5. Bilirubin, total  
6. Creatinine  
7. Eosinophil #  
8. Hepatitis C serology  
9. beta-HCG 
10. HgB 
11. HIV 
12. HLA type  
13. LDH 
14. Potassium  
15. RF 
16. Urinalysis  
17. WBC 
 
Any abnormal laboratory values captured w hich are not included in the above list, but are 
considered to be pertinent positive clinical signs/symptoms, and laboratory results obtained 
as part of routine care of patients w ill be recorded i n the UVA Cancer Center database and 
reported as described in Section 7.6.  If there is any doubt on the part of study personnel 
concerning w hat constitutes a pertinent positive finding, the sponsor  is to be consulted.  
 
7.8   Adverse Event Stopping Guidelines  
Based on results from previous vaccinations w ith 12 -MP and tetanus peptide preparations , 
and w ith findings from use of resiquimod and polyICLC, significant toxicity is not anticipated.   
The study w ill be monitored continuously for treatment -related adverse  events w ithin each 
vaccine preparation by the sponsor .  Data from the UVA - Mel44 vaccine trial (Arm A) (using 
12-MP and tetanus peptide) indicate an 8% rate of treatment -related unexpected Grade 3 
adverse events.   
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 54  
Adverse events w ill be described and co ded based upon the NCI CTCAE v4.0 3.   
 
A DLT is defined as any unexpected adverse event that is possibly, probably 
or definitely related and:  
 ≥ Grade 3 , w ith the exception of grade 3 injection site reaction w ith 
ulceration ≤ 2 cm 
 ≥ Grade 1 ocular adverse events as defined under Section 7.5 
 ≥ Grade 2 allergic/autoimmune reactions  
 
7.9   Responsibility  
7.9.1   The University of Virginia Cancer Center Data and Safety Monitoring Committee 
(DSMC) w ill  provide oversight of the conduct of this study.  The CC DSMC w ill report to the 
UVA Protocol Review  Committee (PRC).  
7.9.2   The UVA CC DSMC w ill review  the follow ing:  
 All adverse events  
 Audit results  
 Application of study designed stopping/decision rules  
 Whet her the study accrual pattern w arrants continuation/action  
 Protocol violations  
7.9.3   The UVA CC DSMC w ill meet every month for aggregate review  of data.  Tracking 
reports of the meetings are available to the PI for review .  Issues of immediate concern by 
the DS MC are brought to the attention of the sponsor  (and if appropriate to the PRC and 
IRB) and a formal response from the sponsor  is requested.   Per the UVA Cancer Center 
NIH approved institutional plan , this study w ill be audited approximately every 6 months.  
 
7.10   Endpoint Data  
7.10.1   Endpoint data w ill be collected using HITC IML data forms, participant -specific 
binders, and the HITC laboratory database.  
 
7.10.2   The HITC laboratory database, w hich has passw ord -restricted  access, is stored on 
the UVA Health System Computing Services secure server.  
 
 
8.0   EVALUATION OF IMMUNOLOGIC RESULTS  
 
A primary goal is to evaluate imm unogenicity of LPV7 in each of 7 adjuvant  preparations, 
including IFA , w ith or w ithout TLR agonists.  The pr imary immunological response of interest 
is the CD8+ T cell response to the defined minimal peptides epitopes contained w ithin each 
of the 7 long peptides ( Table 2 ).  This w ill be assessed primarily by ELIspot assay as 
outlined b elow .  Associated analyses w ill include the durable immune response (w eek 26), 
and the peak magnitude of the CD8+ T cell responses. Details related to study design are in 
Section 9 . 
 
Studies in the peripheral b lood w ill also assess CD4 T cell responses, T cell persistence, 
antibody response, Th1/Tc1 deviation  and cytokine functionality. The antitumor immune 
response to vaccination w ith LPV7  w ith TLR agonists w ill be compared to vaccination w ith 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 55 IFA alone , and th e highest immune response rate w ill be selected . Blood w ill be collected as 
described in Section 6 .   
 
Skin biops y specimens from the vaccine sites after 1 (day 8) and 3 vaccines (day 22) (and 
from normal skin controls) w ill be evaluated for  changes induced by TLR agonists, and these 
w ill be evaluated as w e have for a prior study 50: immuno histochemistry of the vaccine -site 
immune cells to define the cell types and function; mu ltiparameter flow  cytometry to identify 
activation status of antigen specific cells, regulatory T cells, and MDSC; ELIspot assays for 
the ability to produce IFN ; and Luminex studies to define the cytokine and chemokine 
profiles of the VSME.   
  
The follow ing laboratory criteria w ill be used to evaluate effects of the vaccines and the TLR 
agonists in circulating peripheral blood mononuclear cells (PBMC) and in the vaccine sites.  
In general, immunological evaluations w ill be performed in batch.   
 
8.1   Immunohistochemistry and  Immunofluorescence  of skin biopsy specimens  
For the immunohistochemical studies of the VSME, w e w ill employ  stains w ith single 
antibodies (eg CD8), w ith multiple antibodies (eg CD8 and FoxP3), and  a technique 
developed by our colle ague Jim Mandell, w hich w e have w orking our lab now . This 
technique, called SIMPLE, enables repeated IHC stains on the same section, w ith w hole -
slide imaging using an Aperio  or Leica  system, and multiparameter evaluation of these cells 
in situ by combining  the multiple images w ith each antibody.67 Immunofluorescence studies 
w ill also be available in the event they are helpful.  
 
We w ill obtain CD8/FoxP3 ratios to evaluate w hether higher (more favorable) ratios are 
induced by adjuvants that are associated w ith improved circulating immune responses.  
 
For optimization of antibodies in IHC, w e have used positive control tissues, w hich w ill 
continue to be useful controls in the proposed studies.  These include ,  but are not limited to,  
normal human peripheral blood lymphocytes (PBL), PBL activated w ith CD3/CD28 beads 
(activated PBL), human lymph node tissu e from non -melanoma patients (LN), and inflamed 
human tissue from a surgical specimen of Crohn’s disease (Crohn’s).  
 
8.2   ELIspot assay  
We w ill evaluate CD4+ and CD8+ T cell responses  in the peripheral blood using a direct  (ex 
vivo)  ELIspot assay  for IFN as re ported.12  This w ill be perform ed in a core laboratory  
dedicated to immune monitoring, and w ith SOPs, controls, and quality assurance measures, 
w hich w e have reported.12. Vaccination site infiltrating lymphocytes  w ill be evaluated  by 
ELIspot as w ell.  Vaccine site infiltrating lymp hocytes w ill be compared to those in peripheral 
blood.    ELIspot assays after one in vitro stimulation (stimulated ELIspot) may also be 
employed if appropriate, as reported 33. 
 
CD4+ T cell responses  w ill be assessed by IFN ELIspot assay using the mixture of  7 long 
peptides and also pools of 15 -mer peptides (overlapping by 5 residues) from each peptide 
(4 peptides for each long peptide) as antigen sources.  
 
Durability of CD8  and helper T cell responses w ill be assessed by me asuring T cell activity 
at 26 w eeks, and for longer intervals w hen available , w ith the hypothesis that there w ill be 
increased durability of T cell responses w hen compared to prior experience w ith short 
peptides13 and w ill be improved w ith TLR agonis ts w hen compared to IFA alone in this 
study .  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 56  
We have  extensive stores of cryopreserved T cells reactive to minimal epitope peptides  
included in the 12 short peptides (12MP)  mixture , and detectable by IFN -gamma ELIspot 
assay 8;12 and by cytotoxicity assays.68;69.  These cells w ill serve as positive controls for 
reactivity to the minimal epitopes contained w ithin the long peptides used in this trial.     
 
8.3   Tetramer assay  and multiparameter flow  cytometry  
Peripheral blood lymphocytes  and VSME lymphocytes  w ill be evaluated by flow  cytometry 
after incubation w ith MHC -peptide tetramers  or pentamers  for the number of peptide -
reactive T -cells.  We have validated tetramers for  all 5 of the minimal CD8 epitopes  restricted 
by HLA -A2 or A3 among  the LPV7  peptides.  W e w ill use these MHC multimers  w ith w hich 
w e also have substantial  experience.12 Tetramers w ill likely detect more antigen -specific T 
cells than are detected in the functional ELIspot assay, but the primary measure of CD8 T 
cell response w ill be the ELIspot assay, on w hi ch the statistical pow er w as based.  
Tetramers w ill also be used in multiparameter flow  cytometry to determine the 
effector/ memory status of the antigen -specific T cells 70 (CD45RA, CD27, CD28, CCR7, 
CD62L), and evaluation fo r multiple functions of the CD8 T cells (degranulation (CD107a), 
IFN, MIP -1β, TNF, and IL-2) 71  
 
We w ill also use multiparameter flow  cytometry to measure myeloid suppressor cells  
(CD14+ HLA -DR lo/neg), and several subty pes of MDSC in PBMC to determine if they are 
increased or decreased by any of these vaccine approaches, compared to our current 
experience w ith MDSC numbers using our short 12MP vaccine (data not show n).  
 
8.4   Proliferation assay / Cytokine Analysis  
To characte rize responding T cells more completely, w e w ill evaluate w ith multiparameter 
flow  cytometry after short -term culture w ith antigen. CD4+ T cell s responding to antigen by 
CFSE dilution w ill be assayed for intracellular cytokine production to evaluate Th1/Th 2/Th17 
bias ( Th1: IL-2, IFN, TNF; Th2: IL4, IL -5, IL-10; Th17 : IL-17a).  Antigen specific T -regs w ill 
also be assayed as described 72.  
 
We w ill also assay supernatants of PBMC, and of immune cells infiltrating the VSME, 
cultured 2 and 5 days w ith the  7 long peptides to define secreted cytokines and chemokines 
representat ive of the w hole cell population.  We anticipate that the long peptides w ill induce 
Tc1 and Th1 dominant responses, w ith a high proportion of memory phenotype after several 
vaccines.  
 
Peripheral blood mononuclear cells (PBMC) and vaccine -site inflammatory  cells from 
participants in this clinical trial may also  be evaluated for CD4 T cell reactivity, using a 3H -
thymidine uptake assa y, CFSE dilution or other assays as summarized above.  
 
Responses to the tetanus helper peptide w ill be assayed as w ell as responses to the 30 -mer 
melanoma peptides and 15 -mer pools comprising those peptides.  Either or both of t w o 
peptides w ill be used as negative controls  for CD4+ T cell responses : one being  the PADRE 
peptide ( aK(X)VAAWTLKAa ), w here X = L -cyclohexylalanine  73;74. 
 
8.5   Antibody responses  
Antibody responses to 30 mer peptides (and  to pools of 15 -mer peptides) w ill be measured 
by ELISA assay using methods described by Sabbatini et al 2. 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 57 8.6   Evaluation of tumor  
Tumor tissue collected prior to enrollment or at the time of progression w ill be evaluated by 
routine histology and immunohistochemistry.  In addition, in vitro  evaluations of tumor tissue 
and tumor infiltrating lymphocytes may be completed.  
 
9.0   STATISTICAL CONSIDERATIONS   
This is an open -label, Phase I/II study evaluating the safety and immunogenicity of a long 
peptide vaccine (LPV7) + TLR for resected stage IIB – IV melanoma. There are tw o part s to 
the study.  
 
For Part 1, the trial w as designed to find the range of optimal combination therapies, defined 
as combinations w ith high immunologic response and an acceptable level of toxicity. The 
primary outcomes include d the frequency of treatment related dose limiting toxicities (DLTs) 
and frequency of immunologic response.  For Part 2, the goal is to obtain preliminary safety 
and immunogenicity data on the optimal combination identified in Part 1 w hen administered 
in the  same skin site for all 6 vaccines (same site vaccination).  
  
For part 2, the vaccine regimen is selected based on available data from Part 1, in w hich the 
strongest immune responses w ere observed in participant s enrolled on Arms E and G 
(Table 1A ).  Resiquimod is no longer available; so the regimen for Arm G is not currently 
feasible.  Also, the total enrollment on Arm E is larger (15 vs 6) so that outcomes from Part 2 
w ill be evaluable in a similar sample size as for Part 1, Ar m E.  This group w ill be called 
Study Arm E2.  
 
9.1   Study design  Part 1 (completed)  
In order to assess the first tw o objectives, the co-primary objective  is to determine a range 
of optimal combination therapies, among the combinations provided in the follow ing table 
w here an optimal combination is a combination that is estimated to have an acceptable 
toxicity profile as measured by DLT’s and a high rate of immunologic response (IRR) as 
measured by peak immune response.  
 
 
Table 14:  Study Design  
Zone  Arm/Combination  Peptide vaccine  Adjuvant preparation  
1 A LPV7 + tet  IFA  
1 B LPV7 + tet  PolyICLC   
1 C LPV7 + tet  Resiquimod  
2 D LPV7 + tet  PolyICLC + Resiquimod  
2 E LPV7 + tet  IFA + PolyICLC   
2 F LPV7 + tet  IFA + Resiquimod   
3 G LPV7 + tet  IFA + PolyICLC + Resiquimod  
 
DLTs are defined in Section 7.8  of the protocol.  
 
Within the range of optimal doses a co-primary objective  is if more than one combination is 
contained w ithin the range of optimal combinations, to estimate the difference in 
immunologic response rates betw een combinations, among those in the range of optimal 
combinations.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 58 9.2   Combination allocation  Part 1 (complet ed) 
The goal is to determine the range of optimal combinations, w here optimal combination 
allocation w ill occur in tw o stages. The initial stage w ill accrue eligible participant s in cohorts 
of one on each arm per the allocation process  in 9.2.1  until a  participant  experiences a DLT. 
The second stage w ill allocate eligible participant s based upon a continual reassessment 
method (CRM )81 for combinations of agents82.  Randomization w ill be based on equal 
allocation among allow able arms unless a w eighted allocation scheme is triggered ( Section 
9.2.1 ). Randomization w ill not be stratified by institution.  Participant s must be observed for a 
minimum of 3 w eek s after the initial vaccine  for initial escalation betw e en zones, and 
betw een the 1st and 2nd participant s w ithin an arm . 
9.2.1   Combination allocation in Stage 1:  
The initial stage w ill accrue eligible participant s on combinations in cohorts of one until a 
participant  experiences a dose -limiting toxicity (DLT). The e scalation plan for the first stage 
is based on grouping treatment combinations into “zones.” With this dose escalation design 
participant s can be accrued and assigned to other open combinations w ithin a zone but 
escalation w ill not occur outside the zone u ntil the minimum follow -up period is observed for 
the first participant  accrued to a combination.  Allocation w ill begin in Zone 1.  
 
 Allocation in Zone 1:  
a) The first eligible participant  in Zone 1 w ill be entered onto combination A, B or C, 
chosen at random.  
b) The second eligible participant  in Zone 1 w ill be randomized to one of the tw o 
remaining combinations in the zone that have not yet been tried.  
c) The third eligible participant  w ill b e entered onto the combination in Zone 1 that 
has not yet been tried.  
d) Escalation to a Zone 2 occurs only w hen all combinations in Zone 1 have 
accrued at least 1 participant  and no participant s have experienced a DLT.  
 
 Allocation in Zone 2:  
a) After completion of Zone 1, the first eligible participant  in Zone 2 w ill be entered 
onto combination D, E or F, chosen at random.  
b) The second eligible participant  in Zone 2 w ill be randomized to one of the tw o 
remaining combinations in the zone that have not yet been tried.  
c) The third eligible participant  w ill be entered onto the combination in Zone 2 that 
has not yet been tried.  
d) Escalation to a Zone 3 occurs only w hen all combinations in Zone 2 have 
accrued at least 1 participant  and no participant s have experienced a DLT.  
 
 Allocation in Zone 3:  
a) Note Zone 3 contains a single combination, so the first eligible participant  on 
Zone 3 w ill be entered onto combination G.  
b) If 0/1 participant s experience a DLT, the next eligible participant  w ill be entered 
onto c ombination G. If 0/2 participant s experience DLT, the next eligible 
participant  w ill be randomized to any combination.  
c) In the absence of DLT’s, participant s w ill continue to be randomized to 
combination A through G until a DLT occurs (upon w hich the model ing stage 
begins), or until at least 3 participant s have been treated at every combination, at 
w hich point allocation w ill be based on w hich combination has the highest IRR. In 
the absence of DLT’s, participant s w ill continue to be entered on the combinati on 
w ith the highest IRR until sufficient information has been obtained regarding the 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 59 optimal combination, according to the stopping rules described below . Once a 
DLT has been observed, Stage 2 using CRM modeling begins.  
9.2.2   Combination allocation in Stage 2:  
The second stage w ill allocate eligible participant s based upon a continual reassessment 
method for combinations of agents  (R package, pocrm) . The modeling stage uses (a) a 
selected set of possible orderings for the DLT probabilities and (b) a w orking mode l for the 
DLT probabilities under each ordering.  
 
Table 15 :  Possible Orderings of DLT Probabilities  
Possible orderings of DLT probabilities  
1) A-B-C-D-E-F-G 
2) A-C-B-D-F-E-G 
3) B-A-C-E-D-F-G 
4) B-C-A-E-F-D-G 
5) C-A-B-F-D-E-G 
6) C-B-A-F-E-D-G 
 
 
 
Table 16 :  Working Model of DLT Probabilities Under Each Ordering  
Working model of DLT probabilities under each ordering**  
Order  A B C D E F G 
1 0.01 0.05 0.12 0.20 0.28 0.36 0.45 
2 0.01 0.12 0.05 0.20 0.36 0.28 0.45 
3 0.05 0.01 0.12 0.28 0.20 0.36 0.45 
4 0.12 0.01 0.05 0.36 0.20 0.28 0.45 
5 0.05 0.12 0.01 0.28 0.36 0.20 0.45 
6 0.12 0.05 0.01 0.36 0.28 0.20 0.45 
**Working models were chosen according to the algorithm of Lee and Cheung (2009)  
 
Within each ordering, the continual reassessment method (CRM) is fit, using the w orking 
model and the accumulated data. The second stage w ill accrue eligible participant s in 
cohorts of one and use a CRM model fit to estimate DLT probabilities at each arm 
combination. For each order,  𝑚=1,⋯,6, in Table 16, the DLT probabilities for each  arm 
combination 𝑖=1,⋯,7, are modeled via a one -parameter pow er model, 
𝑃𝑟⁡(DLT at combination ⁡𝑖)≈𝑝𝑚𝑖𝜃𝑚, w here the 𝑝𝑚𝑖 are the w orking model values for order 𝑚 
given in Table 16. After accrual of each participant  into the trial, the parameter 𝜃𝑚 is 
estimated for each ordering by maximum likelihood estimation  w here the likelihood is given 
by ∏(𝑝𝑚𝑖𝜃𝑚)𝑦𝑖
(1−𝑝𝑚𝑖𝜃𝑚)𝑛𝑖−𝑦𝑖7
𝑖=1 w here 𝑦𝑖= the number of DLTs  and 𝑛𝑖=the number of treated 
participant s in arm combination 𝑖. The order w ith the largest likelihood is chosen and, w ithin 
this ordering, DLT probability estimates are updated for each combination. If there is a tie 
betw een the likelihood values of tw o or more orderings, then the selected order is randomly 
chosen from among the tied orderings. These DLT probabilities w ill be used to define a set 
of “acceptable” combinations, defined as any dose w ith estimated DLT probability less than 
or equal to 33%. This toxicity tolerance of 33% w as chosen based on the expectedness of 
adverse events.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 60 9.2.3   Combination recommendation:  
Once the set of “acceptable” combinations is determined, the recommended combination 
w ill be based upon how  many participant s have been ent ered into the study to that point. If 
less than 3 participant s have been treated on any acceptable dose, then the recommended 
combination for the next entered participant  w ill be chosen at random from the acceptable 
combinations. If at least 3 participant s have been treated at every acceptable combination, 
the recommended combination for the next participant  entered is defined as the 
“acceptable” combination w ith the highest observed IRR. After each participant , a new  
recommended combination is obtained, an d the next entered participant  is allocated to the 
recommended combination. Part 1 of t he trial w ill stop once sufficient information about the 
optimal dose range has been obtained, according to the stopping rules outlined in Section 
9.6.1.  
 
9.3   Statistical properties  Part 1 (completed)  
Simulation results w ere run (R package , pocrm ) to display the performance of the design 
characteristics. For each scenario, 1000 simulated trials w ere run. Each table reports the 
true DLT probability at each combination, the true IRR at each combination, the percentage 
of trials in w hich each combinati on w as recommended as the optimal combination, and the 
average number of participant s treated in a simulated study.  
9.3.1   Scenario 1:  
All true DLT probabilities are safe (i.e. less toxic than 33%) and one combination has the 
highest IRR. The true optimal combina tion is indicated in italicized bold type.  
 
Table 17:  Study Scenario 1  
Zones  1 2 3 
Combination  A B C D E F G 
True DLT probabilities  1% 2% 5% 7% 11% 14% 20% 
True IRR  35% 35% 40% 55% 60% 65% 80% 
% optimal combination recommendation  0% 1% 1% 7% 10% 18% 62% 
% participant  allocation  8% 8% 9% 12% 14% 17% 33% 
Average trial size: 45 participant s (25th, 50th, 75th percentile = 40, 43, 48)  
0.4% of simulated trials were stopped for safety  
The overall toxicity rate was 11.8%. The overall IRR was 60.9%.  
 
9.3.2   Scenario 2:  
One combination (G) has true DLT probability more toxic than 33% and the three 
combinations in Zone 2 have the highest IRR among safe combinations. The true range of 
optimal combinations is indicated in italicized bold type.  
 
Table 18:  Study Scenario 2  
Zones  1 2 3 
Combination  A B C D E F G 
True DLT probabilities  5% 6% 8% 22% 23% 25% 45% 
True IRR  45% 50% 50% 65% 65% 65% 80% 
% optimal combination recommendation  6% 10% 10% 25% 22% 20% 5% 
% participant  allocation  12% 14% 13% 18% 18% 17% 8% 
Average trial size: 45 participant s (25th, 50th, 75th percentile = 39, 44, 52)  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 61 2.2% of simulated trials were stopped for safety  
The overall toxicity rate was 18.3%. The overall IRR was 60.0%.  
 
9.3.3   Scenario 3:  
Combinations in Zones 2 and 3 have true DLT probabilities more toxic than 33% and th e tw o 
combinations in Zone 1 have the highest IRR among safe combinations. The true range of 
optimal combinations is indicated in italicized bold type . 
 
Table 19:  Study Scenario 3  
Zones  1 2 3 
Combination  A B C D E F G 
True DLT probabilities  18% 20% 25% 45% 48% 54% 64% 
True IRR  65% 70% 70% 80% 80% 80% 90% 
% optimal combination recommendation  19% 28% 25% 1% 1% 0% 0% 
% participant  allocation  25% 29% 29% 6% 6% 5% 1% 
Average trial size: 29 participant s (25th, 50th, 75th percentile = 21, 33, 39)  
25.2% of simulated trials were stopped for safety  
The overall toxicity rate was 25.4%. The overall IRR was 70.6%.  
 
9.3.4   Scenario 4:  
All true DLT probabilities are unsafe (i.e. more toxic than 33%).  
 
Table 20:  Study Scenario 4  
Zones  1 2 3 
Combination  A B C D E F G 
True DLT probabilities  50% 55% 56% 65% 66% 74% 80% 
True IRR  70% 70% 70% 80% 80% 80% 90% 
% optimal combination recommendation  1% 1% 3% 0% 0% 0% 0% 
% participant  allocation  32% 28% 35% 2% 2% 1% 0% 
Average trial size: 7 participant s (25th, 50th, 75th percentile = 2, 3, 6)  
96% of simulated trials were stopped for safety  
The overall toxicity rate was 45.6%. The overall IRR was 70.3%.  
 
9.4   Study design  Part 2 
A fixed sample size design w ill be used in p art 2. The vaccine regimen is selected based on 
available data from Part 1, in w hich the recommended combination w as Arm E . For Part 2 , 
all accruals w ill be to S tudy Arm E2.  
 
9.5   Sample size/accrual  
9.5.1   Part 1 (completed)  
Maximum sample size is based upon acquiring sufficient information to assess the objective 
of selecting the arm w ith the highest IRR, assuming at least one optimal combination has 
been found.  
 
Data from our prior Mel43 trial in the arms not getting GM -CSF 12 indicated a high T cell 
response (5 -fold increase in reactivity, at least 1200  cells per 100,000 CD8, and no overlap 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 62 of 2 SD) to the 12 peptide vaccine in PBMC in 30 of 60 participant s (50%, 95%CI (37 %, 
63%)). Using the range as an approximate guideline, maximum sample size is established 
to ensure that if IRR among all seven arms d iffer by 30%, w ith the smallest expected rate of 
50%, then the arm w ith the higher IRR w ould be selected w ith high probability, P=0.90. The 
initial maximum target accrual of 20 eligible participant s per arm is based upon the ranking 
and selection procedure , BSH 75, w hich allow s selection of the best treatment w orthy of 
further investigation in single -factor Bernoulli response experiments. How ever, it is not 
anticipated that all arms w ill fall in the range of optimal combinations, thus, sample size is 
estimated from the simulations and w ill be determined by the stopping rul es below . Although 
maximum accrual is set at 140, in the simulation results below , on average a total of 
betw een 7 and 46 participant s w ere required to complete the study.  
  
Accrual is estimated at 2 participant s per month at each site (4 per month overall). The 
maximum accrual to the study is estimated from the simulations to be approximately 52 
participant s. Adjusting for 10% ineligibility/dropout/w ithdraw al rate, maximum total target 
accrual  for Part 1  is esti mated at 58 participant s. 
9.5.2   Part 2 
Immune response w as observed in 6/16 (37.5%, 90%CI [17.8, 6 0.9%]) from Part 1 . For Part 
2 target accrual is set at 16 eligible participants. At study conclusion, if w e observe that at 
least 12/16 (a doubling of the response  rate) eligible participants satisfy the definition of 
immune response then the low er limit of a one -sided 80% CI around the observed immune 
response rate for Arm E2 w ould be 61.5% w hich w e w ould conclude support s that the 
immune response rate is likely to be higher for single site injections .  If few er responses are 
observed then additional studies w ill be needed to better understand the impact of site 
rotation w ith  the use of the tetanus helper peptide.  
 
Accrual is estimated at 2 participant s per month. A djusting for 10% dropout rate, maximum 
total target accrual  for Part 2  is estimated at 18 participant s. 
 
9.6   Stopping rules:  
9.6.1   Part 1 (completed)  
The study w ill be stopped according to the follow ing rules:  
1. The study w ill stop early for safety if the first three entered participant s in Zone 1 
experience DLT on combinations in Zone 1 in Stage 1.  
2. If at any point in Stage 2, the set of acceptable combinations is empty, the trial w ill stop 
for safety.  
3. The study  w ill stop if the recommendation is to assign the next participant  to a 
combination that already has 20 participant s treated at that combination.  
9.6.2   Part 2  
Safety w ill be assessed by monitoring the number of participant s w ho experience a DLT. In 
Part 1, 1/16  (6.3%, 95%CI [0.2, 30.2%]) participant s treated on Arm E experienced a DLT. 
For Part 2 the upper boundary of a sequential probability ratio test (SPRT) based upon a 
binomial test of proportions for DLT w ill be used for monitoring to protect against excess ive 
DLT rates.  The stopping boundary is for a SPRT contrasting a 5% versus 30% DLT rate, 
w ith nominal type I and II errors of 5% and 20%, respectively. Safety stopping guidelines for 
the occurrence of DLTs are detailed in the follow ing table. If a stoppin g bound is crossed 
then accrual to the study w ill be suspended until the study PI, co -investigators and the 
DSMC can review  the data, and determine if the study should  continue, be amended or be 
closed to further accrual.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 63            Table 21: Incidence of  Treatment -Related DLTs  
Incidence of treatment related DLTs  
Number of participant s Stopping boundary  
2-4 ≥ 2 
5-11 ≥ 3 
12-18 ≥ 4 
 
9.7   Analyses  
9.7.1   Safety:  
All participant s w ho receive any study intervention w ill be monitored for adverse events. 
Adverse events w ill be described and coded based upon the NCI CTCAE v4.03. A DLT is 
defined as any unexpected adverse event that is possibly, probably or definitely related to 
treatment and satisfies the criteria in section 7. 8.  Occurrence of DLTs w ill guide escalation 
and stopping decisions.  At study conclusion frequency, proportion and severity of adverse 
events, and DLTs by arm w ill be tabulated.  
 
9.7.2   Immunologic response:  
Subjects are evaluable for immune response if at least one post treatment sample is 
measurable for response. Peak immunogenicity w ill be evaluated by direct ELIspot assay 
against the defined nonamer peptides in the peripheral blood. The presence or absence  of 
an immune response w ill be defined by induction of at least a 2 -fold increase in IFN -gamma -
secreting cells over background, and over pre -existing responses, and at least 30 IFN -
gamma secreting spots per 100,000 CD8 T cells, as described 34.  This assessment w ill be 
performed  on blood through w eek 12, although a minimum of 4 w eeks of data w ill be used 
to guide decisions about the range of optimal dose combinations.  IRR is defined as the 
proportion of participant s w here presence (as defined above) of an immune response has 
been observed.  
 
Durable immunogenicity w ill be evaluated w eek 26 by ELIspot assay against the defined 
nonamer  peptides in the peripheral blood. The presence or absence of an immune response 
at that time w ill be defined by induction of at least a 2 -fold increase in IFN -gamma -secreting 
cells over background, and over pre -existing responses, and at least 30 IFN -gamm a 
secreting spots per 100,000 CD8 T cells, as described 34.  This assessment w ill be 
performed on blood through w eek 26.  
 
9.7.3   At study conclusion:  
Frequency and magnitude of adverse events w ill be summarized by arm. Point estimates 
and confidence intervals w ill be calculated for a ll dichotomous endpoints. If more than one 
combination is contained w ithin the range of optimal combinations, estimates and 
confidence intervals w ill be used to estimate the difference in IRR betw een pairs of 
combinations among those in the range of optima l combinations.  
 
Immunogenicity w ill be evaluated by direct ELIspot assay against the defined nonamer 
peptides in vaccine site biopsies using the above criteria.  Disease -free survival is defined as 
the duration of time from start of treatment to time of recurrence/progression or death from 
any cause, w hichever occurs first. Participant s w ho do not experience an event 
(recurrence/progression or death) w ill be censor ed at date of last contact. Overall survival is 
defined as the duration of time from start of treatment to time of death from any cause. 
Participant s w ho do not experience an event (death) w ill be censored at date of last contact.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 64 Disease -free survival an d overall survival distributions w ill be estimated by the product limit 
method of Kaplan and Meier.  
 
10.0   Appendices  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 65 10.1   Appendix 1: X -page  
 
Studies & Tests    Active Treatment  Follow -up 
Day Pre  1 8 15 22 36 43 57 78 85 183 365 730 
Week   0 1 2 3 5 6 8 11 12  26 52 104 
Vax #   1 2 3  4  5 6     
Informed consent a  X                       
Class I HLA -typing a  X                       
Pathology review a  X                       
-HCG c   X                       
HIV / Hepatitis C d  X                       
HGBA1C b  X                       
Urinalysis b  X                       
CBC with differential b  X       X       X X     
Comprehensive chemistry b, f  Xe       X       X X     
LDH b  X       X       X X     
Anti-nuclear antibody / Rf 
factor     X      X       X  X    
Chest x -ray / CT b, g  X                 X X   
Abdominal CT b, g  X                       
Pelvic CT b, g  X                       
Head MRI / CT b, g  X                       
History & physical b  X X X X X X X X X X X X X 
120cc green top tubes     X                     
80cc green top tubes      X  X   X    X X X X 
20cc red top tubes     X X  X   X    X X X X 
Vaccination     X X X  X  X X        
Biopsy normal skin,  pts 1 -6, 
in Part 1     X i  X i         
Vaccine Site Biopsies      X   X             
Visual acuity, and color 
acuity examinations     X             X     
Note hair and eye color    X        X    
Note vitiligo    X   X     X X    
Note neurologic function    X   X     X X   
Distribute/review participant 
toxicity diary    X X X X X X X X Xh    
 
a Any  point prior to randomization   
b Pre-study  within 6 weeks of  randomization  
c Within 2 weeks of  randomization (f or childbearing women)  
d Within 6 months of  randomization 
e   To include f asting glucose .  Fasting blood sugars may  be ev aluated 4h or more af ter last eating.    
f   Comprehensiv e chemistry  panel to include sodium, potassium, creatinine, glucose, calcium, total bilirubin, AST, ALT, and alka line phosphatase  
g   PET-CT may  replace CT of  the chest, abdomen, and/or pelv is. New abnormalities of  AST, ALT, or LDH lev els, or new nodules on CXR will 
warrant more complete staging with CT scans of  the chest, abdomen and pelv is  or PET -CT and with CT or MRI of  the brain as a ppropriate.  
h     Rev iew only   
i   Biopsies of  normal skin to be done just f or the f irst 6 patients enrolled in Part 1.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 66 10.2   Appendix 2: AJCC Staging System , 7th Edition  
 
Melanoma TNM Classification  
T Classification  Thickness  Ulceration Status  
T1 ≤ 1.0 mm  a:  without ulceration and level II/III  
b:  with ulceration or mitoses ≥1/mm2  
T2 1.01 – 2.0 mm  a:  without ulceration  
b:  with ulceration  
T3 2.01 – 4.0 mm  a:  without ulceration  
b:  with ulceration  
T4 > 4.0 mm  a:  without ulceration  
b:  with ulceration  
   
N Classification  # of Metastatic Nodes  Nodal Metastatic Mass  
N1 1 node  a:  micrometastasis*  
b:  macrometastasis † 
N2 2 – 3  nodes  a:  micrometastasis*  
b:  macrometastasis † 
c: in transit met(s)/satellite(s) without 
metastatic nodes  
N3 4 or more metastatic nodes, 
or matted nodes, or  
in transit met(s)/satellites(s) 
with metastatic node(s)   
   
M Classification  Site Serum Lactate Dehydrogenase  
M1a Distant skin, subcutaneous  
or nodal mets  Normal  
M1b Lung metastases  Normal  
M1c All other visceral metastases  Normal  
Any distant metastasis  Elevated  
* Micrometastases are diagnosed after sentinel or elective lymphadenectomy.  
† Macrometastases  are defined as clinically detectable nodal metastases confirmed by therapeutic 
lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.  
 
 
  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 67 Stage Groupings for Cutaneous Melanoma  
 Clinical Staging  Pathologic Staging  
 T N M T N M 
0 Tis N0 M0 Tis N0 M0 
IA T1a N0 M0 T1a N0 M0 
IB T1b 
T2a N0 
N0 M0 
M0 T1b 
T2a N0 
N0 M0 
M0 
IIA T2b 
T3a N0 
N0 M0 
M0 T2b 
T3a N0 
N0 M0 
M0 
IIB T3b 
T4a N0 
N0 M0 
M0 T3b 
T4a N0 
N0 M0 
M0 
IIC T4b N0 M0 T4b N0 M0 
III‡ Any T  N1 
N2 
N3 M0  
IIIA  T1-4a 
T1-4a N1a 
N2a M0 
M0 
IIIB  T1-4b 
T1-4b 
T1-4a 
T1-4a 
T1-4a/b N1a 
N2a 
N1b 
N2b 
N2c M0 
M0 
M0 
M0 
M0 
IIIC  T1-4b 
T1-4b 
Any T  N1b 
N2b 
N3 M0 
M0 
M0 
IV Any T  Any N  Any M1  Any T  Any N  Any M1  
* Clinical staging includes microstaging  of the primary melanoma and clinical/radiologic evaluation 
for metastases.  By convention, it should be used after complete excision of the primary 
melanoma with clinical assessment for regional and distant metastases.  
† Pathologic staging includes micros taging of the primary melanoma and pathologic information 
about the regional lymph nodes after partial or complete lymphadenectomy.  Pathology stage 0 or 
stage 1A patients are the exception; they do not require pathologic evaluation of their lymph 
nodes.  
‡ There are no stage III subgroups for clinical staging.  
 
 
Addendum:  Staging for Mucosal Melanomas  
This system is based on the staging of cutaneous melanomas.  
 
Stage IIB:  Clinically localized primary melanoma > 4mm thick  
Stage III:  Lymph node metastases  
Stage IV:  Distant metastases  
 
 
 
 
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 68 10.3   Appendix 3: ECOG Performance Status  
 
Grade  Performance  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g. light house work, office work  
2 Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and 
about more than 50% of waking hours  
3 Capable of only limited self-care, confined to be d or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any self-care.  Totally confined to bed or chair  
5 Dead  
* As published in Am. J. Clin. Oncol.:  Oken, M.M., Creech, R.H., Tormey , D.C., Horton, J., Davis, T.E., 
McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. 
Am J Clin Oncol 5:649 -655, 1982.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 69 10.4   Appendix 4: New  York Heart Association Disease Classification  
 
Functional Capacity  Objective Assessment  
Class I.  Patients with cardiac disease but 
without resulting limitation of physical activity. 
Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain.  No objective evidence of cardiovascular 
disease.  
Class II.  Patients with cardiac disease resulting 
in slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or 
anginal pain.  Objective evidence of minimal cardio vascular 
disease  
Class III.  Patients with cardiac disease 
resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, dyspnea, or 
anginal pain.  Objective evidence of moderate ly severe 
cardiovascular disease.  
Class IV.  Patients with cardiac disease 
resulting in inability to carry on any physical 
activity without discomfort. Symptoms of heart 
failure or the anginal syndrome may be present 
even at rest. If any physical activity  is 
undertaken, discomfort is increased.  Objective evidence of severe cardiovascular 
disease.  
* The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels . 9th ed. Boston, M ass: Little, Brown & Co; 1994:253 -256 
 
  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 70 10.5   Appendix 5: Lot Testing   
A. Preparation of the synthetic melanoma and tetanus peptides  
All peptides have been synthesized under  GMP conditions  by Polyp eptide Group  (San 
Diego, CA)  or comparable provider .  Certificates of analysis and technical summaries for 
each of the peptides w ill be  included in the chemistry and manufacturing portion of the 
IND application.  
 
Peptide preparation and vialing has been performed under GMP conditions by 
Clinalfa/Merck for the tetanus pep tide, and Bachem for the NY -ESO-1 long peptide, and  
w ill be  performed under GLP conditions by the UVA Human Immune Therapy Center 
laboratory  for the 6 peptides in the LPV6 long peptide mixture .  Documentation relating 
to the procedures used to prepare and vial the peptides w ill comply w ith the CFR and 
w ill be  included in the Chemistry and Manufacturing Section of the IND application.   
 
B. Lot Release Quality Assurance Testing  
Prepared peptides w ill be  subjected to the follow ing tests:  
 
1. Identity :  Identity w ill be  confirmed by structural studies.  The individual peptides w ill 
be tested for identity by mass spectrometry (to define molecular mass and amino 
acid sequence) and high performance liquid chromatography  (HPLC, to confirm 
purity) in a GMP laboratory (P olypeptide Group ). Amino acid analysis w ill also be 
performed to confirm identity further.  
 
Before mixing, the amino acid sequence of each individual peptide preparation w ill 
be reconfirmed by mass spectrometry or co -elution.  
 
After com bining the peptides, the mixture w ill be  subjected to HPLC analysis.  
 
2. Purity :  Purity w ill be  assessed before and after vialing the peptide mixtures.  Before 
vialing the peptide mixtures, each synthetic peptide w ill be  evaluated for the 
presence of a si ngle dominant species by high performance liquid chromatography 
(HPLC).  Purity of each peptide component w ill exceed 90% ( expected 94%-98%).  
Variants of the original peptide may include incomplete products of synthesis, minor 
degradation products due to oxidation of methionine residues, and dimerization of 
cysteine -containing peptides.  After vialing the peptide mixture, purity w ill be  
reconfirmed by HPLC.  
 
3. Aggregation:  Aggregation of peptides w ill be assessed by HPLC.  Aggregation is not 
expected.  
 
4. Trifluoroacetic acid (TFA) :  The amount of total fluorine  in each peptide preparation 
w ill be less than 0.5% or 5000 ppm.  
 
5. Potency :  The net peptide content w ill be  calculated for each  synthesis .  The 
amounts of each peptide (mcg quantities) added to th e vaccine vials are calculated 
based on the net peptide content of the original stock of lyophilized peptides.  
The amount of peptide in each sterile filtered peptide solution w ill be measured by 
amino acid analysis . The final vials w ill also be tested for quantity of total peptide by 
amino acid analysis.  Lot release criteria are defined in the Chemistry and 
Manufacturing section of the IND application.  
 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 71 6. Endotoxin :  Endotoxin testing w ill be  conducted in accordance w ith CFR guidelines.  
 
7. General Safety :  General safety testing w ill be  conducted in accordance w ith US 
CFR guidelines.  
 
8. Sterility :  Sterility testing w ill be conducted in accordance w ith CFR guidelines.  
 
C. Ongoing  Quality Assurance Testing  
Stability :  We w ill follow  guidelines for quality  assurance studies to assure stability of the 
peptide preparation over time during the trial76.   The peptide preparations w ill be 
assayed for stability every six months for 2 years and every year thereafter .  The 
follow ing analyses w ill be performed to confirm stability:  
1. HPLC :  HPLC w ill be performed to confirm purity.  A comparison to previous HPLC  
data w ill be performed.  Ideally, the purity of each peptide  component w ill exceed 
90% (94% -98%).  Variants of the original peptide may include incomplete products 
of synthesis, minor degradation products due to oxidation of methionine residues, 
and dimer ization of cysteine -containing peptides.  Such minor variants w ill be 
tolerated as long as the intended peptide represents at least 75% of the total peptide 
species.  With liquid formulations of this peptide preparation, w e have observed 
dimerization of cy steine -containing peptide s, yet this peptide retained 
immunogenicity even w hen as little as 10% remains as monomer.  For the present 
study, dimerization of cysteine -containing  peptide s w ill be acceptable as long as at 
least 25% remains as monomer by HPLC.  Because measures of peptide quantity 
are subject to variability, a peptide lot w ill be rejected only if tw o sequential 
measures fail to meet the criterion stated above.  If a second measure is required, 
the lot w ill be held until the second reading is obt ained and show n to be acceptable.  
 
2. Aggregation.  Aggregation w ill also be assessed by HPLC.  
 
3. Mass spectrometry .  This w ill be performed on each peptide peak to define the 
molecular sequence and mass  if there is any ambiguity about the identity of the 
peptides based on HPLC.   New  peaks on HPLC, or significant change in the elution 
profiles w ill w arrant determination of the peptide identities by mass spectrometry on 
each peak.  
 
4. Sterility :  One vial of  peptide w ill be submitted to the Clinical Microbiology Laboratory 
at the University of Virginia or Microbiology Research Associates, Inc. (Acton, MA).  
Sterility testing w ill be conducted in accord w ith FDA guidelines in 21 CFR part 
610.12.  
  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 72 10.6   Appendix 6: NCI Common Terminolog y Criteria for Adverse Events v4 .03 
 
http://evs.nci.nih.gov/ftp1/CTCAE  
 
 
  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 73 10.7   Appendix 7:  Summary of Changes  
 
07-31-17 1) Updated Table of Contents . 
2) Section 1.1: updated to address current treatments for resected 
melanoma in the adjuvant setting . 
3) Section 1.2.6: updated to address ipilimumab  approval for treatment of 
resected melanoma in the adjuvant setting.  
4) Section 4.1: removed reference to interferon  packet.  
5) Sectio n 5.6.1: added  targeted molecular therapy (e.g. vemurafenib, other 
inhibito r of mutant BRAF, MEK, or cKit) as nonmerpitted treatments . 
6) Section 5.6.2.6: edited to indicate that any live vaccines (e.g. FluMist) are 
permitted, but should be administered at least 2 weeks prior to or at least 
2 weeks after a study vaccine . 
7) Updated reference list.  
06-26-17 1) Updated cover sheet  
2) Updated study personnel  
3) Updated formatting and numbering throughout study document  
4) Additional administrative changes and  typographical errors corrected 
throughout the document to improve readability.  
5) Table of Contents:  Updated  
6) Protocol precis  
 Design: T he study has been divided into Part 1 and P art 2.  Part 1 
required rotating vaccine sites and accrual to this part was  
completed .  Part 2 of the study has been added and the regimen 
requires that each vaccine is administered in the same skin site for 
all 6 vaccines.  
 The objectives have been revised to add objectives specific for part 
2. 
 Table 1 has been re -labeled as Tabl e 1A.  The title of the table has 
been revised to specify that Table 1A is relevant for Part 1 of the 
study.  
 Addition of Table 1B:  Study Arm E2 has been specified for Part 2 of 
the study.  
 The rationale for choosing the vaccine regimen from study arm E 
has been added.  
 Regimen:  Revised to describe regimen for Parts 1 and 2 of the 
study.  
 Vaccine site biops ies:  revised to specify that 3 punch biopsies of 
normal skin will be completed in the first 6 patients enrolled in Part 1 
of the study.  
 Leadership:  Revis ed to specify that Part 2 of the study will be 
conducted just at the University of Virgina.  
 Accrual:  Adjusted to allow for an additional patients to be enrolled 
to part 2 of the study.  
 
7) Section 1.0:  Updated accrual information.  
8) Section 1.1:  Updated information describing incidence of melanoma and 
deaths from melanoma in 2017 and a dded a section on vaccine site 
selection to provide a rationale for evaluating same site vaccinations.  
9) Section 1.2.6:  Updated information on approved adjuvant therapies for  
melanoma.  
10) Section 1.2.10:  Added prior experience with same site vaccinations.  
11) Added Table 5 to describe vaccine site reactions for prior Mel44 and 
Mel58 studies.  
12) Section 2.0:  Revised objectives to add objectives for Part 2.   
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 74 13) Section 3.1:  Regimen -added t he regimen for Part 2, which includes 
same site vaccinations.  
14) Section 4.2.7(1):  Corrected section reference.  
15) Section 4.4.2:  Revised randomization section and specified that Part 2 of 
the study will not include randomization.  
16) Section 5.2.1: Added a descri ption for preparing drug for Study Arm E2.  
17) Section 5.4.2:  Deleted prior text describing the vaccine regimen and 
replaced with a description for the administration of vaccines for Part 1 
and Part 2  and a description of expected  vaccine site toxicities . 
18) Section 5.4.3:  A section describing doses for part 2 of the study has 
been added.  
19) Section 5.4.6  , 6.2.2, 6.2.4 , Appendix 1 :  Clarified that biopsies of normal 
skin will be completed in the first 6 participants who are enrolled in Part 1.  
20) Section 5.6:  Cla rified that patients will be randomized in Part 1 and 
assigned to an  arm in Part 2  of the study.  
21) Section 7.4.3:  Clarified that grade 3 injection site reactions with  
significant ulceration of the skin (> 2 cm) will be considered DLTs.   
Clarified dermatolo gic toxicities for resiquimod.  
22) Section 7.8:  Added grade 3 injection site reaction with ulceration ≤ 2 cm  
as an exception to the DLT rule  
23) Section 9.0:  Revised introduction to statistical considerations to add 
information about Part 2 of the study.  
24) Section  9.1-removed the DLT rule from this section and revised to refer to 
section 7.8 of the protocol.  
25) Sections 9.2, 9.3, 9.4, 9.5, 9.6:  clarified which sections pertain to Part 1 
and added statistical language for Part 2.  
26) Reformatted headings for the appendices  
27) Appendix 7:  added a summary of changes list for prior versions of the 
protocol  
06-17-14 1) Sapna Patel’s role was changed from co -investigator to PI at MD 
Anderson Cancer Center.  
2) Table of Contents page numbers were updated.  
 
06-06-14 1) Section 1.2.3:  Editorial change for clarification  
2) Section 1.2.4:  Editorial change for clarification  
3) Section 1.2.5:  The dosing for resiquimod  was revised to include an 
acceptable dose range of 400 -600 mg. Instructions about coverage and 
washing the affected area have been incorporated into the study protocol.  
4) Section 1.2.8:  Reference added  
5) Table 3:  Reformatted  
6) Table 4:  Updated with new data  
7) Section 4.1.4:  Clarification of inclusion criterion and whether repeat scans 
are needed after stereotactic radiotherapy.  
8) Section 4.1.5:  Clarification of inclusion criterion and the description of 
required lymph node basins.  
9) Section 4.1.8:  Clarification of inclusion criterion a) specifications for patients 
with Gilbert’s disease and b) re -defined acceptable limit for Hgb -A1C level.  
10) Section 4.2.11:  Addition of the following to allowable autoimmune disorders:  
       Hypothyroidism of any etiology on stable  thyroid hormone replacement 
therapy.  
11) Section 5.2.1:  Arms E and G:  Change in mixing instructions for PolyICLC.  
PolyICLC will be incorporated into the vaccine mixture rather than 
administered as a separate injection.   
12) Section 5.2.1:  Clarification of vaccine components for Study Arms C, D, F 
and G.  The dose of resiquimod was adjusted from 500 mg to approximately 
500 mg.  Instructions aoubt coverage and washing the affected area have 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 75 been incorporated into the study pro tocol.  
13) Reference List:  Updated.  
 
03-25-14 1) Dr. Geoffrey Weiss and Dr. Elizabeth Gaughan have been added to the list of 
co-investigators.  
2)  The Table of Contents was updated.    
3) The dose of resiquimod  has been corrected throughout the study document.  
The correct dose is 1000 mcg and the drug will be supplied in multi -dose tubes.  
Section 1.2.6 also includes information on prior usage with this dose.  
4) Section 4.1.4:  An editorial change was made and also a clarification that the 
brain metastases in this section refer to treated brain metastases.  
5) Section 4.1.8:  The lab parameters inclusion criteria were reformatted.  HIV 
and HCV requirements were moved to the exclusion criteria (Section 4.2.6).  
6) Section 4.2.3:  The reference to Section 4.2.3 within this section was corrected 
to Section 4.2.4.  
7) Section 4.4.1:  Information about the interferon education packets was 
changed to include a statement that participants mus t convice the study team 
that the answered the questions accurately or understand the correct answers.  
8) Section 5.4.1:  A clarification was made to this section to specify that chronic 
inflammation is expected in subjects who receive Montanide ISA -51.  Also, 
editorial changes were ma de to this section.  
9) Section 6.2.2:  “Vaccine site biopsy (3)” was removed from the Day 8 schedule 
of events as the biopsy procedures were listed twice for this day.  
10) Sections 6.2.1, 6.2.2, 6.2.3, 6.2.4, 6.2.5, 6.2.6, 6.2.7, 6.2.8:  Clarfication was 
made to the language pertaining to the interval history and physical exam.  
Examination of vaccine sites was added to each of the study visit days, when 
applicable.  
11) Section 7:  Editorial correction was made to change “or” to “for”.  
12) Section 7.4.3:  A redundant section related to AEs that do not require 
expedited reporting.  Reporting guidelines are provided in Table 12.  
13) Section 7.4.3:  A clarification was made to  the dosing regimen that was used 
for resiquimod  in prior studies.  
14) Section 7.6. 1:  A clarification was made to the process of reporting AEs.  AEs 
determined to require expedited reporting to the sponsor, must also be reported 
to a site’s institution according to local policy and procedures.  
15) Section 7.6.3:  A clarification was mad e regarding reporting AEs to the sites.  
Serious and unexpected suspected adverse reactions will be reported to the sites 
no later than 15 calendar days after the Sponsor determines that the the 
requirements for an IND safety report have been met.  
16) Sect ion 7.7.2:  The phrase “and at UVA by the UVA melanoma team” was 
removed from this section as it did not apply to the outside sites.  Individual AEs 
will be reviewed at each site.  
17) Section 7.7.3:   The term “weekly” was removed when describing the 
melan oma team meetings.  The melanoma team meets 20 times a year, as 
specified in section 7.7.4 of the DSMP.  The term “may” was included in the 
description of the events that are reviewed at each meeting as the agenda varies 
depending upon study accruals.  
18) Section 7.7.4 :  The DSMP was modified to specify that month conference 
calls will be held between the Sponsor and the sites.  
19) Section 9.2.2:  “R -package, pocrm” was added for clarification.  Additional 
statistical methods were added to clarify the mode l of DLT probabilities.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 76 20) 9.6.3: The endpoints of disease -free survival and overall survival have been 
defined.  
21) Appendix 1:  editorial change made to subscript “i”.  
22) Appendix 5:  Clarifications were made to the descriptions of the peptide 
preparat ion and vialing.  
10-10-13  
1) Cover sheet has been updated  
2. New study staff members have been added and the formatting for contact 
information has been corrected.  
3. Zone information has been added to the précis (Table 1) and Table 5 and the 
description of the regimen has been modified to reflect changes in the statistical 
section.  
4. Table of Contents has been updated.  
5. List of abbreviations has been updated.  
6. The timing of the negative control biopsies has been clarified throughout the 
protocol. The negative control biopsies will be completed on days 8 and 22 in the 
first 6 patients.  
7. Table 3: An explanation of the grading criteria are provided.  
8. Secti on 1.2.6 and 5.2.1: additional directions for applying the resiquimod have 
been added.  
9. Section 4.4.1: Replaced the section that participants will have to complete the 
interferon packet questions satisfactorily with a statement that answers to 
questions  in the packet will be reviewed with the participant.  
10. Section 4.4.2: A description of when randomization is to take place in relation 
to registration and the start of treatment has been added.  
11. Section 4.4.3: “suture removal” was removed from the evalution following the 
biopsies as punch biopsies will not require sutures.  
12. Section 5.2 and 5.4.3: The dosage of and preparation of the vaccines were 
clarified.  
13. Section 5.4.6.4: Information on specimen collection delays and the associated 
docume ntation are provided.  
14. Section 5.6.2.6: clarification made to permitted influenza vaccines  
15. Section 6.2 Treatment: The schedules for the immunologic bloods, vaccines, 
and biopsies have been moved to this section.  
16. Section 7.0 Regulatory and Rep orting Requirements: This entire section has 
been revised and reformatted to clarify the reporting requirments for the study. 
The original reporting tables have been replaced with a template table from the 
UVA Cancer Center DSMP and an IRB reporting table has been added. In 
addition, reporting criteria for reporting to the FDA have been replaced.  
17. Section 7.1.3: A clarification for the definition of hospitalization for expedited 
AE reporting has been added.  
18. Section 7.5: Adverse event classification s have been updated and the 
hospitalization category has been moved to the description for an SAE.  
19. Section 7.5: AE classifications have been updated to include 
Hematologic/Metabolic and Non -Hematologic/Non -metabolic categories. 
Autoimmune has been add ed to the allergic category.  
20. Section 7.7.1: Replaced section stating that someone from the research team 
would be available 24 hours a day 7 days a week for questions with the statement 
that subjects would be given information on how to contact their providers if they 
have questions or problems.  
21. Section 9.1: The table has been modified to correct the description of the 
adjuvant preparation for each arm/combination.  
22. Section 9.2: A description of the randomization has been added.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 77 23. Appendix 1: Administrative changes have been made to the X -page to 
improve readability.  
24. Additional administrative changes and typographical errors corrected 
throughout the document to improve readability.  
 
08-06-13 1) An additional study group has been added in response to the 
recommendations of the FDA and of our collaborators at MD Anderson Cancer 
Cente  
2) The study design has been changed to incorporate an adaptive design in order 
to minimize data with the least number of patients. This reduces the target 
sample size by half.  
3) Section 4.4 of the study protocol has been modified to include additional details 
regarding the registration and randomization of study patients.  
4) A section for study drug accountability and distribu tion has been added 
(section 5.3)  
5) Table of Contents has been updated.  
6) The source of Hiltonol (polyICLC) has been updated, in section 1.2.5.  
7) Updated section 1.2.10 to specify that the peptides for the vaccines have been 
synthesized under GMP conditions, rat her than GLP.  
8) Appendices about vaccine preparation, immunologic assays, and details of 
tissue handling with the biopsies has been removed from the protocol and will be 
included ina Study Manual and Investigator Brochure.  
9) Numerous small administrative chang es have been made to improve clarity, 
consistency and readability and to provide appropriate citations.  
10) Details about the quality assurance studies to be done on the peptides have 
been added to respond to the FDA after our preIND meeting.  
11) Skin biopsies hav e been amended: Patients 1 -6 will have 3 skin punch 
biopsies rather than 2, on day 1.  The 3rd sample from skin on day 1 in those 
patients and from all patients on days 8 and 22 will be stored in RNA later rather 
than be collected for viable cell studies.  
12) Signature page and study staff contact information has been added.  
13) X-page has been corrected with regards to the timing of the normal skin 
biopsies.  
 
12/05/11  1) Section 4.4 of the study protocol has been modified to include additional 
details regarding the registration and randomization of study patients.  
2) A section for study drug accountability and distribution has been added 
(section 5.3)  
3) Table of Contents has been updated.  
 
  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 78 11.0   Reference List  
 
 
 (1)  Kenter GG, Welters MJ, Valent ijn AR et al. Vaccination against HPV -16 oncoproteins 
for vulvar intraepithelial neoplasia. N Engl J Med  2009;361:1838 -1847.  
 (2)  Sabbatini P, Tsuji T, Ferran L et al. Phase I Trial of Overlapping Long Peptides from 
a Tumor Self -Antigen and Poly -ICLC Show s Rapid Induction of Integrated Immune 
Response in Ovarian Cancer Patients. Clin Cancer Res  2012;18:6497 -6508.  
 (3)  Gnjatic S, Saw hney NB, Bhardw aj N. Toll -like receptor agonists: are they good 
adjuvants? Cancer J  2010;16:382 -391. 
 (4)  Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell 
responses to vaccination w ith peptide, IFA, and CpG oligodeoxynucleotide 7909. J 
Clin Invest  2005;115:739 -746. 
 (5)  Schw artzentruber DJ, Law son DH, Richards JM et al. gp100 peptide v accine and 
interleukin -2 in patients w ith advanced melanoma. N Engl J Med  2011;364:2119 -
2127.  
 (6)  Ascierto PA, Gogas HJ, Grob JJ et al. Adjuvant interferon alfa in malignant 
melanoma: an interdisciplinary and multinational expert review . Crit Rev Oncol 
Hematol  2013;85:149 -161. 
 (7)  Agarw ala SS, Lee SJ, Flaherty LE et al. Randomized phase III trial of high -dose 
interferon alfa -2b (HDI) for 4 w eeks induction only in patients w ith intermediate - and 
high-risk melanoma (Intergroup trial E 1697) . [abstract]Ag arw ala SS, Lee SJ, 
Flaherty LE et al. J Clin Oncol  2011;29 suppl:Abstract 8505  
 (8)  Slingluff CL, Jr., Petroni GR, Chianese -Bullock KA et al. Immunologic and clinical 
outcomes of a randomized phase II trial of tw o multipeptide vaccines for melanoma 
in the  adjuvant setting. Clin Cancer Res  2007;13:6386 -6395.  
 (9)  Slingluff CL, Jr., Chianese -Bullock KA, Bullock TN et al. Immunity to melanoma 
antigens: from self -tolerance to immunotherapy. Adv Immunol  2006;90:243 -95.:243 -
295. 
 (10)  Kirkw ood JM, Lee S, Land S et al. E1696: Final analysis of the clinical and 
immunological results of a multicenter ECOG phase II trial of multi -epitope peptide 
vaccination for stage IV melanoma w ith MART -1 (27 -35), gp100 (209 -217, 210M), 
and tyrosinase (368 -376, 370D) (MGT) +/ - IFNa2b and GM -CSF. [abstract]Kirkw ood 
JM, Lee S, Land S et al. J Clin Oncol (Meeting Abstracts)  2004;22:7502  
 (11)  Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite 
the induction of very high levels of self/tumor antigen -specific  CD8+ T cells in 
patients w ith melanoma. JI 2005;175:6169 -6176.  
 (12)  Slingluff CL, Jr., Petroni GR, Olson WC et al. Effect of GM -CSF on circulating CD8+ 
and CD4+ T cell responses to a multipeptide melanoma vaccine: Outcome of a 
multicenter randomized tri al. Clin Cancer Res  2009;15:7036 -7044.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 79  (13)  Slingluff CL, Jr., Petroni GR, Yamshchikov GV et al. Immunologic and clinical 
outcomes of vaccination w ith a multiepitope melanoma peptide vaccine plus low -
dose interleukin -2 administered either concurrently or  on a delayed schedule. J Clin 
Oncol  2004;22:4474 -4485.  
 (14)  Slingluff CL, Jr., Petroni GR, Olson W et al. Helper T cell responses and clinical 
activity of a melanoma vaccine w ith multiple peptides from MAGE and melanocytic 
differentiation antigens. J Clin Oncol  2008;26:4973 -4980.  
 (15)  Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond 
current vaccines. Nat Med  2004;10:909 -915. 
 (16)  Rosenberg SA, Yang JC, Kammula US et al. Different adjuvanticity of incomplete 
freund's adjuvant der ived from beef or vegetable components in melanoma patients 
immunized w ith a peptide vaccine. J Immunother  2010;33:626 -629. 
 (17)  Slingluff CL, Jr., Petroni GR, Smolkin ME et al. Immunogenicity for CD8+ and CD4+ T 
cells of tw o formulations of an incomplet e Freund's adjuvant for multipeptide 
melanoma vaccines. Journal of Immunotherapy  2010;33:630 -638. 
 (18)  Hailemichael Y, Dail Z, Jaffarzad N et al. Persistent antigen at vaccination sites 
induces tumor -specific CD8+ T cell sequestration, dysfunction and de letion. J Exp 
Med 2013;in press.  
 (19)  Salerno EP, Shea SM, Olson WC et al. Activation, dysfunction and retention of T 
cells in vaccine sites after injection of incomplete Freund's adjuvant, w ith or w ithout 
peptide. Cancer Immunol Immunother  2013.  
 (20)  Law son DH, Lee SJ, Tarhini AA, Margolin KA, Ernstoff MS, Kirkw ood JM. E4697: 
Phase III cooperative group study of yeast -derived granulocyte macrophage colony -
stimulating factor (GM -CSF) versus placebo as adjuvant treatment of patients w ith 
completely resec ted stage III -IV melanoma. [abstract]Law son DH, Lee SJ, Tarhini 
AA, Margolin KA, Ernstoff MS, Kirkw ood JM. J Clin Oncol  2010;28:abstract 8504  
 (21)  Song XT, Turnis ME, Zhou X et al. A Th1 -inducing adenoviral vaccine for boosting 
adoptively transferred T c ells. Mol Ther  2011;19:211 -217. 
 (22)  Ly LV, Sluijter M, Versluis M et al. Peptide vaccination after T -cell transfer causes 
massive clonal expansion, tumor eradication, and manageable cytokine storm. 
Cancer Res  2010;70:8339 -8346.  
 (23)  Song S, Zhang K, Y ou H et al. Significant anti -tumour activity of adoptively 
transferred T cells elicited by intratumoral dendritic cell vaccine injection through 
enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Clin Exp Immunol  
2010;162:75 -83. 
 (24)  Lou Y, Wang G, Lizee G et al. Dendritic cells strongly boost the antitumor activity of 
adoptively transferred T cells in vivo. Cancer Res  2004;64:6783 -6790.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 80  (25)  Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death 
ligand 1 enhances the t herapeutic efficacy of combination immunotherapy against 
melanoma. J Immunol  2010;184:3442 -3449.  
 (26)  Rosenberg SA. A new  era for cancer immunotherapy based on the genes that 
encode cancer antigens. [Review ] [79 refs]. Immunity  1999;10:281 -287. 
 (27)  Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five 
melanoma -specific human cytotoxic T cell lines. Science  1994;264:716 -719. 
 (28)  Skipper JC, Kittlesen DJ, Hendrickson RC et al. Shared epitopes for HLA -A3-
restricted melanoma -reactive human CTL include a naturally processed epitope from 
Pmel-17/gp100. JI 1996;157:5027 -5033.  
 (29)  Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against 
epitopes in the human melanoma antigen gp100 follow ing patient immunization w ith 
synthetic peptides. Cancer Res  1996;56:4749 -4757.  
 (30)  Parkhurst MR, Salgaller ML, Southw ood S et al. Improved induction of melanoma -
reactive CTL w ith peptides from the melanoma antigen gp100 modified at HLA -
A*0201 -binding residues. J Immunol  1996;1 57:2539 -2548.  
 (31)  Slingluff CL, Jr., Petroni GR, Yamshchikov GV et al. Clinical and immunologic results 
of a randomized phase II trial of vaccination using four melanoma peptides either 
administered in granulocyte -macrophage colony -stimulating factor in adjuvant or 
pulsed o n dendritic cells. J Clin Oncol  2003;21:4016 -4026.  
 (32)  Slingluff CL, Jr., Petroni GR, Yamshchikov GV et al. Immunologic and clinical 
outcomes of vaccination w ith a multiepitope melanoma peptide vaccine plus low -
dose interleukin -2 administered either con currently or on a delayed schedule. J Clin 
Oncol  2004;22:4474 -4485.  
 (33)  Slingluff CL, Jr., Petroni GR, Chianese -Bullock KA et al. Immunologic and Clinical 
Outcomes of a Randomized Phase II Trial of Tw o Multipeptide Vaccines for 
Melanoma in the Adjuvant Setting. Clin Cancer Res  2007;13:6386 -6395.  
 (34)  Slingluff CL, Jr., Petroni GR, Chianese -Bullock KA et al. A randomized multicenter 
trial of the effects of melanoma -associated helper peptides and cyclophosphamide 
on the immunogenicity of a multipeptide m elanoma vaccine.  J Clin Oncol  
2011;29:2924 -2932.  
 (35)  Kaw akami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the 
human melanoma antigen gp100 by tumor -infiltrating T lymphocytes associated w ith 
in vivo tumor regression. J Immunol  1995;154:3961 -8. 
 (36)  Kittlesen DJ, Thompson LW, Gulden PH et al. Human melanoma patients recognize 
an HLA -A1-restricted CTL epitope from tyrosinase containing tw o cysteine residues: 
implications for tumor vaccine development. J Immunol  1998;160:2099 -2106 . 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 81  (37)  Yamshchikov GV, Barnd DL, Eastman S et al. Evaluation of peptide vaccine 
immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. 
Int J Cancer  2001;92:703 -711. 
 (38)  Skipper JC, Hendrickson RC, Gulden PH et al. An HLA -A2-restricted tyrosinase 
antigen on melanoma cells results from posttranslational modification and suggests a 
novel pathw ay for processing of membrane proteins. J Exp Med  1996;183:527 -534. 
 (39)  Chaux P, Luiten R, Demotte N et al. Identification of five MAGE -A1 epitopes 
recognized by cytolytic T lymphocytes obtained by in vitro stimulation w ith dendritic 
cells transduced w ith MAGE -A1. J Immunol  1999;163:2928 -2936.  
 (40)  Slingluff C, Petroni G, Chianese -Bullock K et al. Effects of melanoma -derived helper 
peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma 
vaccine [abstract]Slingluff C, Petroni G, Chianese -Bullock K et al. Journal of 
Immunotherapy  2009;32:976  
 (41)  Huang LQ, Brasseur F, Serrano A et al. Cytolytic T lymphocytes recognize an 
antigen encoded by MAGE -A10 on a human melanoma. J Immunol  1999;162:6849 -
6854.  
 (42)  Valmori D. Use of HLA -A2/peptide tetramers for the analysis of CD8+ T -cell 
responses to CT antigens in melanoma patients [abstract]Valmori D. Cancer 
Vaccines Meeting (October 2 -4, 2000), sponsored by the Cancer Research Institute  
2000;S12  
 (43)  Karbach J, Gnjatic S, Bender A et al. Tumor -reactive CD8+ T -cell responses after 
vaccination w ith NY -ESO-1 peptide, CpG 7909 and Montanide ISA -51: association 
w ith survival. Int J Cancer  2010;126:909 -918. 
 (44)  Nicholaou T, Ebert LM, Davis ID et al. Regulatory T -cell-mediated attenuation of T -
cell responses to the NY -ESO-1 ISCOMATRIX vac cine in patients w ith advanced 
malignant melanoma. Clin Cancer Res  2009;15:2166 -2173.  
 (45)  Gnjatic S, Altorki NK, Tang DN et al. NY -ESO-1 DNA vaccine induces T -cell 
responses that are suppressed by regulatory T cells. Clin Cancer Res  2009;15:2130 -
2139.  
 (46)  Bioley G, Guillaume P, Luescher I et al. Vaccination w ith a recombinant protein 
encoding the tumor -specific antigen NY -ESO-1 elicits an A2/157 -165-specific CTL 
repertoire structurally distinct and of reduced tumor reactivity than that elicited by 
spontaneous immune responses to NY -ESO-1-expressing Tumors. J Immunother  
2009;32:161 -168. 
 (47)  Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A. Induction of protective 
cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a hum an-
compatible adjuvant (Montanide ISA 720). Journal of Virology  1995;69:1306 -1309.  
 (48)  Fernandez IM, Snijders A, Benaissa -Trouw  BJ, Harmsen M, Snippe H, Kraaijeveld 
CA. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 82 of a synthetic peptide vaccine against Semliki Forest virus. Journal of Virology  
1993;67:5843 -8. 
 (49)  Ahlers JD, Dunlop N, Alling DW, Nara Pl, Berzofsky JA. Cytokine -in-adjuvant 
steering of the immune response phenotype to HIV -1 vaccine constructs: 
granulocyt e-macrophage colony -stimulating factor and TNF -alpha synergize w ith IL -
12 to enhance induction of cytotoxic T lymphocytes. J Immunol  1997;158:3947 -58. 
 (50)  Schaefer JT, Patterson JW, Deacon DH et al. Dynamic changes in cellular infiltrates 
w ith repeated cutaneous vaccination: A histologic and immunophenotypic analysis.  
Journal of Translational Medicine  2010;8:79.  
 (51)  Lore K, Betts MR, Brenchley JM et al. Toll -like receptor ligands modulate dendritic 
cells to augment cytomegalovirus - and HIV -1-specific  T cell responses. J Immunol  
2003;171:4320 -4328.  
 (52)  Perrot I, Deauvieau F, Massacrier C et al. TLR3 and Rig -like receptor on myeloid 
dendritic cells and Rig -like receptor on human NK cells are both mandatory for 
production of IFN -gamma in response to d ouble -stranded RNA. J Immunol  
2010;185:2080 -2088.  
 (53)  Levy H, Salazar A. Interferon inducers. In: Baron S, Copenhaver D, Dianzani F, et 
al., eds. Interferon: Principles and Medical Applications . Galveston, TX: Galveston 
University, University of  Texas Medical Branch; 1992;65 -76. 
 (54)  Peng G, Guo Z, Kiniw a Y et al. Toll -like receptor 8 -mediated reversal of CD4+ 
regulatory T cell function. Science  2005;309:1380 -1384.  
 (55)  Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune 
respo nse modifier, resiquimod gel, to modify the recurrence rate of recurrent genital 
herpes: a pilot study. J Infect Dis  2001;184:196 -200. 
 (56)  Pockros PJ, Guyader D, Patton H et al. Oral resiquimod in chronic HCV infection: 
safety and efficacy in 2 placebo -controlled, double -blind phase IIa studies. J Hepatol  
2007;47:174 -182. 
 (57)  Kirkw ood JM, Straw derman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. 
Interferon alfa -2b adjuvant therapy of high -risk resected cutaneous melanoma: the 
Eastern Cooperative Onco logy Group Trial EST 1684 [see comments]. J Clin Oncol  
1996;14:7 -17. 
 (58)  Kirkw ood JM, Ibrahim JG, Sondak VK et al. High - and low -dose interferon alfa -2b in 
high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin 
Oncol  2000;18:2444 -2458.  
 (59)  Kirkw ood JM, Ibrahim JG, Sosman JA et al. High -dose interferon alfa -2b significantly 
prolongs relapse -free and overall survival compared w ith the GM2 -KLH/QS -21 
vaccine in patients w ith resected stage IIB -III melanoma: results of intergroup trial 
E1694/S9512/C509801. J Clin Oncol  2001;19:2370 -2380.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 83  (60)  Kaw akami Y. Immunobiology of human melanoma antigens MART -1 and gp100 and 
their use for Immuno -gene therapy. Int Rev Immunol  1997;142:173 -192. 
 (61)  Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity 
in patients after clonal repopulation w ith antitumor lymphocytes. Science  
2002;298:850 -854. 
 (62)  Judge JM, Chianese -Bullock KA, Schroen AT, Slingluff CL, Jr. Usefulness of 
prestudy assessment of patient w illingness to undergo tissue biopsy for correlative 
studies in a melanoma vaccine trial. Clin Trials  2013;10:143 -150. 
 (63)  Balch CM, Gershenw ald JE, Soong SJ et al. Final version of 2009 AJCC melanoma 
staging and classificati on. J Clin Oncol  2009;27:6199 -6206.  
 (64)  Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph 
nodes show  profound dow nregulation of antigen -presenting cells of the paracortex: 
implications for tumor biology and treatment. Mod Pathol  2001;14:604 -608. 
 (65)  Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC. A phase II dose -
ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol  
2008;159:205 -210. 
 (66)  Tam RC, Hong Z, Moran M, Varnavski A, Kim SK. Th erapeutic strategies targeting 
the innnate antiviral immune responses (section heading: TLR agonists as 
therapeutic IFN inducers). In: Wu -Pong S, Rojanasakul Y, eds. Biopharmaceutical 
Drug Design and Development . 2nd ed. Humana Press; 2008;241.  
 (67)  Glass G, Papin JA, Mandell JW. SIMPLE: a sequential immunoperoxidase labeling 
and erasing method. Journal of Histochemistry & Cytochemistry  2009;57:899 -905. 
 (68)  Chianese -Bullock KA, Pressley J, Garbee C et al. MAGE -A1-, MAGE -A10-, and 
gp100 -derived peptides  are immunogenic w hen combined w ith granulocyte -
macrophage colony -stimulating factor and montanide ISA -51 adjuvant and 
administered as part of a multipeptide vaccine for melanoma. JI 2005;174:3080 -
3086.  
 (69)  Yamshchikov GV, Barnd DL, Eastham S et al. Eva luation of peptide vaccine 
immunogenicity in draining lymph nodes and blood of melanoma patients. Int J 
Cancer  2001;92:703 -711. 
 (70)  Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Tw o subsets of memory T 
lymphocytes w ith distinct homing potentia ls and effector functions. Nature  
1999;401:708 -712. 
 (71)  Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain 
highly functional HIV -specific CD8+ T cells. Blood  2006;107:4781 -4789.  
 (72)  Welters MJ, Kenter GG, de Vos van Steenw i jk PJ et al. Success or failure of 
vaccination for HPV16 -positive vulvar lesions correlates w ith kinetics and phenotype 
of induced T -cell responses. Proc Natl Acad Sci U S A  2010;107:11895 -11899.  
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 84  (73)  Alexander J, Sidney J, Southw ood S et al. Development  of high potency universal 
DR-restricted helper epitopes by modification of high affinity DR -blocking peptides. 
Immunity  1994;1:751 -761. 
 (74)  Del Guercio MF, Alexander J, Kubo RT et al. Potent immunogenic short linear 
peptide constructs composed of B cel l epitopes and Pan DR T helper epitopes 
(PADRE) for antibody responses in vivo. Vaccine  1997;15:441 -448. 
 (75)  Bechhofer RESTJaGDM. Design and analysis of experiments for statistical selection, 
screening, and multiple comparisons .  New  York: John Wiley & Sons, 1995.  
 (76)  Chianese -Bullock KA, Lew is ST, Sherman NE, Shannon JD, Slingluff CL, Jr. Multi -
peptide vaccines vialed as peptide mixtures can be stable reagents for use in 
peptide -based immune therapies. Vaccine  2009;27:1764 -1770.  
 
(77)  Slingluff CL, Jr., Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh 
WW, Boisvert ME, Kirkw ood JM, Chianese -Bullock KA. Effect of 
granulocyte/macrophage colony -stimulating factor on circulating CD8+ and CD4+ T -
cell responses to a multipeptide melanoma vaccine:  outco me of a multicenter 
randomized trial. Clini Cancer Res 2009; 15:  7036 -7044.  
 
(78) Mauldin IS, Wages NA, Stow man AM, Wang E, Olson WC, Deacon DH, Smith KT, 
Galeassi N, Teague JE, Smolkin ME, Chianese -Bullock KA, Clark RA, Petroni GR, 
Marincola FM, Mullins DW, Slingluff CL, Jr. Topical treatment of melanoma 
metastases w ith imiquimod, plus administration of a cancer vaccine, promotes 
immune signatrues in the metastases. Cancer Immunol Immunother 2016; 65:  1201 -
1212.  
 
(79) Mauldin IA, Wages NA, Stow man AM, Wang E, Smo lkin ME, Olson WC, Deacon 
DH, Smith KT, Galeassi NV, Chianese -Bullock KA, Dengel LT, Marincola FM, 
Petroni GR, Mullins DW, Slingluff CL, Jr.  Intratumoral interferon -gamma increases 
chemokine production but fails to increase T cell infiltration of  human me lanoma 
metastases.  Can cer Immunol Immunother 2016; 65:  1189 -1199.  
 
(80) Siegel, RL, Miller, KD, Jemal, A.  Cancer Statistics . CA:  A Cancer Journal for 
Clinicians 2017 ; 67:  7 -30. 
 
(81) O'Quigley, J, Pepe M, Fisher L. Continual reassessment method:  a practical de sign 
for phase 1 clinical trials in cancer.  Biometrics 1990; 46:  33 -48. 
 
(82) Wages NA, Conaw ay MR, O'Quigley, J.  Continual reassessment method for partioal 
ordering.  Biometrics 2011; 67:  1555 -1563.  
 
(83) Higano, C. S., P. F. Schellhammmer, E. J. Small, P. A. B urch, Nemunaitis J, L. Yuh, 
N. Provost, and M. W. Frohlich. Integrated data from 2 randomized, double -blind, 
placebo -controlled, phase 3 trials of active cellular immunotherapy w ith sipuleucel -T 
in advanced prostate cancer. Cancer  115: 3670 -3679.  
 
(84) Eggermont AMM, Chiarion -Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus 
placebo after complete resection of high -risk stage III melanoma (EORTC 18071): a 
randomised,  double -blind, p hase 3 trial. Lancet Oncol 2015 ; 16: 522 –30 
PRC# 1143 -10 / IRB -HSR#15931 / IND# 15891   
Version Date: 07-31-17                          
 
 85  
(85) Tarhini  A, Lee  S, Kirw ood  J, et al. A phase III randomized study of adjuvant 
ipilimumab (3 or 10 mg/kg) versus high -dose interferon alfa -2b for resected high -risk 
melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilim umab 
arms.  Abstract . J Clin Oncol 2017; 35. 
 
 
 
 
 
 
 